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Abstract 
Chamuvarinin (22) is a unique annoanceaeous acetogenin isolated from the roots of 
Senegalese medicinal plant Uvaria chamae by Laurens and co-workers in 2004. It 
displays highly potent cytotoxicity towards the cervical cancer cell lines (KB 3-1, IC50 =  
0.8 nM). Structurally, chamuvarinin is the first reported acetogenin to contain an 
adjacently linked bis-THF-THP ring system spanning the C15-C28 carbon backbone. 
However, initial efforts to assign the relative and absolute configuration within this  
stereochemical array, on the basis of 1H and 13C NMR analysis, provided only partial 
information pertaining to the relative configuration of C15-C19 region. As a 
consequence, 32 diastereomeric structural possibilities exist for the highly unusual 
structure of chamuvarinin; an unrealistic target for total synthesis. The synthesis of the 
central core tricyclic (BCD) intermediate represents the most challenging aspect in the 
entire synthesis, which in turn will aid ultimate structural proof.  
At the outset of the project the stereochemical configuration of C15-C28 (BCD) of 
chamuvarinin was uncertain and a library approach was proposed to enable structure 
elucidation (Scheme A-1). Chapter 2 and Chapter 3 detail the synthesis of possible 
diastereomers of the C9-C21 (51) and C22-C34 fragments (52). Chapter 4 details the 
intial strategy to couple the key diastereomeric fragments in a series of model studies. 
Chapter 5 describes the successful coupling strategy via an revised synthetic approach to 
reach the advanced C9-C34 intermediate 251 (Scheme A-2).  
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Compound Numbering 
 
 
All compounds intended toward the structure elucidation or total synthesis of 
chamuvarinin (22) will be numbered according to the carbon chain of the natural 
product. This numbering is given on the structure and is used in 1H NMR 
assignments. 
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The naming of the compound in the Experimental Section uses IUPAC 
convention. 
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Chapter One 
 
Introduction 
 
Nature has evolved a structurally diverse array of secondary metabolites, isolated from 
terrestrial and marine sources, which possess potent biological activities, that provide a 
vast and virtually unlimited source of new lead agents for both the pharmaceutical and 
agrochemical industries.1 Today, natural products are responsible for about half of the 
approved drugs that are currently available. This percentage rises for treatment of 
infection or cancer, as natural product-derived treatments account for approximately 
60% of the drugs either in use or awaiting FDA approval in the period between 1981 
and 2002.2,3,4 
 
1.1 Natural products in drug discovery 
 
In cases where supply issues are critical to the success of the emerging pharmaceutical 
agent, total synthesis, or the synthesis of more accessible natural product analogues 
continues to facilitate the viability of natural products as lead compounds in drug 
discovery.4 One such example is paclitaxel or Taxol® (1) (Figure 1.1), it was the 
world’s first billion dollar anti-cancer drug and was originally isolated from the bark of 
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the Pacific yew tree (taxus brevifolia).5 Its potential was recognised during research in 
the 1960s and 1970s. However, only one gram of metabolite could be extracted from 24 
kg of dried bark. Since a 125 year old tree was only capable of producing around 2 kg 
of bark and this species relatively rare, the supply issue was particularly acute, and 
slowed its development as a drug.6 However, the supply problem was eventually 
resolved after it was found the needles of the common European yew (taxus baccata) 
where rich in 10-deacetylbaccatin-III7 (10-DAB, 2 in Figure 1.1). The total synthesis of 
Taxol® was completed by Holton and Nicolaou, independently.6,7 This work later 
allowed for the large-scale manufacture using a semi-synthetic approach.8 
 
O
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Figure 1.1: Structure of Taxol® (1) and 10-deacetylbaccatin (2)  
 
Two further examples where total synthesis plays an important role in alleviating the 
problem of supply are galantamine 3 (alzheimer’s) and mycophenolate sodium 4 
(immune suppression).9 In both cases these two natural product drugs are produced by 
total synthesis and have recently reached the market. 
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Figure 1.2: Strucutres of galantamine (3) and mycophenolate sodium (4). 
 
1.1.1 Structural reassignments in natural products  
 
The massive improvement in analytical techniques over the last half century continues 
to simplify the elucidation of natural product structures. Whilst it is true that the vast 
majority of newly elucidated natural products are accurately proposed by the careful 
use of these techniques, a significant number of structures are subsequently shown to 
have been misassigned.10 These misassignments are regularly only recognised on 
completion of a total synthesis.11, 12 Amphidinolide A1 (5) and azaspiracid (6) provide 
notable examples where synthesis has been crucial in the structural elucidation of 
complex marine natural products. In other examples, porritoxin (7) and batzelladine F 
(8), their structures have been revised upon extensive reinvestigation by detailed 2D 
NMR analysis, together with total synthesis. Indeed, structural misassignments clearly 
provide opportunities for synthetic chemists to make discoveries through total 
synthesis, and certainly show that there is still adventure to be had in the process of 
structure assignment and ultimate structural proof.13 
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Figure 1.3: Some examples of revised structures by total synthesis 
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1.2 Plant-derived natural products and drug discovery 
 
Among natural products, plants possess great chemical versatility; due to ecological 
necessity, many secondary metabolites accumulate in plants as a chemical defensive 
strategy against microbes and other predator threats, thus preventing over-browsing of 
the plant. Some of the defensive strategies may become useful directly or indirectly in 
the design of pharmaceuticals for human use.22 The variety of secondary metabolites 
produced by plants is broader than those of other organisms. The realm of drugs 
obtained from plants is vast, wider than any other source of natural products, and they 
are the basis for the traditional medicinal philosophies and practices in China, India and 
isolated tribal populations.23   
Plant-derived pharmaceuticals and phytochemicals retain their historic significance in 
the drug industry.4 Such materials are still commonly used in the treatment and 
prevention of many human diseases. A substantial portion of all the currently 
prescribed drugs are derived directly or indirectly from plant sources.23 Many potent 
drugs with novel features have been isolated. For example, the potent antimalarial drug 
artemisinin24 (9, Figure 1.4). Azadirachtin25 (10), which displays strong antifeedant 
activity against numerous insects is produced by the Indian neem tree (Azadirachta 
indica) (Figure 1.4)26. The tree has been used for centuries to protect other plants and 
clothes from insects. The structure of active compound is very complex and was not 
elucidated until 1985. Due to its potency and selectivity against insects this compound 
has been commercialised as an antifeedent.27 The better-defended, more-competitive 
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plants have generated more progeny, and so the capacity to produce and safely store 
such useful metabolites.28,29  
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Figure 1.4: Structures of artemisinin (9) and azadirachtin (10)  
 
A chemical class that has not been explored in this discussion, but has proven to be a 
viable source of cytotoxic compounds, is that of the acetogenins.  The acetogenin 
family of natural products is a class of polyketide-derived metabolites, originally 
isolated from the tropical and subtropical plants, of the Annonaceae genus.30,31 In 1982, 
uvaricin (11) was discovered in the root extracts of Uvaria accuminata, and displayed 
in vivo activity as an antileukemic (P-388) agent. This invigorated the wide interest in 
this plant family.32 Today, more than four hundred annonaceous acetogenins have been 
isolated from various annonaceae plant species.33  
 
O O
OAc OH
O
O
11  
Figure 1.5: Structure of uvaricin (11) from Uvaria accuminata 
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1.2.1 The annonaceae plant family    
 
The annonaceae is a large family of tropical and subtropical trees, shrubs and lianas 
comprising ca. 130 genera and more than 2300 species.30 Some of annonaceae produce 
edible fruits; custard apple, sugar apple, atemoya, cherimoya and pawpaw. 
 
Many members of this family are used in traditional medicinal practices for the 
treatment of antiparasitic, anti-tumour and the treatment of intestinal disease.34 
However, their phytochemical study has not been extensively carried out due to their 
distribution in tropical and subtropical areas. Since 1980, many interesting compounds 
have been reported. One such source of acetogenins is Annona cherimolia, a tropical 
plant from Peru, used traditionally to kill insects and parasites. The seeds from this 
plant have yielded two anti-tumour compounds: annomolin (12) and annocherimolin 
(13, Figure 1.7).35 The former showed selective inhibitory effects against human 
prostate tumor (PC-3) cell line, while the latter has shown activity against both breast 
(MCF-7) and colon (HT-29) cancer cell lines. Both compounds appear to be 104 times 
as potent as adriamycin (14, Figure 1.8).35 
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Figure 1.7: Structures of acetogenins annomolin (12) and annocherimolin (13) 
 
Human cancer cell lines ED50 (µg/mL) Compoundi BSTa LC50 
(µg/mL) 
A-549b            MCF-7c             HT-29d             A-498e            PC-3f            MIA PaCa-2g 
12 
13 
Adriamycin(14)h 
9.40 x 10-3 
5.80 x 10-3 
          NT 
   2.37            1.15 x 10-4         8.92 x 10-5       6.88 x 10 -4         5.39 x 10 -6             2.18 
  1.56            4.06  x 10-6        2.49 x 10 -6       1.53 x 10-1           1.02                   1.20 x 10-5 
1.13 x 10-3    1.82 x 10-2         1.28 x 10-2        2.26 x 10-3         5.02 x 10-2           2.62 x 10-3 
aBrine shrimp test. bHuman lung carcinoma. cHuman breast carcinoma. dHuman colon adenocarcinoma. eHuman kidney carcinoma. 
fHuman prostate adenocarcinoma. gHuman pancreatic carcinoma. hPositive control standard. fNT: Not tested. iTable reproduced 
from ref 35 
 
Table 1.1: BST and cytotoxicities in human solid tumour cell lines for 12 and 13 
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Figure 1.8: Structure of adriamycin 14 
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1.3 Classification of acetogenins 
 
Annonaceous acetogenins are classified according to their relative stereostrucutres 
across the tetrahydrofuran (THF) rings; and the typical structures of annonaceous 
acetogenins consist of an unbranched chain of 30-32 carbon atoms with a central core 
unit of one, two or three adjacent terahydrofuran rings near the mid-point of the carbon 
backbone. One end of the chain is generally attached to the 2-position of a (S)-4-methyl 
butenolide, which is thought to be the biological pharmacophore.36 The clearest 
classification are mono-THF, adjacent bis-THF, non-adjacent bis-THF, tri-THF, and 
non-classical acetogenins (containing tetrahydropyran (THP) ring and hydroxylated 
THF compounds), followed by the sub-classification of γ-lactone, substituted γ-lactone, 
or ketolactone variations (Figure 1.9).37  
 
O
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O
O
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O
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O
R1
(where R = R1 = R2 = H, OH)
mono-THF adjacent bis-THF non-adjacent bis-THF
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Figure 1.9: Classification of core units in acetogenins 
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Scheme 1.1: Proposed biosynthetic pathway of THF moiety 
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1.3.1 Biosynthesis of tetrahydrofuran acetogenins 
 
Since annonaceous acetogenins are believed to arise from fatty acid derivatives, these 
would have been biosynthesised via the polyketide pathway. The THF ring systems 
arise from isolated Z-double bonds through poly-epoxidation of an unconjugated 
polyene, followed by tandem inter- or intramolecular THF ring formation as shown in 
Scheme 1.1. The semisynthesis of additional THF rings from double bond containing 
acetogenins strongly supports this hypothesis.37 This elegant biosynthetic route has 
stimulated chemists to undertake the development of new synthetic routes to reach 
these biologically important molecules.  
 
1.3.2 Bioactivity and mechanism of action 
 
The biological properties of acetogenins have been appreciated for a long time by 
Indian tribes from the South American rain forest, who still use the extracts from these 
plants as pesticidal and antiparasitic agents. Many other activities, like anthelmic, 
antimalarial, antimicrobial and antiprotozoal have been reported. The most important 
biological activity seems to relate to their cytotoxic activity and their potential as 
antitumour agents.34,38 
Acetogenins are one of the most potent inhibitors of the mitochondrial respiratory chain 
complex I.39 For example, bullatacin 15 (ED50 = 10-15 µg/mL) and rolliniastatin I 16 
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(ED50 = 4.5 x 10-5 µg/mL) (Figure 1.10) are the most potent inhibitors of the bovine 
heart mitochondrial complex I identified to date.40 
OO
OH OH
O
O
OH
15
OO
OH OH
O
O
OH
16
 
Figure 1.10: Structures of bullatacin (15) and rolliniastatin I (16)  
 
Although acetogenins are thought to act at the terminal electron transfer step of 
complex I (Figure 1.11), there is still no definitive experimental evidence to verify 
whether they in fact bind to the ubiquinone reduction site.41 Complex I has been 
implicated in several diseases including Idopathic Parkinson’s disease, Huntington’s 
disease, and the onset of diabetes stroke-like episodes.42,43 However, the precise mode 
of complexation of acetogenins with the target proteins has not been delineated. In view 
of the promising bioactivity profiles of acetogenins, it would be interesting to 
investigate their interaction with the relevant proteins at the molecular level. As 
inhibiting complex I reduces the ATP levels in the cell, this leads to the onset of 
apoptosis.44 
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Membrane/ Water interface
THF-ring moiety with flankingOH groups
Lactone-ring moiety
Complex I
 
Figure 1.11: General schematic for the mechanism of action of acetogenins 
 
There are few structural similarities between acetogenins and established mitochondrial  
complex I inhibitors, such as rotenone (17), piericicdin-A (18), fenpyroximate (19) and 
pyridaben (20) which are known to induce programmed cell death within 12-18 h in a 
wide variety of mammalian cell lines (Figure 1.12).42,45 When mitochondrial complex I 
is fully inhibited, cells suffer an extensive failure of the mitochondrial oxidative 
metabolism leading to ATP depletion, and thus cause the energetic collapse of cellular 
function, resulting in cell death by necrosis.44,46 It can occur even under slight inhibition 
in a time-dependent manner. Resistance of the cells to this energetic collapse mainly 
depends on their ability to obtain energy from anaerobic metabolism.47  
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Figure 1.12: Reported inhibitors rotenone (17), piericicdin-A (18), fenpyroximate (19) 
and pyridaben (20) of Complex I 
 
It is also hypothesised that the mechanism of action may also be related to ionophoric 
abilities, based on observed complexation with cations.48 Although acetogenins present 
no ionophoric effects in biological studies with living cells,49 it has been shown that 
structurally related analogues of acetogenins present strongly selective abilities to 
complex divalent cations, such as Ca2+ (Figure 1.13). This depends on both the nature 
of the studied cation and the spatial, stereochemical relationship of the stereogenic 
centres in the molecules.50 It is proposed, that when acetogenins are complexed with 
Ca2+, they adopt spatial structures different from those the free molecules.51  
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Figure 1.13: Schematic view of complexation of annonacin (21) with Ca2+ 
 
1.3.3 Structure Activity Relationships (SAR) 
 
Acetogenins are the most potent inhibitors of mitochondrial complex I.  These 
compounds are characterised by two functional units [i.e. hydroxylated tetrahydrofuran 
(THF) and α,β-unsaturated γ-lactone ring moieties] separated by a long alkyl spacer. To 
elucidate the structure-activity relationship and the mechanism of action, it is necessary 
to develop a simplified synthesis of natural acetogenins and analogue libraries, which 
maintain essential functionalities needed for inhibitiory effect. In structure-activity 
relationship studies using a series of natural acetogenins and synthetic analogues, 
several research groups studies agree that key points concerning SAR in acetogenins 
are:52  
  
                                                                                                         Chapter One 
16 
 
1.  The presence of polar functional groups such as hydroxyl group in the spacer, 
the number of THF rings, and the stereochemistry around the THF ring(s) with 
flanking hydroxyl groups are not essential structural factors for potent activity. 
2. The natural γ-lactone ring is itself not crucial for activity and can be substituted 
with a ubiquinone ring.53 
3. Acetogenins acts as strong inhibitors only when the γ-lactone and the THF ring 
moieties are directly linked by an alkyl spacer, with an optimum length of 13 
carbon atoms. 
 
The presence of α,β unsaturated γ-lactone ring is one of the common structural features 
of the vast majority of acetogenins. Recent synthetic studies suggest that the teriminal 
γ-lactone is essential for the potency of the acetogenins as complex I inhibitors, 
although some reports propose that the alkyl chain plays a more crucial role. However, 
the roles of other ring moieties have not been sufficiently emphasised. Miyoshi et al.54 
reported that the inhibitory potency was almost completely retained even after the 
saturation of the double bond in the γ-lactone ring. But it is also said that the ring can 
be substituted and further analogues show considerable inhibition even without the ring 
moiety.54b Neverthless, there is a broad consensus on the proposition that the ring 
moiety has to be directly linked to the compound core by the alkyl spacer of appropriate 
length.  
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1.4 Chamuvarinin- isolation and biological activity 
 
Chamuvarinin (22, Figure 1.14) was isolated in 2004 by Laurens et al. from the roots 
of Uvaria chamae.55 It is a unique acetogenin bearing an unusual THP ring adjacent to a 
bis-THF ring system. This species has proven to be a rich source of bioactive 
metabolites. Prior to chamuvarinin, eight mono-THF acetogenins were also obtained 
from this plant’s roots.36 Initial biological screening of chamuvarinin showed it to be a 
highly potent cytotoxic agent with an IC50 = 0.8 nM against KB 3-1 (human epidermoid 
carcinoma) cells. 
 
O O O
OH
O
O
A
BCD
22  
Figure 1.14: Structure of chamuvarinin 22  
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1.4.1 Structure elucidation 
 
The determination of the absolute configuration of 22, and of acetogenins in general, is 
cumbersome, as X-ray structure analysis is often difficult due to the amorphous nature 
of these compounds, plus the definite sterochemical assignments can not readily be 
made by 1H and 13C NMR spectroscopy.  Despite advances in characterisation methods, 
the stereochemical assignment of a certain number of this important family of natural 
products is still incomplete. For example, whilst the stereochemistry in the butenolide 
ring is known to be S, the relative chemistry of the THF regions of certain mono- and 
bis- THF acetogenins still remains undetermined.33 As a result, total synthesis provides 
the only viable approach to solve these stereochemical puzzles. 
 
The partial stereochemical structure of chamuvarinin (22) was proposed by Laurens et 
al. using 1H and 13C NMR spectra alongside HRMS, IR and UV data.55 The 1H NMR 
spectrum of chamuvarinin 22 defied complete stereochemical analysis and the relative 
stereochemistry of the C15-C19 region was assigned on the basis of correlation with the 
preferred coincidence data of several other acetogenins (Figure 1.15).56 A total of thirty 
seven 13C signals and apparently, six well resolved 1H signals in the range of δ H 3.00-
4.00 appeared. Those at δ 3.37 (H-15), 3.82 (H-16), 3.88 (H-23) and 3.93 (H-19, H-20) 
were assigned to a bis-THF ring with a flanking hydroxyl group. The two remaining 
signals at δ 3.23 (H-28) and 3.28 (H-24) were consistent with the presence of the THP 
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ring motif. The unambiguous determination of stereochemistry in chamuvarinin is a 
prerequisite to structure activity relationships and it may also provide important 
information regarding the biosynthetic pathway to this unusual secondary metabolite. 
However, it became apparent that a synthetic approach would provide the only 
conclusive means of determining the relative stereochemistry within the C15-C28 
region, and ultimately the absolute configuration of chamuvarinin. 
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Figure 1.15:  C15-C28 region stereochemical issues in chamuvarinin (22) 
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1.5 Selected approaches to acetogenin synthesis 
 
Since the initial isolation of uvaricin in 1982, annonaceous acetogenins have 
increasingly captured the attention of synthetic and medicinal chemists, owing to the 
variation of stereochemistry around the central tetrahydrofuran motifs and at the sites 
bearing additional hydroxyl groups,37,56c,d coupled with their impressive biological 
profiles. 
 
Although numerous efforts by research groups have generated approaches to the 
acetogenin class of molecules over the last two decades, there still remains a lot of 
work to be done. Most investigations have been focussed on the construction of the 
adjacent bis tetrahydrofuran acetogenins bearing six oxygenated stereocentres. The first 
successful approach was reported in 1991 by Hoye and co-workers57 who employed a 
two-directional inside-out cascade sequence with diepoxide 23 to prepare the bis-THF 
24 in the synthesis of a diastereomer of uvaricin 25 (Scheme 1.2). This synthesis was 
particularly important in establishing the absolute stereostructure of the natural product. 
Subsequently, numerous synthetic approaches to related core tetrahydrofuran arrays 
have been reported. This section will review selected total syntheses of acetogenins. 
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Scheme 1.2: Hoye’s synthesis of 15,16,19,20,23,24-hexaepi uvaricin (25)57 
 
1.5.1 Roush’s synthesis of asimicin 
 
Asimicin (26) and bullatacin (15) are two diastereomeric annonaceous acetogenins. 
Asimicin 26 was isolated from the pawpaw tree, Asimina triloba dunal,58 and bullatacin 
15 was discovered in Annona bullata.59 The first total synthesis of asimicin was 
reported by Hoye et al.60 in 1997 and numerous reports have appeared since regarding 
the total synthesis of this molecule.  
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Figure 1.16: Structures of asimicin (26) and bullatacin (15). 
 
Recently, the Roush group has completed the synthesis of both asimicin (26) and 
bullatacin (15).61 Presented here is Roush’s approach to asimicin (26). This study relied 
on two sequential chelate controlled [3+2] annulation reactions of chiral allylsilanes (27 
and 29) with appropriately substituted aldehydes (28 and 30) (Scheme 1.3) to build the 
central bis-THF core.62 The total synthesis of asimicin 26 was completed by the 
installation of the butenolide unit in the final stages of the synthesis.  
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Scheme 1.3: Roush et al. retrosynthesis of asimicin (26)61a  
 
The synthesis of asimicin began with the stereoselective [3+2] annulation, reaction of 
allylsilane 29 with α-benzyloxy acetaldehyde 30 to afford the 2,5-trans substituted THF 
31 (Scheme 1.4). Conversion of 31 to aldehyde 28 was achieved by reductive removal 
of the benzyl group and subsequent oxidation of the alcohol.  
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Scheme 1.4: Roush et al. synthesis of THF aldehyde 28 
 
The synthesis of functionalised allylsilane 27, which contains functionality necessary 
for installing the butenolide was realised via an asymmetric allylboration of aldehyde 
32 with γ-silyl allylborane 33,63 followed by the TBS protection gave 27 (Scheme 1.5). 
Treatment of aldehyde 28 with allylsilane 27 mediated by SnCl4 afforded the bis-THF 
fragment 34. Finally, the butenolide ring was installed using a procedure developed by 
Marshall and co-workers64 to provide synthetic (+)-asimicin.  
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Scheme 1.5: Roush et al. synthesis of asimicin 2661a 
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1.5.2 Crimmin’s synthesis of mucocin 
 
In 1995, McLaughlin and co-workers65 reported the isolation and structure 
determination of mucocin (35), the first member of the annonaceae family bearing a 
tetrahydropyran motif non-adjacently linked to a tetrahydrofuran motif. This compound 
was shown to exhibit high activity in the BST assay (IC50 1.3 µg/mL), as well as 
demonstrating remarkable inhibitory effects towards cancer cell lines. Early reports by 
Sinha and co-workers towards the synthesis of this molecule exploited a tandem 
oxidative cyclisation with rhenium oxide.66 In 2006, Crimmins and co-workers reported 
the total synthesis of mucocin,67  in which the key transformation involved sequential 
ring closing metathesis to access both key fragments 36 and 37 (Scheme 1.6). These 
individual fragments were coupled together by the application of cross metathesis, 
which finally provided mucocin (35), by the introduction of butenolide unit 39 via 
Pd(0)-catalysed Sonogoshira reaction.  
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Scheme 1.6: Crimmins et al. retrosynthetic plan to mucocin 35 
 
The strategy for the C18-C34 fragment relied on ring closing metathesis to construct 
syn-THP 36 (Scheme 1.7). To this end, employing the aldol reaction of intermediate 40 
with acrolein, gave the desired syn-aldol adduct 41 with good diastereoselectivity (11:1 
dr).68 Subsequent silyl protection of the secondary hydroxyl, followed by the removal 
of the chiral auxillary, allowed the conversion to triene 42. Intermediate 42 underwent 
ring closing metathesis using Grubbs second generation catalyst 43. This was followed 
by the acidic work-up to remove the TES group and complete the C18-C34 fragment 
36.   
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Scheme 1.7: Crimmins et al. synthesis of THP fragment 36 
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Next, the intermediate 44 was synthesised by Crimmins asymmetric glycolate-aldol 
reaction sequence, which then allowed the installation of the olefin by Wittig two 
carbon extension. In order to effect the regioselective formation of the five membered 
ring over the six membered cyclic ether, Hoye’s “activation” strategy was utilised.69 To 
apply this strategy, intermediate 44 was now taken onto tetraene 45 over four steps. 
Exposure of tetraene 45 to Grubbs second generation catalyst gave excellent 
regioselectivity and provided five and six membered rings in 7:1 ratio (Scheme 1.8).  
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Scheme 1.8: Synthesis of THF fragment 37 using Hoye’s activation strategy  
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Next, the two fragments 36 and 37 were coupled by cross metathesis using the 
Hoveyda-Grubbs catalyst (46) to afford bicyclic ether 47 (E:Z/6:1). Finally, coupling of 
advanced acetylene 47 and the fully elaborated butenolide side chain 38 was achieved 
by a Sonogoshira-type cross-coupling (Scheme 1.9).70 This was followed by the 
selective hydrogenation of the pentaenyne moiety 54 with diimide. The completion of 
the synthesis was achieved after the removal of protecting groups in 4.3% overall yield, 
and 19 longest linear sequences from commercially available 5-hexyn-1-ol.  
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Scheme 1.9: Crimmins et al. final steps to synthesis of mucocin 3567 
  
                                                                                                         Chapter One 
32 
 
1.6 Retrosynthesis                                               
 
As outlined in section 1.3.1, the primary objective of this project was to develop a total 
synthesis which is capable of resolving the stereostructure of chamuvarinin. This 36-
carbon annonaceous acetogenin is a highly complex structure, containing eight 
secondary sterocentres, six of which are bridging stereocentres associated within the 
contiguous bis-THF-THP ring system in 22. Stepwise advancement, followed by a 
systematic interconnection of these motifs, is expected to bring about a complete 
synthesis and enable the structure elucidation.  
Such a synthetic strategy must be flexible and be able to address the unique features of 
chamuvarinin, in addition to formulating and evaluating general solutions to the 
problems of the structure determination that are common to the annonaceous 
acetogenin class of compounds. The pioneering work on acetogenins has offered a 
valuable insight into the challenges that exist in executing a total synthesis and the 
structural determination of such a complex target.  
The synthesis of the central BCD core represents the most challenging aspect of the 
synthesis, as not only does it contain as many as seven asymmetric centres, the 
unknown stereochemistry also presents up to sixteen diastereomeric possibilities for 
chamuvarinin 22. Shown in Scheme 1.11, are the most plausible structures of 
chamuvarinin, which demonstrate the stereochemical complexity of a targeted synthesis 
of this molecule.37  
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Scheme 1.11: Flexible and modular approach to library of chamuvarinin (22) 
congeners. 
Accordingly, our approach to chamuvarinin dissects the target molecule via Wittig 
olefination into two major fragments, BCD central C9-C34 fragment 49 and butenolide 
moiety C1-C9 fragment 50, which will be introduced at a late stage (Scheme 1.12). In 
the course of planning our synthetic approach towards the BCD C9-C34 subunit, we 
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realised that a modular and flexible route utilising contemporary methods would allow 
a general and efficient synthesis to chamuvarinin as well as some analogs of biological 
interest. To this end, it was expected that the most valuable C9-C34 fragment 55 could 
be realised by a tandem etherification and ring-closing metathesis of the two key C9-
C21 fragment 51 and C22-C34 fragment 52.  The following chapters of this report 
separately address the issues of identifying the validity of this approach to synthesis the 
chamuvarinin. 
1
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Scheme 1.12: Retrosynthetic analysis of chamuvarinin (22). 
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Chapter Two 
Results and Discussion 
  
Synthesis of C9-C21 Fragment 
 
According to our proposed retrosynthetic analysis for chamuvarinin (Scheme 1.12), the 
C9-C21 subunit (51) would incorporate the B-ring THF motif. Overall, this subunit 
contains four stereocentres, two of which are part of the tetrahydrofuran ring fixed on a 
seven-carbon backbone. Therefore, the installation of correct stereochemistry in a 
concise order was critical.  
 
2.1 Retrosynthesis 
 
It was envisioned that the tetrahydrofuran system could arise from an epoxy alcohol 
cyclisation of epoxydiol 53 (Scheme 2.1). In turn, the two oxygenated central carbons 
at C15 and C16 were expected to be derived by Sharpless asymmetric dihydroxylation 
of olefin 54, which arises from Julia-Kocienski coupling of aldehyde 55 and sulfone 56. 
Access to aldehyde 55 could be readily achieved from a TBS-protected glycidol 57 
opening, while sulfone 56 could be synthesised from the mono protected 1,7-
heptanediol 58. 
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Scheme 2.1: Retrosynthetic analysis for subunit C9-C21 51 
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2.2  Preparation of chiral epoxide 57 
 
To enable a realistic assault on the total synthesis of chamuvarinin, it was necessary to 
provide sufficient amounts of C9-C21 subunit. To this end, an efficient synthesis of 
chiral epoxide 57 was required. This chiral epoxide will serve to install the C19 centre 
on C9-C21 subunit 52 (Scheme 2.1).  
 
In order to prepare the key C9-C21 subunit, several factors were considered, including 
ease of preparation and access to either enantiomer with high levels of 
enantioselectivity. Despite the rise of numerous prominent approaches for the 
introduction of epoxides with high yield and enantiomeric excess, methods targeted at 
the formation of enantiopure terminal epoxides have always proven disappointing.71 To 
date, the most efficient way to prepare enantiopure terminal epoxides from readily 
available racemic epoxides is to exploit the resolution mode of chiral salen catalysts to 
enrich enantiopurity (Scheme 2.2). Pioneering work by Jacobsen et al.72,73 has 
dominated this field,  and provides a highly efficient method for the synthesis of 
enantiopure terminal epoxides and 1,2-diols. The Jacobsen hydrolytic kinetic resolution 
(HKR) using the (R,R)-Co(II)[salen] catalyst 59 (Figure 2.1), in the presence of  H2O 
and AcOH at ambient temperature has found widespread application in organic 
synthesis.  
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Figure 2.1: Structure of the [(R,R)(salen)]Co catalyst 59. 
 
Where X = OAc, Cl, OH, OBz, OPh, OTs, SbF6
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Scheme 2.2: General reaction for HKR reaction. 
 
The synthesis of C9-C21 subunit began with the preparation of TBS protected glycidol 
ether (Scheme 2.3). Protection of glycidol epoxide 62 as its tert-butyldimethylsilyl 
ether with TBSCl and imidazole in DCM provided (±)-63. This reaction was performed 
on scales of up to 50 g and subsequent material was carefully filtered through a silica 
gel plug in a minimum amount of solvent to provide 63 in excellent yield. 
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Scheme 2.3:  Preparation of TBS-protected glycidol ether 63 
 
Using the HKR reaction process, treatment of the racemic TBS-protected epoxide 63 
under Jacobsen’s standard conditions yields enantiomerically pure epoxide 
(Scheme 2.4). Activation of the (R,R)-Co(II)[salen] catalyst in situ by stirring with neat 
epoxide 63 and acetic acid at room temperature. This was followed by dilution with 
THF and addition of H2O to provide the enantiomerically enriched (S)-epoxide 57 in 
41% yield along with diol 64 in 32% yield.  The optical rotation of 
! 
["]
D
20  +12.6 (c, 3.1 
C6H6) was comparable with the value reported 
! 
["]
D
20  +13.5 (c, 2.8 C6H6), consistent 
with high levels of enantioselectivity.74 
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O
(R,R)-Co(II)[salen] (59 )
AcOH, H2O, THF
16 h, RT
TBSO
O
OHTBSO
OH
+
63 64(41%, 57)  
 
Scheme 2.4: HKR reaction of glycidol ether. 
 
 
 
                                                                                                                        
 Chapter Two 
40 
 
2.2.1 Synthesis of aldehyde 55 
 
With the chiral epoxide 57 in hand, the synthesis of aldehyde 55 could begin. This 
required a regioselective epoxide opening with allylmagnesium bromide (Scheme 2.5). 
Treatment of epoxide 57 with the cuprate derived from allylmagnesium bromide and 
copper (I) iodide in THF at -40 oC afforded the desired product 65 as the only 
observable isomer in an excellent 82% yield.73b The resultant hydroxyl group in 65 was 
readily protected as its TBS-ether 66 in excellent yield via treatment with TBSCl, 
imidazole and catalytic DMAP in DCM.   
 
O
TBSO
BrMg
CuI, THF, -40 oC
(82%)
TBSO
OH
TBSCl, imidazole
DMAP, DCM
(98%)
TBSO
OTBS
57 65
66  
Scheme 2.5: Synthesis of olefin fragment 66 
 
Finally, oxidative cleavage of terminal olefin 66 was required (Scheme 2.5). A two-
step sequence was employed to this effect. Firstly, dihydroxylation of the terminal 
olefin 66 with catalytic OsO4 and NMO provided the 1,2-diol 67, as an diastereomeric 
mixture in 78% yield.75 Subsequent, oxidative cleavage of the 1,2-diol 67 with NaIO4 
in MeOH required careful optimisation and provided the desired aldehyde 55 in 98% 
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yield. The aldehyde was obtained in sufficiently pure form to be utilised directly in 
further transformations, as prolonged storage resulted in further aerobic-oxidation.  
TBSO H
OTBS
O
TBSO
OTBS
66
OsO4 (2.5 mol%), NMO
THF/H2O, RT, 5h
(78%)
TBSO
OTBS
OH
OH
67
55
NaIO4
MeOH/H2O (3:2)
0 oC, 30 min.
(98%)
 
 
Scheme 2.6: Synthesis of aldehyde 55 
 
2.2.2 Synthesis of C9-C15 Sulfone 56 
 
For the Julia-Kocienski olefination, sulfone 56 was required. The synthesis of sulfone 
56 began with the monobenzylation of 1,7-heptanediol 58 (Scheme 2.7). Upon on the 
realisation that the conventional approach for installing the benzyl ether protecting 
group using benzyl bromide and sodium hydride could not produce more than 25% 
yield of the desired product 68, alternative methods were investigated. Modified 
conditions employing tert-butylammonium iodide as a catalyst in 3:1 THF/DMSO 
resulted in only a slight improvement, i.e. 49% yield over the conventional procedure 
(entry 2, Table 2.1).76 However, treatment of excess alcohol 58 with NaH and benzyl 
bromide in dry THF afforded an acceptable yield 75% (based on benzyl bromide). 
Initially, in order to separate the product from unreacted diol, column chromatography 
was used. However, this proved to be impractical upon scale-up (~50 g and above). To 
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circumvent this shortcoming, the mixture of product and unreacted starting material 
was distilled under reduced pressure. The three fractions collected were alcohol, ca. 1:1 
mixture alcohol/product, and finally the pure product 68 (entry 4, Table 2.1). Although 
this slightly lowered the yield to 69%, the purification time was significantly reduced.  
  aproduct purified by column chromatography; bproduct purified by distillation under reduced pressure. 
Table 2.1: Benzylation conditions for 58. 
 
With mono-benzyl protected diol 68 in hand, the introduction of phenyltetrazolyl (PT)-
sulfide was readily achieved using the Mitsunobu protocol.77 Treatment of alcohol 68 
with triphenylphosphine (PPh3), diisopropylazodicarboxylate (DIAD), 1-H-
phenyltetrazole-5-thiol in THF provided the corresponding sulfide 69 in excellent yield.   
 
HO OH HO OBn
S OBnN
N
N N
Ph
NaH, BnBr, TBAI
THF,RT, 10h
(69%)
N
N
N
N
SH
Ph
PPh3, DIAD, THF
0 oC to RT (83%)
58 68
69
 
Scheme 2.7: Synthesis of sulfide 69 
Entry Condition(s) (68) Yield (%) 
1 58 (1 eq.), BnBr (1.1 eq.), NaH, DMF, RT 25 
2            58 (1 eq.), BnBr (1.0 eq), NaH, TBAI, 
THF/DMSO (3:1), RT 
49 
3 58 (1.2 eq.), BnBr (0.5 eq), NaH, THF, RT 75a 
4 58 (1.0 eq.), BnBr (0.5 eq), NaH, THF, RT 69b 
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Oxidation of the resultant sulfide 69 proceeded with unexpected challenges (Scheme 
2.8).  With quantities of  69 in hand, oxidation of sulfide 69 to sulfone 56 using m-
CPBA in DCM only provided the desired sulfone in 30% yield.78 Initially, we opted for 
m-CPBA, available directly from a commercial supplier. In addition to the 
disappointingly low and unreliable yields on a larger scale, this transformation was also 
found to be slow in most settings. Use of 10 equivalents of NaHCO3 to buffer the m-
chlorobenzoic acid present in the commercial reagent only slightly improved the 
reaction outcome. On the other hand, the yield and purity of sulfone 56 were provided 
superior levels after a preliminary m-CPBA purification step, which included several 
pH 7.2 buffer washes and recrystallisation, to provide 56 in 42% yield.79 Gratifyingly, 
oxidation with catalytic Mo-catalyst [Mo7O24(NH4)6.H2O] using 30 vol% H2O2 as a co-
oxidant in EtOH gave a smooth conversion of sulfide to sulfone in 80% yield.80 
SBnO N
N
NN
Ph
69
SBnO N
N
NN
Ph
56
O O
m-CPBA, NaHCO3
DCM, RT
(42%)
(NH4)6Mo7O24. 4H2O (0.22 eq.) ,
30% H2O2 (10 eq.), EtOH,
0 oC to RT (80%)
 
Scheme 2.8: Oxidation of sulfide to sulfone 56 
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2.3 Julia coupling of aldehyde 55 and sulfone 56 
 
Having successfully synthesised the sulfone 56, investigation of the selective Julia 
olefination between the aldehyde 55 and sulfone 56 was required. A variety of different 
approaches to olefin synthesis have been developed, which attempt to address the 
stringent demands required in the total synthesis of natural products.81 However, no 
single method yet provides a universal solution to the problem of E:Z selectivity.82 
Arguably, the most efficient and generally applicable methods for alkene synthesis 
remain those involving direct olefination of carbonyl compounds. Such methods are 
best exemplified by the Wittig reaction83 and also include the Horner-Wittig,83b, 84 
Horner-Wadsworth-Emmons (HWE),83b, 85 Peterson,86 Johnson,87 and classical Julia 
olefinations.88  
 
2.3.1 Julia olefination 
 
In 1973, Julia and Paris88a reported an Julia olefination procedure which utilised the 
reductive elimination of β-acyloxysulfones as the alkene forming step.89 A new variant 
of the classical Julia olefination, the so called one-pot or modified Julia olefination90 
allows for a single-step synthesis of olefins from carbonyl compounds and heterocyclic 
sulfones via a novel condensation process initially described by S. Julia in 1991 
(Scheme 2.9). The reaction commences with the deprotonation of an aryl or alkyl 
benzothiozol-2-yl sulfone 70, because the resulting anion 71 acts as the nucleophile 
partner in the reaction manifold. This species subsequently adds to the carbonyl 
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component 72, forming a transient β-alkoxysulfone intermediate 73. The alkoxide 
continues along the reaction pathway, attacking the electrophilic C=N bond of 
benzothiazole (BT) portion of the molecule in an intramolecular fashion. This series of 
consecutive reactions results in a putative spirocyclic intermediate 74 that selectively 
breaks down via an overall Smiles rearrangement to afford the alkene 77 together with 
loss of sulfur dioxide 78 and elimination of metallated benzothiazolone 76.  
 
S
N
S
N
R2 H
O
S
N
SO2
O
R1
R2
S
N
S
O2
O
R2
R1
S
N
O
S
N
O
R2
SR1
O
O
base
addition
72
Smiles
rearrangement
R1
R2
SO2+ +
70 71
73 74
75 76 77 78
O2
S
H
R1
O2
S R1
 
Scheme 2.9: The modified Julia olefination with (BT) sulfones mechanism 
 
The observed steroselective formation of E-olefins in stabilised-metallated BT-sulfones 
with aromatic aldehydes was reported by S. Julia et al.90,91 accordingly he postulated 
that there was the creation of a positive charge at the benzylic position during the 
course of the reaction, through rapid collapse of intermediates 80 or 81 to form 
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zwitterions 82 and 83 upon E1 elimination of 84 (Scheme 2.10). Steric repulsion 
between the R1 and R2 groups in 82 would then favour 83 and the subsequent formation 
of (E)-olefin 85 over (Z)-olefin 86 upon final extrusion of sulfur dioxide.   
 
N
S
SO2
R1
H R2
O
N
SO2S
O
R1
R2
Li N
SO2S
O
R1
R2
Li
NS
OLi
R1
R2
SO2
R2
R1
R1
SO2
R2
+
R1
R2
R1
R2
SO2SO2
70
8382 8586
8180
79
Z-minor E-maj or
R2 = aryl
84
 
Scheme 2.10: Mechanistic explanation for modified Julia reaction 
 
However, the stereochemical outcome of the one-pot Julia reaction is influenced 
strongly by both substrate and reaction conditions. One such example was reported in 
1996 by Kocienski and co-workers,92 who used it to synthesise the triene portion of 
rapamycin (Scheme 2.11). Using LiHMDS, as the base to deprotonate benzothiazolyl 
sulfone 88, the metallated BT-sulfone was then condensed with aldehyde 87 giving a 
68% yield of alkene 89 with a 19:1 E:Z ratio. They also observed the substrate 
dependence of the reaction when aldehyde 90 was condensed with BT-sulfone 91, the 
opposite olefin geometry was preferred (Z:E = 2.4:1) in a 75% yield. This second 
                                                                                                                        
 Chapter Two 
47 
 
reaction exemplifies that stabilised BT-sulfone anions have a preferential tendency to 
give (Z)-configured products.  
 
O
SS
OMe
OTBS
H 19
20
21
22
O
SS
CHO
OMe
H
S
O2
OTBS
BT
O
SS
CHO
OMe
H
OTBS
S
O2
BT
M
yield
89
E :Z
[C19-C20]
Li 75% 29:71
Na 21% 43:57
K ---- 18:82
M
yield
89
E :Z
[C21-C22]
Li 68% 95:5
Na 21% 78:22
+
+
MN(SiMe3)2, THF
-78 oC to RT
MN(SiMe3)2, THF
-78 oC to RT
87
88
89
90 91  
 
Scheme 2.11: Substrate dependence in modified Julia olefination 
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The modified Julia olefination was first described using BT-sulfone, but has since been 
extended to a range of heteroaryl sulfones (Figure 2.2). In fact, any aryl unit that may 
support a Smiles rearrangement can potentially be employed in the Julia olefination 
chemistry, and many other activators have been investigated. Julia described reactions 
where pyridine and pyrimidine heterocyclic sulfones could be employed in olefination. 
Later, Kocienski extended the library of heteroarenes that were able to perform the 
reaction to 1-isoquinolinoyl, 1-methyl-2-imidazolyl, 4-methyl-2-imidazolyl, 4-methyl-
1,2,4-triazol-3-yl, and 1-phenyl-1H-tetrazol-5-yl (PT).93 Advantageously, the 
carbanions of PT-sulfones exhibit a reduced propensity to self-condense as compared to 
the analogous BT-sulfones. More recently, non-heterocyclic aromatics have been used, 
for example bistrifuromethylphenyl94 and hexachlorophenyl,95 to affect the modified 
Julia reaction (Figure 2.2).  
 
S
N N
R
N
NN
N
PYR PT : R = Ph
TBT: R =
t
Bu
N
N
N
N
N N
N N
CF3
F3C
BTFPBT
 
 
Figure 2.2: Aromatic activators commonly used in modified-Julia olefination reactions 
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2.3.2 Recent applications of the modified-Julia olefination 
 
Applications of the modified Julia olefination in target directed synthesis began to 
appear soon after its disclosure. In the asymmetric total synthesis of (-)-callystatin A 
(92) by Smith et al.96 two separate modified Julia olefinations were used to install two 
(E)-olefin moieties (Scheme 2.12). The C6-C7 (E)-alkene was installed using the 
Kocineski-modified process, in which the PT-sulfone 93 was dissolved along with the 
α,β-unsaturated aldehyde 94 in DME and treated with NaHMDS in the presence of 
HMPA. The (E)-olefin 95 was the only product and due to the relative instability of the 
anion of the PT-sulfone 93 the isolated yield of the product 95 was modest. 
 
O
OMe
SO
O
N
N
N
N
Ph
OHC
TESO
(Z) (E )+
O
OMe
TESO
(Z)NaHMDS, HMPA
DME, -78 oC
(35%)
93 94 95
O
92
O
OOH
6
7
6
7
 
Scheme 2.12:  Smith’s Julia example to (-)-callystatin A (92). 
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In a further example, Jacobsen et al.97 observed unprecedented base and solvent effects 
for their PT-sulfone coupling reaction for the advanced intermediate 96 in their 
synthesis of the antifungal agent, (+)-ambruticin. Addition of cyclopropyl PT-sulfone 
97 to aldehyde 98 was strongly dependent on the polarity of the solvent (Scheme 2.13). 
In this specific case, the nature of the counterion was perhaps not the most influential 
factor, since very polar and strongly coordinating solvents such as DMF, HMPA and 
DMPU likely annihilated the possible differences between lithium, sodium and 
potassium cations. Hence, the E/Z ratio correlated well with the increasing polarity and 
coordinating ability of the solvents with counter ion  and afforded 96, the desired E-
isomer almost exclusively (entries 5 and 6, Table 2.2). 
 
OMeO
S
O
O
PT
O
OTBS
CHO
OTBS
TBDPSO
+
O
MeO
O
OTBS
OTBS
TBDPSO
96
97 98
condi tions
(see table)
 
Scheme 2.13: Modified Julia olefination in Jacobsen’s synthesis of (+)-ambruticin  
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Table 2.2: Julia olefination conditions for Jacobsen’s synthesis of (+)-ambruticin 
 
Since its discovery the modified-Julia olefination reaction has become one of the more 
commonly used tools for the assembly of advanced and functionalised intermediates in 
the course of target-directed synthesis.98 Although many of such examples have been 
recently reported, access to functionalised olefins and the grounds for poor 
stereoselectivity of specific substrates are still somewhat unclear and the use of 
functionalised aldehydes or ketones often remains a matter of trial-and-error.99  
 
23.3 Synthesis of C9-C20 olefin 
 
With aldehyde 55 and sulfone 56 in hand, the coupling of the two components was 
required. As outlined above, this transformation proved to be more challenging then 
expected, as detailed in Scheme 2.14 and Table 2.3. Initially employing KHMDS at 
-78 oC (entry 1), led only to recovered starting materials. Elevating the reaction 
temperature from -78 oC to -50 oC following the addition of aldehyde 55 (entries 2-6), 
led to unreliable yields with modest E:Z selectivity, along with significant 
decomposition of the aldehyde coupling partner 55. Gratifyingly, upon switching the 
Entry Condition(s) E/Z 
1 NaHMDS, THF, -78 oC 1:8 
2 KHMDS, DME, 18-crown-6, -60 oC 1:3 
3 KHMDS, DMF, -60 oC 1:1 
4 LiHMDS, THF:HMPA (4:1), -60 oC 3:1 
5 LiHMDS, DMF:HMPA (4:1), -35 oC >30:1 
6 LiHMDS, DMF:DMPU (1:1), -35 oC >30:1 
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base to NaHMDS (entry, 7) the E:Z selectivity improved to synthetically useful levels 
(E:Z = 92:8). However, the yield of the olefin remained unsatisfactory. Gratifyingly, 
upon switching the solvent to DME, efficient coupling of 55 with 56 provided 54 in 
75% yield with essentially complete (E)-selectivity.100  
 
OBn
TBSO
OTBS
TBSO H
OTBS
O
SN
N
N N
Ph
+
OBn
KHMDS, THF, -78 oC
or
NaHMDS, THF, -78 oC
(see table 2.2)
NaHMDS, DME, -78 oC
(75%)
55 56
54
O O
 
Scheme 2.14: Synthesis of (E)-olefin (54) via Julia olefination  
 
 
 
 
 
 
 
 
Entry Condition(s) 55 (mmol) Yield (%) E : Za 
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 a E:Z ratios determined by 1H NMR analysis of crude product mixtures; b not determined 
Table 2.3: Optimisation of reaction conditions for Julia olefination between 55 and 57 
 
2.3.4  Synthesis of olefin epoxide 100 
 
With the olefin 54 in hand, attention was now directed towards the construction of the 
B-ring THF system found in 22. The construction of ether rings through intramolecular 
attack of hydroxyl groups on epoxides has often been applied in the total synthesis of 
polycyclic ethers101 such as monesin,102 lasalocid A,103 and uvaracin.104 Consequently, 
the development of methodology using different parameters such as olefin geometry, 
solvent and epoxidation catalyst to control, the nature of selectivity has remained an 
important synthetic endeavour.  
 
A recent application along these lines in epoxidation-cyclisation methodology was used 
by Forsyth et al.105 for the synthesis of THF rings. In order to utilise this protocol, the 
efficient access to epoxy olefin from 54 was realised. To this end, first both the TBS 
1 KHMDS, THF, -78 oC 0.25 SM - 
2 KHMDS, THF, -78 oC 0.15 15 ndb 
3 KHMDS, THF, -78 oC 0.43 61 80 : 20 
4 KHMDS, THF, 0 oC 1.43 16 ndb 
5 KHMDS, THF, -50 oC 0.49 30 87 : 13 
6 KHMDS, THF, -50 oC 0.1 37 80 : 20 
7 NaHMDS, THF, -78 oC 1.4 34 92: 8 
8 
9 
NaHMDS, DME, -78 oC 
LiHMDS, DME, -78 oC 
0.6 
0.36 
75 
72 
97: 3 
90:10 
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protecting groups were cleanly removed with TBAF to give the diol 99 in excellent 
yield (Scheme 2.15).  
 
OBn
TBSO
OTBS
OBn
HO
OH
99
TBAF, THF
RT, (88%)
54
 
 
Scheme 2.15: Synthesis of diol olefin 99 
 
Formation of the requisite epoxide was facilitated in a one-pot reaction by  treatment of 
99 with NaH and trisyl-imidazole to afford epoxide 100 in excellent yield (Scheme 
2.16).105b However, the use of tosylated-imidazole failed to provide the corresponding 
epoxy olefin, due to the formation of bis-tosylated intermediate 102. This is not found 
in 101, it is due to the increased steric bulk of the triisopropyl benzenesulfonyl group, 
and thus facilitated in achieving discrimination of the primary alkoxide. 
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OBn
HO
OH
99
OBn
TsO
OTs
102
OBn
TrisO
ONa
101
NaH,Ts- Im,THF
0 oC to RT
(60%)
NaH, Tr is-Im,THF
0 oC to RT
OBn
100
O
81%
 
Scheme 2.16: Synthesis of epoxy olefin 100 
 
2.4 Sharpless asymmetric dihydroxylation (SAD) 
 
To strategically position ourselves for tetrahydrofuran ring formation, the origin of the 
diastereoselectivity and regioselectivity for THF cyclisation processes requires the 
consideration of the two chemical transformations, independently.  In the first step, 
Sharpless asymmetric dihydroxylation of olefin 100, the origin of the 
diastereoselectivity arises purely from the choice of cinchona alkaloid ligand,106 either 
(DHQD)2-PHAL (103) in AD-mix-β and (DHQ)2-PHAL (104) in AD-mix-α (Figure 
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2.3). Following the Sharpless mnemonic as outlined in Scheme 2.17. The designations 
L, M and S refer to substituents that are large, medium and small, respectively. 
Employing AD-mix-β will lead to high levels of β-facial selectivity and vice versa for 
AD-mix-α. This model generally predicts the stereochemical outcome of the 
process.107,108  
 
N
MeO
O
NNN
H
N
OMe
N
H
Et Et
(DHQD)2-PHAL- 103
O
N
MeO
O
NN
H
N
OMe
O
N
Et
N
H
Et
(DHQ)2-PHAL- 104
 
Figure 2.3: Two cinchona ligands used in Sharpless asymmetric dihydroxylation 
 
 
S M
H
L
AD-mix-!
AD-mix-"
(DHQD)2PHAL-OsO4
(Add ition f rom above the plane)
(DHQ)2PHAL-OsO4
(Addition from below the plane)
L H
S M
L H
S M
HO OH
HO OH
 
 
Scheme 2.17:  Sharpless mnemonic for prediction of stereochemistry 
 
                                                                                                                        
 Chapter Two 
57 
 
2.4.1 Application of Sharpless asymmetric dihydroxylation 
 
Recent applications of the Sharpless asymmetric dihydroxylation (SAD) reaction in 
acetogenin synthesis include the synthesis of asimicin (26) by Marshall et al.109  The 
bis-THF core unit 105 was constructed through a bidirectional outside-in hydroxyl-
mesylate cascade cyclisation route from 106. Selective dihydroxylation of the central 
non-conjugated double bond in 106 was effectively achieved by exposure to AD-mix-α 
(Scheme 2.18). The resultant diol was converted to mesylate 107 which was subjected 
to treatment with AD-mix-β to effect dihydroxylation of the two (E)-enoates. Upon 
exposure of the intermediate to refluxing pyridine, cyclisation afforded the trans-bis-
tetrahydrofuran 105.          
 
EtO
OEt
O
O
EtO2C CO2EtMsO OMs
O O
EtO2C CO2Et
OH OH
1. AD-mix-!
(73%)
2. MsCl, Et3N
(99%)
1. AD-mix-"
2. Pyridine
(64%, over 3 steps)
106 107
105
O O
OH OH
26
O
OH
O
 
Scheme 2.18:  Marshall’s synthesis towards asimicin 26  
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In a further example, mucoxin (108) was synthesized by Borhan et al.110 using SAD 
conditions to the proposed structure of mucoxin via regio- and stereoselective THF 
ring-forming strategies. Stereoselectivity in the SAD reaction of (Z)-disubstituted 
olefins is generally less than optimal. Evidently, dihydroxylation of 109 is less selective 
and provided triol 110 with 5:1 diastereomeric ratio. The 2,5-disubstituted THF ring in 
111 was conveniently assembled from 110 via a 1,2-n-triol cyclisation strategy.   
 
2.4.2 Dihydroxylation of 100  
 
Having successfully synthesised olefin epoxide (100), the tetrahydrofuran ring 
formation was investigated. The hydroxyl groups had to be stereoselectively installed at 
C15 and C16 simultaneously via an Sharpless asymmetric dihydroxylation.106 To this 
end, the epoxy olefin 100 was treated with a premixed solution of AD-mix-β (0.1 mol% 
of potassium osmate dihydrate, 0.4 mol% of a cinchona alkaloid ligand, 3 eq. of 
K3Fe(CN)6, and 3 eq. of MeSO2NH2) in 1:1 t-BuOH/H2O (Scheme 2.20).108 The 
standard work up sequence, provided the intermediate diol epoxide 53, which could not 
be purified at this stage, due to the susceptibility of the diol epoxide to cyclisation.  
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Scheme 2.19: Borhan’s synthesis of mucoxin 108 
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OBn
100
O
AD-mix!"
CH3SO3NH2
tBuOH-H2O (1:1)
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OBn
53
O
OH
OH
O
HO
OBn
OH
O
OH
OBn
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K2CO3, MeOH
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(67%)
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113 112
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HO
9
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Scheme 2.20: Synthesis of THF ring 112  
 
The second stage of the sequence required the selective 5-exo cyclisation of diol 
epoxide 53 to provide the desired THF ring in 112. In the application of tandem epoxy 
alcohol cyclisations to the synthesis of trans fused polycyclic ethers from epoxides to 
undergo intramolecular opening in a 5-exo, rather than a 6-endo, fashion.101,111 The 
crude epoxy diol readily underwent intramolecular epoxy ring-opening cyclisation in an 
exclusive 5-exo-tet manner upon treatment with K2CO3/ MeOH to give the desired THF 
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derivative 112, which was isolated as a single diastereomer in 67% yield over two steps 
(Scheme 2.20). The regioselective formation of the THF ring 112, i.e 5-exo versus 6-
exo, was found to be predominant.  This inferred that 5-exo-tet cyclisation is kinetically 
favoured over 6-exo-tet.112 
 
With installation of the 2,5-anti substituted THF in 112, the next stage in our synthesis 
was to install the two carbon extension at C20 to complete the construction of the C9-
C21 subunit 51. 
 
2.5 Synthesis of C9-C21 fragment  
2.5.1 C20 oxidation of THF diol 112 
 
With the desired THF diol 112 in hand, we next attempted the selective oxidation of the 
C20 alcohol over the C15 alcohol.113 To this end, treatment of diol 112 with TEMPO, 
BAIB and pH 7 Buffer in CH3CN solvent resulted in decomposition, with no detectable 
formation of aldehyde 114 (Scheme 2.21). The product of decomposition was 
identified as a highly polar substance. It was suspected that the problem with this 
reaction might be the instability of newly formed aldehyde, which was possibly 
forming a lactol by cyclisation of the free secondary C15 hydroxyl. Hence, it was clear 
that protection of the hydroxyl would be required.  
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TEMPO, BAIB,
CH3CN
pH 7 Buffer
O
OH
112
9
15
20
OBnHO
O
OH
114
OBnO
H
 
Scheme 2.21: Attempted oxidation of diol 112  
 
To this end, the secondary and primary hydroxyl groups in diol 112 were protected as 
their TES ethers. Treatment of 112 with TES-triflate and 2,6-lutidine gave the 
corresponding bis-TES ether 115 in 78% yield (Scheme 2.22). It was known that a 
primary TES ether in the presence of a secondary TES ether having an α-oxygen, can 
be selectively oxidised under Swern conditions to provide an aldehyde.114 
Unfortunately the desired product 116 was not isolated. Therefore, a more reliable 
reaction sequence was sought.  
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TESOTf, 2,6-lutidine
DCM, -78 oC
(78%)
(COCl)2, DMSO
Et3N, DCM
-78 oC
O
OH
112
OBnHO
O
OTES
115
OBnTESO
O
OTES
116
OBnO
H
 
Scheme 2.22:  Swern oxidation of TES protected diol 115 
 
Since the selective oxidation with TEMPO, and the corresponding primary TES ether 
oxidation had proven unsuccessful, an alternative strategy was envisioned. Thus, both 
C15 and C20 hydroxyls of diol 112 were protected as their TBS ethers. Selective 
removal of the primary TBS-ether should allow access to the C20 alcohol which would 
be used to access the required aldehyde. This detour, albeit introducing an extra two 
steps, protection and selective deprotection, would conveniently provide reliable access 
to the intermediate aldehyde. 
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2.5.2 Synthesis of THF aldehyde 119 
 
Protection of the diol 112 with TBSOTf and 2,6-lutidine at -78 oC gave the bis-TBS 
ether 117 in 91% yield (Scheme 2.23). Selective removal of primary TBS ether was 
initially attempted by treating the compound 117 with CSA (20 mol%) in DCM/MeOH 
(3:1) and this provided the desired alcohol 118 in 39% yield (Table 2.4). However, the 
selective removal of primary TBS ether in 117 with PPTS (0.2 equiv) in DCM/MeOH 
(3:1) provided the desired mono desilylated product 118, in 65% yield (88% yield 
based on recovered 117).115  
TBSOTf, 2,6-lutidine
DCM, -78 oC
(91%)
conditions
1 or 2
O
OH
112
OBnHO
O
OTBS
117
OBnTBSO
O
OTBS
118
OBnHO
 
 
Scheme 2.23: Synthesis of mono protected diol 118 
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Entry Conditions Yield 
1 
 
 
2 
CSA(20 mol%), DCM:MeOH (3:1), 
30 min., 0 oC 
 
PPTS (20 mol%), DCM:MeOH (3:1), 
3 h, RT 
118 39% 
112 54% 
117 6% 
118 65% 
117 23% 
 
Table 2.4: Conditions for synthesis of mono protected diol 118 
 
With the mono-protected THF diol 118 in hand, oxidation to the aldehyde was 
required. Initial attempts to oxidise the primary alcohol 118 under Swern conditions 
(oxalyl chloride, DMSO and Et3N in DCM) provided the desired aldehyde in low 
yields.  A further attempt employing Parikh-Döering oxidation conditions (SO3.pyr, 
DMSO, DIEA) also proved to be similarly low yielding.116 Gratifyingly, oxidation of 
the alcohol 118 with the Dess-Martin periodinone (DMP), buffered with solid NaHCO3 
in DCM, gave the desired aldehyde 119 in good yield. Purification of 119 was not 
required and aldehyde could be isolated readily by filtration of the reaction mixture 
through a small pad of celite and used immediately in the next step.117  
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9
1520
O
OTBS
119
OBnO
H
condi tions
see table
O
OTBS
118
OBnHO
 
 
Entry Conditions Yield 
1 
2 
3 
(COCl)2, DMSO, Et3N, DCM, -78 oC 
SO3. Pyr, DMSO, DIEA, DCM, RT 
DMP, NaHCO3, DCM, RT, 30 min. 
43% 
49% 
80% 
 
Scheme 2.24: Synthesis of aldehyde 119 
 
2.5.3 Final steps to C9-C21 fragment 
 
The next stage in our synthesis was to install the 2-carbon vinyl extension at C20 to 
complete the construction of diastereomeric THF allylic alcohols 120 and 121. This 
was achieved by the addition of vinylmagnesium bromide to aldehyde 125. This 
provided a 1:1 mixture of diastereomeric allylic alcohols 120 and 121 in 76% combined 
yield (Scheme 2.25). However, this diastereomeric ratio could be improved 
significantly to 4:1 by using divinylzinc in THF, which provided diastereomers 120 and 
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121 in 63% yield (Scheme 2.25). This was expected that the enhanced co-ordination of 
the zinc species through both the furanyl and aldehyde oxygens would deliver the vinyl 
group from one face under chelation control. The mixture of diastereomers (4:1) 
obtained was used directly without further efforts to separate them by HPLC at this 
point. If the proposed synthesis C9-C34 went as expected, then we could have certainly 
looked either for a more selective vinyl addition reaction by using diastereoselective 
zinc catalysts in the later stage or oxidising the C-20 alcohol to ketone followed by 
selective reduction to alcohol. This alternative route could possible to access either 
diastereomer 120 or 121, which will be required at the late stage of the synthesis. 
 
O
OTBS
119
O
OBn
H
O
OTBS
120
OBn
O
OTBS
121
OBn
MgBr
Zn
THF, -40 oC
(76%) dr = 1:1 (120/121 )1.
2.
THF, -40 oC
(63%) dr = 4:1 (120/121 )
HO HO
21 21
9 9
or
15 15
 
 
Scheme 2.25: Synthesis THF (C9-C21) fragments 
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With a successful synthesis of the diastereomeric THF vinyl alcohols in hand, the 
stereochemistry of the C20 hydroxyl group in the major diastereomer was assigned by 
Mosher ester analysis and will be discussed in next section.  
 
2.5.4 Mosher analysis of C-20 hydroxyl in 120 
 
The Mosher method for assigning the configuration of secondary alcohols is based 
upon the assumption that their MTPA derivatives will adopt a preferred conformation 
in solution.118 In CDCl3 solution the carbinol proton, ester carbonyl and trifluoromethyl 
group of the MTPA substituent all lie in the same plane (Fig. 2.4). Consequently, the 
1H NMR signals of protons Ha, Hb, and Hc in the (R)-MTPA ester appear upfield 
relative to the corresponding signals of the (S)-MTPA ester, due to the diamagnetic 
effect of the phenyl group. Conversely, Hx, Hy and Hz in the (R)-MTPA ester appear 
downfield. The absolute configuration is assigned by calculating ∆δ = δS-δR for as 
many as signals as possible. By confirming that protons with δ>0 and protons with δ<0 
lie on opposite sides of the MTPA plane, and by constructing a molecular model, it is 
possible to ascertain the absolute configuration.  
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O
O
CF3
H
HzHyHx
!' "' #'
HaHbHc
! " #
MTPA Plane
Ph OMe (S)-MTPA
(R)-MTPA(OMe) (Ph)
O
H
MTPA
!<0 !>0
Hx
Hy
Hz
Hc
Hb
Ha
 
 
Figure 2.4: Configurational models for Mosher ester analysis 
 
To this end, both (R)- and (S)-MTPA derivatives of the 120 were prepared by treatment 
of 126 with DCC and DMAP in DCM followed by the addition of corresponding (R)- 
or (S)-Mosher acids [α-(trifluoromethyl)phenylacetic acid] (Scheme 2.26). 
 
The presence of phenyl group creates through-space shielding effect on nearby protons 
that occupy the same face. If the predicted stereochemical outcome is correct, the (S)-
MTPA derivative should experience an upfield shift of the CHtrans-C20 protons as the 
phenyl group shields them (Figure. 2.5).  
 
Conversely, the (R)-MTPA derivative should experience an upfield shift on C19-C15 
region. Given this assumption, subtraction of the 1H NMR δ values for the (R)-MTPA 
ester from the (S)-MTPA ester should result in a negative value for the CHtrans-C20 
region and a positive value in the C19-C15 region (Figure. 2.5).  
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Figure 2.5: (S)- and (R)- Mosher NMR expansions for 123 and 122 
 
Analysis of the spectral data for (S) and (R)-Mosher ester derivatives for 120 (Table 
2.5) confirmed the (S)-configuration at C20, which supports that the aldehyde 119 
underwent a Felkin-Anh addition, rather than expected chelation controlled vinyl 
addition to actually provide 1,2-syn product. 
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120
O
OBn
OTBS
122
O
OBn
OTBSOO
MeO
CF3
123
O
OBn
OTBSOO
CF3
(S)-MTPA, DCC,
DMAP,DCM
(47%)
(R)-MTPA, DCC
DMAP, DCM
(54%)
MeO
99
1515
2020
HO
 
Scheme 2.26: (R) and (S)-Mosher ester derivatives of 120 
 
Position δS (ppm) δR (ppm) δS-δR (Δ  ppm) 
CHtrans 5.34 5.38 -0.04 
CHcis 5.27 5.30 -0.03 
H21 5.76 5.89 -0.13 
H20 5.43 5.52 -0.09 
H19 4.20 4.00 +0.20 
H18 Obs† Obs - 
H17 Obs Obs - 
H16 3.99 3.47 +0.52 
H15 4.35 4.20 +0.15 
†Obscured 
Table 2.5: Preparation of (R)- and (S)-MTPA ester derivatives of alcohol 120 
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In summary, a convergent synthesis of the C9-C21 subunit of chamuvarinin has been 
realised. Our approach highlights the application of the Kocienski modification of the 
Julia olefination followed by the Sharpless asymmetric dihydroxylation (SAD) for 
forming the trans-fused tetrahydrofuran ring. A fully functionalised fragment of C9-
C21 subunit was achieved.  
 
With the two diastereomers of THF allylic alcohol (C9-C22 fragments) in hand, our 
attention turned to the synthesis of eight diastereomers of THP alcohols. Those would 
set the stage to attempt the synthesis the proposed library of BCD ring systems of 
chamuvarinin. These studies are discussed in the following chapter. 
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Chapter Three 
Results and Discussion 
 
Synthesis of Diastereomeric C22-C34 Subunit Library 
 
Following the synthesis of the C9-C21 subunit, attention was focussed on the synthesis 
of the library diastereomeric C22-C34 subunits. As detailed in Section 1.6, the 
unknown relative stereochemistry within the C20-C28 region required the synthesis of 
all eight C22-C34 subunits. This chapter details the synthesis of all possible eight 
diastereomeric THP fragments. In turn, coupling of each C22-C34 diastereomeric 
fragment with the corresponding C9-C21 subunit would then facilitate the synthesis of 
a library of 16-membered ring systems.  
 
3.1 Retrosynthesis for C22-C34 subunit 52 
 
In planning our synthetic approach to the C22-C34 subunit of chamuvarinin, it was 
hypothesised that the C22-C34 fragment could be obtained from the corresponding 
epoxy alcohol cyclisation (as outlined in Scheme 3.1). Access to both the syn- and anti- 
fused tetrahydropyranyl system (124 and 127) and the access to both diastereomers at 
C23 was required. This could readily acheived via application of a hydroxy olefin 
cyclisation (125 and 128).  In turn, the hydroxyl olefin could be derived from the 
Grignard opening of either enantiomeric epoxide (126 and 129).  
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O
OBoc
O O
O
OH OH
O
H H
O
**
***
(23= 8 possibl e d iastereomers)
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126
O
129
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+
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22
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2428
Vinyl addition
6-exo cyclisation 6-exo cyclisation
Epoxide opening Epoxide opening
 
 
Scheme 3.1: Retrosynthetic analysis of C22-C34 subunit 52 
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3.2 Synthesis of hydroxy olefin 125 
 
The synthesis began with the preparation of enantiopure octane epoxide 126 using the 
Jacobsen hydrolytic kinetic resolution (HKR), as outlined in Scheme 3.2.  Treatment of 
(±)-epoxide 130 with Jacobsen (R,R)-Co(II)[salen] catalyst (59) in the presence of 
AcOH and H2O provided the enantiopure (R)-octane epoxide 126 in 44% yield after 
Kughelröhr distillation with an optical rotation of  
! 
["]
D
20  + 9.1 (c 3.2, CHCl3) consistent 
with the reported value of 25D][!  +11.2 (c 2.7, CHCl3)
74 and a high level of 
enantioselectivity, along with diol 131. 
O
O
OH
OH
(R,R)-Co(II)[salen](59)
AcOH, H2O, THF
16 h, RT
+
(44%, 126)
(39%, 131)
TsCl, Bu2SnO, NEt3,
DCM, RT, (73%)
O
N N
tBu
tBu
O O
tBu
tBu
Co
59
OTs
OH
K2CO3, MeOH
98%
132129
130
 
Scheme 3.2: HKR reaction of octane epoxide 130 
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Diol 131 was cleanly transformed to corresponding enantiopure (S)-epoxide by 
selective sulfonation of the primary alcohol with p-toluenesulfonyl chloride and Et3N of 
in the presence of dibutyltin oxide (Scheme 3.2). This gave the tosylate 132 in 73% 
yield. Treatment of 132 with potassium carbonate in methanol gave corresponding 
enantiomeric epoxide 129 in 98% yield.  
With the chiral epoxide 126 in hand, elaboration to the THP ring system began 
(Scheme 3.3). Opening of epoxide 126 with homoallylmagnesium bromide119 133 in 
the presence of CuI provided alcohol 125 in 77% yield.  
 
O
OH
BrMg
126 125
133
CuI, THF, -40 oC
(77%)  
Scheme 3.3: Synthesis of olefin 125 
 
3.2.1 Hydroxy olefin cyclisation 
 
According to Baldwin’s rules,120 intramolecular cyclisation of epoxy alcohols should 
favour the formation of the rings containing 3 to 7 carbon atoms via the exo-cyclisation 
mode. The exo-cyclisation of epoxy alcohols is an attractive strategy for the synthesis 
of cis or trans-fused cyclic ether rings. These can be prepared via an in-situ epoxidation 
and cyclisation of the corresponding hydroxy olefins. This motif occurs widely in 
marine polycyclic ether compounds, such as brevetoxin,121 maitotoxin122 and 
cigutoxin.123 Methods for stereoselective construction of fused cyclic ethers via 
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intramolecular cyclisation of epoxy alcohols in the exo-mode have been extensively 
studied.122,124 While considering the present system, the competition between the 6-exo 
tet and 7-endo tet cyclisations; according to the Baldwin’s rules, the formation of the 
six-membered ring via a 6-exo hydroxy epoxide opening is favoured in comparison  to 
the alternative formation of a seven membered ring via a 7-endo ring closure.  
In the event, the tandem epoxidation/cycloetherification reaction proceeded smoothly to 
form the diastereomeric THP alcohols 134 and 135 (Scheme 3.4). Thus epoxidation of 
the olefin 125 with m-CPBA, followed by the addition of 20 mol% camphorsulfonic 
acid (CSA) provided separable THP diastereomers 134 and 135 in 48% and 38% yields 
respectively, with a syn : anti ratio of 5 : 4. As outlined, the low selectivity of this 
process was ideal as our studies were directed towards generating a library of THP 
compounds. 
  
OH OH
O
O
OH
O
OH
m-CPBA, DCM
RT
CSA (20 mol%)
+
125
134, 48% 135, 38%
 
Scheme 3.4: Synthesis of THP alcohols (134 and 135) 
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Efforts to establish the relative stereochemistry of THP products 134 and 135 by NMR 
experiments directly proved unfruitful due to the close proximity of H-24 and H-28 in 
the 1H NMR spectrum.  To circumvent this problem, and to gain a X-ray crystal 
structure of a suitable derivative, the C-23 primary hydroxyl group of 134 was 
derivatised as the 2-nitrobenzoate ester (Scheme 3.5). Treatment of 134 with 2-
nitrobenzoic acid under Mitsunobu conditions (using DIAD, PPh3 and THF) provided 
the corresponding ester 136 in 88% yield.  This conversion produced a downfield shift 
of the H-24, clearly the separating the H-24 and H-28 signals and allowed 1H NMR 
coupling patterns to be assigned. The relative 2,6-syn- stereochemistry was confirmed 
by 1D nOe experiments on the ester 136. From the nOe spectrum of 136, irradiation of 
H-24 showed a significant 7% nOe enhancement to H-28 confirming the syn-
relationship across the THP ring 134.  
O
OH
O
O
O NO2
2-n itrobenzoic acid
DIAD, PPh3, THF
(88%)
O
H
H
O
O2NO
7% nOe
134 136
24
28
 
Scheme 3.5: Confirmation of relative stereochemistry via derivatisation of 134  
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3.2.2 Synthesis of diastereomeric C22-C34 subunits 
 
Having successfully synthesised both syn and anti THP alcohols 134 and 135, 
elaboration of the C-23 terminus of the THP alcohol(s) was required, introducing the C-
23 stereocentre in C-ring of BCD core structure.  To reach this objective the two THP 
alcohols were independently elaborated to the respective allylic alcohols. 
 
Firstly, the syn-THP primary alcohol 134 underwent Swern oxidation (oxalyl chloride, 
DMSO, Et3N in DCM) at -78 oC (Scheme 3.6).125 This provided the corresponding 
aldehyde 137 in 88% yield. With the aldehyde 137 in hand; the introduction of the 
requisite vinyl group was achieved by treatment with vinylmagnesium bromide at -40 
oC in THF. The two diastereomeric alcohols 138 and 139 were isolated after column 
chromatography in 32 % and 58 % yields, respectively (Scheme 3.6). 
 
O
OH
134
O
H
137
O
O
OH
O
OH
(COCl)2, DMSO
Et3N, DCM
-78 oC (88%)
+
MgBr
THF, -40 oC
138, 32% 139, 58%  
 
Scheme 3.6: Synthesis of syn-THP allylic alcohols 138, 139 
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The 23S stereochemistry of the new hydroxyl group in THP allylic alcohol (139) was 
confirmed by using Mosher ester analysis.118 
O
OH
O
O O
Ph
MeO
CF3
(R)- or (S) -MTPA, DCC, DMAP,
DCM, RT, 16 h
139 140, (R)-MTPA (43%)
141, (S) -MTPA (54%)
23 23
 
Scheme 3.7: Mosher ester derivatisation of THP allylic alcohol 139 
 
Analysis of the 1H NMR shifts of Mosher derivatives 140 and 141 (Table 3.1) 
confirmed the (S)-configuration of the C23 hydroxyl centre in 139, consistent with the 
vinyl addition product depicted and as a default the hydroxyl group in 138 was assigned 
as 23R.  
Position δS (ppm) δR (ppm) δS-δR (Δ  ppm) 
CHtrans 5.26 5.37 -0.11 
CHcis 5.22 5.30 -0.08 
H22 5.79 5.89 -0.10 
H23 5.59 5.52 +0.07 
H24 3.50 3.43 +0.07 
H25 Obs Obs - 
H26 Obs Obs - 
H27 Obs Obs - 
H28 3.29 3.19 +0.10 
Table 3.1: Mosher analysis of (R)- and (S)-MTPA ester derivatives of alcohol 139. 
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In an analogous manner, the 2,6-trans THP alcohol 135 underwent Swern oxidation 
and followed by the addition of vinylmagnesium bromide to provide anti-THP allylic 
alcohols 143 and 144 in 48% and 30% yields respectively after column 
chromatography (Scheme 3.8). 
 
O
OH
135
O
H
142
O
O
OH
O
OH
(COCl)2, DMSO
Et3N, DCM
-78 oC (76%)
+
MgBr
THF, -40 oC
143, 48% 144, 30%  
 
Scheme 3.8: Synthesis anti-THP allylic alcohols (143, 144). 
 
Similarly, the 23R stereochemistry of the hydroxyl group in THP allylic alcohol (144) 
was determined using Mosher ester analysis.118  
O
OH
O
O O
Ph
MeO
CF3
(R)- or (S) -MTPA, DCC, DMAP,
DCM, RT, 16 h
144 145, (R)-MTPA (42%)
146, (S) -MTPA (45%)
23
23
 
Scheme 3.9: Mosher ester derivatisation of THP allylic alcohol 144 
  
 Chapter Three 
 
 
82 
Analysis of the 1H NMR shifts of Mosher derivatives 145 and 146 (Table 3.2) 
confirmed the (R)-configuration of the C23 hydroxyl centre in 144, consistent with the 
vinyl addition product depicted and as a default the hydroxyl group in 143 was assigned 
as 23S.  
 
Position δS (ppm) δR (ppm) δS-δR (Δ  ppm) 
CHtrans 5.32 5.44 -0.12 
CHcis 5.25 5.33 -0.08 
H22 5.66 5.82 -0.16 
H23 5.73 5.71 +0.02 
H24 3.82 3.75 +0.07 
H25 Obs† Obs - 
H26 Obs Obs - 
H27 Obs Obs - 
H28 3.29 3.21 +0.08 
†obscured 
Table 3.2: Mosher analysis of (R)- and (S)-MTPA ester derivatives of alcohol 144. 
 
Having successfully synthesised four of the required eight diastereomers from (R)-
epoxyoctane 126. Then we turned our attention to the preparation of the antipodal 
series from the corresponding (S)-epoxide 129.   
 
 
 
  
 Chapter Three 
 
 
83 
3.3 Antipodal series of THP Allylic alcohols 
 
With the successful synthesis of four diastereomers in hand, now our attention was 
turned to prepare the necessary (S)-epoxide employing HKR to establish the antipodal 
THP allylic alcohols. Starting from racemic octane epoxide (130). The enantiopure 
epoxide 129 was obtained in 41% yield after Kugelröhr distillation with an optical 
rotation of  
! 
["]
D
20  - 9.6 (c 2.6, CHCl3) compared with reported data of 25D][! - 11.2 (c 
4.2, CHCl3), along with diol 147.74  
O
O
OH
OH
(S,S)-Co(II)[salen] (148 )
AcOH, H2O, THF
16 h, RT
+
(41%, 129)
(32%, 147)
N N
tBu
tBu
O O
tBu
tBu
Co
148
130
 
 
Scheme 3.10: HKR reaction of octane epoxide 130 
 
Following an identical reaction sequence as discussed section 3.2 the enantiomeric 
cyclisation substrate 129 was synthesised as shown in Scheme 3.11. The SN2 
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displacement at the least hindered side of enantiomerically pure epoxide 129 with 
cuprate derived homoallylmagnesium bromide 133 afforded secondary alcohol 128 in 
72% yield. Cyclisation under already established conditions cleanly delivered the 
separable mixture of two diasteromeric alcohols 149 and 150 in 41% and 32% yields, 
respectively.  
 
O
OH
O
OHm-CPBA, CSA
DCM, 6 h
+
149, 41% 150, 32%
O
BrMg OH
129 128
Cat. CuI, THF
-40 oC ( 72%)
133
 
 
Scheme 3.11: Synthesis of syn- and anti-THP alcohols (155, 156) 
 
Using the previously described method (section 3.3), with these two diastereomeric 
alcohols in hand, the stage was set for elaboration to the corresponding allylic alcohols. 
Under the standard conditions of Swern oxidation,125 followed by the addition of 
vinylmagnesium bromide to the syn-THP aldehyde 151, readily provided the 
corresponding THP allylic alcohols 152 and 153 in 46 % and 37 % yields, respectively. 
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(COCl)2, DMSO
Et3N, DCM
-78 oC (76%)
MgBr
THF, -40 oC
O
OH
149
O
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O
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OH OH
 
Scheme 3.12: Synthesis of syn- THP allylic alcohols (152, 153) 
 
Similarly, anti-THP alcohol 150 readily underwent Swern oxidation, followed by the 
vinylmagnesium bromide addition to provide the corresponding THP allylic alcohols 
155 and 156 in 54% and 31% yields, respectively.  
 
(COCl)2, DMSO
Et3N, DCM
-78 oC (91%)
MgBr
THF, -40 oC,
O
OH
150
O
H
O
154
O
155, 54%
O
156, 31%
+
OH OH
 
 
Scheme 3.13: Synthesis of anti-THP allylic alcohols (155, 156) 
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At this stage, all eight possible diastereomeric THP allylic alcohols have been 
synthesised successfully from octane epoxide 130. In the following chapter, the 
possibilities for the union of C9-C21 and C22-C34 sub units will be discussed.   
  
 Chapter Four 
 
 
87 
Chapter Four 
Results and Discussion 
C-ring formation: Model Studies 
 
After the successful construction of the C9-C21 subunit 120 and the diastereomeric 
C22-C34 subunits, the stage was set to investigate the formation of the central C-ring of 
chamuvarinin. Undoubtedly, a viable synthetic strategy must provide a straight forward 
route to access the BCD core library in order to establish the stereochemistry in the 
C15-C28 region (see section 1.6, Scheme 1.11). 
 
4.1 Retrosynthesis for the construction of C-ring 
 
In planning our synthetic approach (Scheme 4.1), we envisioned that the BCD central 
system could arise from the corresponding dienyl ether fragment 158 via a ring closing 
metathesis. In turn, the adoption of Evans stereoselective etherification of Boc 
carbonates126 could allow us to access the dienyl ether fragment 158. Overall, both the 
ring closing metathesis (RCM) and Evans etherification would offer a serviceable 
means for assembling the stereochemically defined subunits, thereby offering an 
operationally efficient approach to the projected C-ring library synthesis.  
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Scheme 4.1: Synthetic plan for construction of C-ring from 159 and 120. 
 
4.2 Ring closing metathesis studies 
 
In order to establish conditions for the ring closing metathesis (RCM) reaction a model 
study was performed. To this end, initial studies were focussed on utilising syn-THP 
allylic alcohol 139 and THF-allylic alcohol 120 as model substrates for elaboration of 
THP-THF and THF-THF ring systems respectively.   
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4.2.1 Ring closing metathesis background 
 
The ability to build complex molecules either from readily accessible precursors or 
advanced intermediates provides an useful strategy in synthesis. One such approach for 
carbon-carbon bond formation is through the olefin metathesis reaction. The area of 
olefin metathesis reactions has experienced tremendous growth and commands a major 
share of recent synthetic attention.127 Olefin metathesis is a unique carbon skeleton 
redistribution in which unsaturated carbon-carbon bonds are rearranged in the presence 
of metal carbene complexes. A number of reviews have been published on this reaction, 
all of which focus on the ever-increasing use of olefin metathesis in organic synthesis. 
Two applications of this reaction have been in ring-opening metathesis 
polymerisation128 (ROMP) and ring-closing metathesis127d,129 (RCM) of acyclic dienes.  
 
Catalysts most frequently used in the ring-closing metathesis are alkylidene complexes 
of ruthenium (43, 46, 160, Figure 4.1), molybdenum 161 and tungsten 162. Catalysts 
based on molybdenum were introduced by Schrock et al.130 They are highly active and 
were reported to catalyse reactions involving very demanding alkenes. However, the 
major draw back  with molybdenum-based catalysts is their unstable nature, in which 
both their preparation and use require strictly inert conditions including glove box 
handling and the use of degassed solvents. On the other hand, complexes based on 
ruthenium, developed by Grubbs et al.,131 are very stable and have proved to be 
compatible with the presence of many sensitive functional groups including esters, 
amides, ammonium salts, silyl ethers and acetals. 
  
 Chapter Four 
 
 
90 
iPr iPr
N
Mo
Ph
CH3
CH3
H3CC(F3C)2O
H3CC(F3C)2O
N NMes Mes
Ru
PCy3 Ph
Cl
Cl
PCy3
Ru
PCy3 Ph
Cl
Cl
N NMes Mes
Ru
Cl
Cl
O
Grubbs I Grubbs II Hoveyda-Grubbs catalyst
Schrock catalyst
160 43 46
161
N
W
tBu
O
O
iPr
iPr
iPr
iPr
iPr
iPr
Schrock catalyst
162  
Figure 4.1: Commonly used olefin metathesis catalysts 
 
4.2.2 General mechanism for ring closing metathesis reaction 
 
In 1970, Chauvin132 proposed the general mechanistic pathway of ring closing 
metathesis where diene 163 undergoes reaction with metal carbenoid 164 to produce 
165 (Scheme 4.2). This in turns undergoes a intramolecular [2+2] cycloaddition with 
the olefin to give the cyclobutane intermediate 166. Subsequently, a [2+2] 
cycloreversion liberates the cyclic olefin 167 and regenerates the metal alkylidene 164. 
This newly generated metal carbenoid reacts with starting diene in a second 
cycloaddition/cycloreversion reaction.  
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Scheme 4.2: General mechanism for RCM reaction 
 
4.2.3 Applications of RCM in total synthesis 
 
The olefin ring-closing metathesis reaction has become one of the most powerful and 
reliable methods for ring formation in natural product synthesis. A countless array of 
ring systems including medium or large, carbocyclic or heterocyclic have been 
synthesised by this sharp tool. 
Hoveyda and co-workers133 were the first to report a successful ring-closing metathesis 
reaction as part of their total synthesis of SCH38516 (168). In this example, they have 
shown that the trisubstituted olefinic compound 170 can be formed via a ring-closing 
metathesis reaction of 169, upon exposure to 20 mol% of Schrock’s catalyst 171 in 
benzene (60 oC)  to provide macrocycle 170 in 90% yield. 
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Scheme 4.3: Hoveyda’s synthesis of SCH38516 (168) using RCM 
 
In 2000, De Brabander and co-workers134 demonstrated that the desired geometrical 
double bond isomer can be exerted by using the appropriate ruthenium catalyst, in their 
total synthesis of (+)-salicylalamide A (172, Scheme 4.4). The (E)-isomer of the 
macrolactone was obtained by using kinetic controlled conditions. The first generation 
Grubbs catalyst 160 kinetically induced the formation of required (E)-isomer 174 of the 
(+)-salicylihalamide A (172) with high selectivity (E/Z = 10:1).  
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Scheme 4.4: De Brabander’s synthesis of (+)-Salicyliamide A (172)  
 
The modern use of RCM can be tracked to a series of published reports that 
demonstrated the high yielding closure of bis-olefins to provide 5-, 6-, and 7-membered 
rings with a diverse functionality and double bond substitution.135 Finally, olefin 
metathesis is not restricted to alkenes, as alkyne bonds are known to undergo similar 
transformations. Both intermolecular and intramolecular reactions between one double 
bond and one triple bond (enyne metathesis) are catalysed by most ruthenium-based 
catalysts (eg: 43, 46, 160).136 
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4.2.4 Ring closing metathesis model studies  
 
The model study began with the preparation of THP bis-allyl ether from alcohol 139. 
Thus, treatment of 139 with allyl bromide and NaH in THF provided the RCM 
precursor 175 in 81% yield. Under high dilution conditions, to suppress unwanted 
homodimerisation employing Grubbs I (first generation) catalyst 160, the cyclic olefin 
176 was isolated in 89% yield. The internal double bond (introduced from RCM) was 
then reduced effectively by hydrogenation using 10% wt Pd/C in EtOH, to give the 
fully saturated THP-THF system 177 in excellent yield (Scheme 4.5). 
 
O
OH
O
O
O O
O O
NaH,THF
(81%)
Br
Grubbs I cat (160) (5 mol%)
DCM (0.005 M), re flux
(89%)
Pd/C, H2
EtOH
(93%)
139 175
176177  
 
Scheme 4.5: RCM model study for THP allylic alcohol 145 
 
Similarly, the THF fragment 120 underwent ring closing metathesis, and followed by 
the hydrogenation of the resulting cyclic olefin. This process began with the preparation 
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of the corresponding THF bis-allyl ether starting from the 4:1 mixture of diastereomers 
of THF allylic alcohol 120 (Scheme 4.6). Treatment of 120 with allylbromide and NaH 
in THF provided the desired THF bis-allyl ether 178 in 86% yield. Which was then 
treated with Grubbs first generation catalyst at high dilution (0.005 M), followed by the 
hydrogenation with 10% wt Pd/C in EtOAc providing 179 in  68% over two steps. 
 
O
OTBS
120
OBn
HO
O
OTBS
OBn
O
O
OTBS
OBn
O
1. Grubbs I cat. (160) (5 mol%)
DCM (0.005 M), reflux
2. Pd/C, H2, EtOH
(2 steps, 68%)
179
178
NaH,THF
(86%)
Br
 
 
Scheme 4.6: RCM model studies for THF allylic alcohol 120 
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4.3 Stereoselective allylic etherification  
 
Having established ring closing metathesis conditions using Grubbs I (160) catalyst 
with model substrates 178 and 175. The next task was the investigation of the key 
coupling step between the C9-C21 subunit 120 and Boc-carbonate 159 via the Evans 
etherification reaction. Toward this end, THP-allylic carbonate, 159 (C22-C34 
fragment) was synthesised to allow optimisation of this pivotal coupling reaction as 
oulined in Scheme 4.1. 
 
4.3.1 Pd-catalysed allylic etherification  
 
Nucleophilic allylic substitution reactions mediated by transition metal catalysts have  
become one of the key reactions for stereoselective functionalisation of allylic positions 
of organic compounds by creating new C-C, C-O, C-N , C-S and C-P bonds.137 In 1973 
Trost and Fullerton first introduced this concept by establishing the use of the carbon-
carbon double bond as “an activator of α (allylic) position for alkylation reactions”.138 
Subsequently, the Trost group reported a stoichiometric asymmetric variant employing 
chiral bisphosphine ligands.139 In 1977, their catalytic version of this reaction set off a 
storm of work that continues to this day.140 Since this report, the asymmetric palladium-
catalysed allylic substitution had been developed into a versatile transformation, able to 
achieve high selectivities with several classes of substrates.141  
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A broad range of substrates can be now used for this transformation: the allylic moiety 
can have few or as many as substituents as required with a variety of leaving groups, 
which include halides, carboxylates, carbonates, phosphate, sulfinates, alkoxides, 
hydroxide, nitrite, tertiary amines or cyanide. When stabilised carbon or heteroatom 
nucleophiles (soft, pKH<25) are used their attack occurs from the face of the allyl 
moiety opposite to the palladium complex.137b However, when hard carbon 
nucleophiles (pKH>25) are used they undergo a more conventional pathway involving 
direct coordination of the nucleophile to the metal centre (182, Scheme 4.7).142  
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Scheme 4.7: Mechanistic rationale for soft and hard nucleophile in Pd-catalysed 
allylic substitution 
 
The widely accepted mechanism by which palladium oversees the asymmetric allylic 
substitution reaction is depicted in Scheme 4.8. The cycle begins by formation of an 
η2-π-allyl-Pd0 complex (183). Oxidative addition of Pd0 to form the π-allyl species then 
occurs with inversion at the leaving group centre, providing the key η3-π-allyl-Pd2+ 
complex (184). This intermediate has been observed spectroscopically and 
crystallographically.143 A suitable nucleophile then approaches displacing the palladium 
with inversion at either the proximal or distal terminus of the allyl moiety generating a 
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second η2-π-allyl-Pd0 complex (185). Upon decomplexation, the Pd-catalyst is 
generated and the product is released.  
LL LL
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LG
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LG
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= Pd
183
185
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Scheme 4.8: General catalytic cycle for Pd-catalysed allylic substituion  
 
A number of metals other than palladium are able to catalyse this reaction,137b,144 
although palladium still seems to be most widely employed. Such versatility was fully 
exploited by Trost and co-workers145 for example a functionalised phenol 186 was used 
as a nucleophile in the reaction with racemic cyclic carbamate 187 to synthesise an 
early intermediate in their enantioselective total synthesis of morphine 189 (Scheme 
4.9).146 
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Scheme 4.9: Trost Pd-catalysed allylic etherification to (-)-morphine 189146 
 
A significant limitation of this process is when allyl substrates incorporate non-
symmetrical substitution patterns leading to regioselectivity issues.147 In non-
symmetrical η3-allyl intermediates (192), palladium tends to favour delivery of the 
nucleophile to the least sterically hindered terminus of the allyl group, favouring 193 
over 194 as shown in Scheme 4.10. Although a wide variety of metals have been 
applied to this problem, rhodium has emerged as the metal of choice for controlling 
regioselectivity in favour of 194.147,148 
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Scheme 4.10: Regioselctivity in Pd-catalysed allylic substitution 
 
4.3.2 Rhodium catalysed allylic etherification  
 
The first regioselective rhodium-catalysed allylic alkylation was reported by Tsuji and 
co-workers in 1984.149 It was demonstrated that the rhodium catalyst has a memory 
effect with respect to the position of the leaving group (Scheme 4.11). This result was 
attributed to the formation of an σ-allylrhodium complex rather than a complete π-allyl 
complex.  
Me
OCO2Me
Me
Nu
Me Nu
Me OCO2Me
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195
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+
M = RhH(PPh3)3, P
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81% (197 : 198 = 86 : 12)
MeO
O
Et
O
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Scheme 4.11: Tsuji et al. rhodium catalysed allylic alkylation 
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Evans and co-workers reported in 1998, the alkylation of secondary and tertiary 
carbonates using a modified-Wilkinson’s catalyst.150 They demonstrated that the 
enhanced regioselectivity is due to the π-accepting nature of the triorganophosphite 
ligands, which increases the propensity for alkylation at the more substituted site 
(Scheme 4.12). 
 
OCO2Me
R1
R2 R1
R2
MeO2C CO2Me
R1
R2
CO2Me
CO2Me
R1, R2 = alkyl, aryl, H 201 : 202 = 13:1 to > 99:1
RhCl(PPh3)3, P(OR)3
NaCH(CO2Me)2
32%-95%
+
Me
OCO2Me
203
200 201 202
RhCl(PPh3)3, P(OR)3
NaCH(CO2Me)2
THF, 30 oC, 86%
Me
CH(CO2CH3)2
204
97% ee 95% ee  
 
Scheme 4.12: Evans et al. allylic carbonate alkylation using modified Wilkinson 
catalyst150 
 
In order to examine the stereospecificity of the rhodium-catalysed allylic alkylation, 
they examined an enantiomerically enriched allylic carbonate 203. The reaction 
provides the enantioenriched product 204 with almost complete transfer of 
enantiomeric excess (Scheme 4.12). This result was attributed to the formation of a 
configurationally stable enyl or (σ+π) allyl intermediate. This type of intermediate 
provides a model for reactivity as outlined in Scheme 4.13. For example, the enyl 
intermediates 207 and 208 result from a SN2-type reaction of allylic compounds 205 
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and 206, which undergo another SN2-type reaction affording 209 and 210 with net 
retention of configuration, provided the rate of alkylation (k2) is faster than 
equilibration rate (k1/k1) of the specific enantiomers.  
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Scheme 4.13: Mechanistic rationale for stereospecificity in the Rh-catalysed allylic 
alkylation151  
 
Evans and Leahy later described the first rhodium-catalysed allylic etherification with 
ortho-substituted phenols, which demonstrated the use of relatively hindered ortho-
substituted derivatives which will undergo regioselective alkylation (Scheme 4.14).151 
However, this reaction was not applicable to hard alkali metal alkoxides. In order to 
overcome this problem, the metal alkoxide was transmetallated with copper(I) salts to 
soften the nucleophilic character of the alkoxide.152 This protocol provides a general 
approach to a series of allylic carbonates using copper(I) salts. 
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Scheme 4.14: Evans et al. allylic etherification  
Four years later Evans and co-workers126 reported the stereoselective synthesis of 
tetrahydrofuran fragment of (-)-gaur acid 214 by slightly altering their original reaction 
conditions. The THF ring construction was efficiently achieved through the 
stereoselective etherification between Boc-protected allyllic alcohol 215 and allylic 
alcohol 216 (Scheme 4.15).   
O
OBn
TBSO
+
[RhCl(PPh3)3], P(OMe)3
LiHMDS, CuI, THF
0 oC to RT (69%)
215 216
217
O
HO2C
OH
214
OBocTBSO
OBn
HO
 
Scheme 4.15: Evans et al. allylic etherification in synthesis of (-)-gaur acid 214126  
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The possibility of assembling molecular frameworks of high complexity in such a 
manner prompted us to investigate this protocol to assemble our key fragments 159 and 
120 in our present synthetic approach (Scheme 4.1) for the construction of the BCD 
library as found in 157.  
 
4.3.3 Etherification model studies 
 
To gain an understanding of the stereoselective etherification reaction, we undertook a 
further model study involving the key fragments. To this end, a model carbonate 219 
was prepared by treatment of allylic alcohol 219 with n-BuLi and (Boc)2O in THF as 
shown in Scheme 4.16. 
 
OH OBoc
n-BuLi, (Boc)2O
THF (87%)
218 219
O
OH
139
219
(PPh3)3RhCl, P(OMe)3
CuI, LiHMDS
THF, (39%)
O
O
220
 
Scheme 4.16: Etherification studies of THP allylic alcohol 120 with model carbonate 
219 
 
Initial attempts to perform the coupling of Boc-protected allylic alcohol 227 with THP- 
allylic alcohol 139 proved unsuccessful. It was found, through extensive optimisation, 
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that the omission of oxygen and moisture would give improved, although still only 
moderate, yields of product 220 (Scheme 4.16). This involved the strenuous 
purification of each reactant, i.e. pyrolising CuI overnight at 220 oC; degassing the THF 
and freshly distilling P(OMe)3 prior to each attempt at the reaction.  
 
Encouraged by this result, the model study was extended to THF allylic alcohol 120 
with allylic carbonate 219 but the reaction gave only comparatively low yields (27%) 
(Scheme 4.17). The reason for low yields might be the presence of an α-oxygen of 
tetrahydropyranyl and/or tetrahydrofuranyl system. Evans and co-workers also reported 
the same observations in their recent publication for some of the examples bearing an 
α-oxygen, which also gave low yields.59  
 
O
OTBS
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O
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O
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Scheme 4.17: Etherification studies for THF allylic alcohol 120 with model carbonate 
219 
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Even though the yields did not achieve a satisfactory level using the model substrates, 
these conditions were applied to the coupling of the real system. To this end, the Boc-
protected THP allylic alcohol 159 was readily obtained by treatment of THP allylic 
alcohol 139 with n-BuLi and (Boc)2O in THF as shown in Scheme 4.18.  
 
O
OH
139
O
OBoc
159
n-BuLi, (Boc)2O
THF (85%)
 
Scheme 4.18: Preparation of syn-THP allylic Boc 159 
 
Our attention was then turned to the coupling of the key fragments of THP allylic Boc 
159 with the C9-C21 subunit 120 utilising our optimised version of the Evans protocol 
(Scheme 4.18). Disappointingly, the reaction did not occur, even at elevated 
temperatures. The use of 20 mol% Wilkinson catalyst loadings and the use of different 
bases, such as KHMDS and NaHMDS, had little effect on reaction outcome.  
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Scheme 4.19: Etherification studies of allylic alcohols 159 and 120 
 
At this point of the project, further information on the relative stereochemistry of the 
C15-C28 region of chamuvarinin (22) was reported by Poupon and Hocquemiller,153 
which will be detailed in the following section. 
 
4.4 Revised target for chamuvarinin synthesis  
 
Chromatographic fractionation of the hexane extract of the roots of Uvaria chamae P. 
Beauv.(Annonaceae) yielded two acetogenins, chamuvarinin (22) and squamocin (222). 
The latter had been isolated previously from the seeds of Annona reticula L. However, 
the concomitment presence of both 22 and 222 in U. chamae and their structural 
similarity suggested a missing biosynthetic link between the two metabolites (Scheme 
4.20).  
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Scheme 4.20: Structures of squamocin 222 and chamuvarinin 22 
 
In order to test this biosynthetic postulation, Poupon and Hocquemiller153 investigated 
the feasibility of accessing chamuvarinin 22 from squamocin 222 as a way of 
demonstrating this plausible link and also to gain further information concerning the 
stereochemistry of chamuvarinin 22. The authors assumed that, biomimetically 
squamocin (222) bearing an extra hydroxyl group at C-28 might serve as a biological 
precursor for chamuvarinin. In order to investigate this, squamocin 222 was first 
reacted via an acid mediated pathway to gave compound 223 (Scheme 4.21). Finally, 
222 was subjected Mitsunobu-type pathway, which provided a mixture of both 223 and 
224.  The relative cofiguration of the newly formed THP (223: cis configuration and 
224: trans configuration) was established by NMR analysis and by comparision with 
literature data.154,155  
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Scheme 4.21: Possible structures of chamuvarinin 223, 224 from squamocin 222 
 
Nevertheless, the 1H NMR data provided a clear distinction between the two possible 
isomers 223 and 224 with the natural isomer of chamuvarinin (22). Therefore, it was 
concluded that chamuvarinin 22 is unlikely to be directly derived from squamocin 222 
in nature. 
From all the information gathered through chemical synthesis and analysis of 
spectroscopic data of chamuvarinin 22, a plausible stereochemical structure 225 for 
chamuvarinin was proposed by Poupon and co-workers (Figure 4.2).153 The syn  
geometry of the THP ring was assigned upon close examination of the shielded H24-
H28 (3.28 and 3.23 ppm, respectively) protons in the 1H NMR spectrum, as well as 
deshielded C-24 and C-28 (79.9 and 78.8 ppm, respectively) from 13C NMR data. 
Whilst the chemical shifts of THF C-ring could possibly account for a cis-relationship 
by comparison of the literature data with other acetogenins.156 As a result, the correct 
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configuration of chamuvarinin could only be confirmed by synthesis of the correct 
diastereomer. Focus was therefore directed towards this primary objective. 
 
O O O
OH
O
O
15 1202428
BCD
225  
Figure 4.2: Proposed plausible structure for chamuvarinin  
 
4.5 Cross metathesis model studies for the synthesis of C-ring   
 
With the relative stereochemical configuration around the BCD system proposed by 
Poupon and co-workers, it was possible to focus efforts upon the synthesis of this 
putative BCD unit.  
 
In order to alleviate points of failure, a revised synthetic approach was required. Since 
the Rh-mediated etherification had failed in our system, small strategic alterations to 
the approach were necessary to provide a viable alternative procedure. To this end, we 
envisioned that cross metathesis between the two key fragments C22-C34 159 and C9-
C21 120 could provide 226 (Scheme 4.22). The resulting hydroxy olefin 226 would 
serve as a precursor for intramolecular etherification with its neighbouring Boc-
protected pyran ring to form the C-ring. Disappointingly, efforts to couple these two 
key fragments failed and resulted in recovery of the large excess of Boc-protected C22-
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C34 fragment 159. This demonstrates the reactivity of olefin 159, where and also the 
bulky t-butyl group may sterically hinder the reaction site. 
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Scheme 4.22: Cross metathesis reaction between 159, 120 
 
In an attempt to overcome this problem, an alternative protecting group in place of Boc 
at C23 in the C22-C34 fragment was considered. Small alterations need to be adopted 
to differentiate the hydroxyl groups in the cross metathesis outcome will allowing the 
formation of THF ring by SN2 cyclisation. It was hypothesised that a suitably protected 
THP allylic alcohol (either acetate, benzoate) would undergo cross metathesis with a 
THF coupling partner, followed by SN2 displacement to form the new THF ring would 
also serve our purpose (Scheme 4.23). 
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Scheme 4.23: Revised retrosynthetic approach to BCD fragment 227 
 
4.5.1 Cross Metathesis: Back ground 
 
The use of olefin cross-metathesis has garnered attention as a viable tool in organic 
synthesis.157,158 Many fundamental studies on the functional group tolerance, electronic 
factors, and steric parameters required for stereoselective synthesis have been 
investigated with a variety of catalyst systems.158 The amount of work in RCM and 
ring-opening metathesis polymerisation (ROMP) has overshadowed work in the 
intermolecular variant of olefin metathesis, olefin cross-metathesis. This is largely due 
to the mixture of products and low stereoselectivity of the products obtained in the 
reaction, limiting its synthetic practicality (Figure 4.3). Six possible products can be 
obtained including unreacted starting material. The lack of olefin stereoselectivity, as 
well as low product selectivity limits the utility of cross metathesis. However, some of 
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the most exciting work is related to the kinetic cross metathesis product formation by 
slowing the homodimerization of one olefin partner.  
 
R1 R2
R1 R1 R2
R2 R1 R2
+
C2H4-
+ +
(6 possib le products)  
Figure 4.3: Complex mixture obtained in cross-metathesis 
 
Recently, a significant number of new substrate classes that participate in selective 
olefin cross-metathesis reactions have been discovered by the research groups of 
Grubbs and others.157 While a descriptive model of selective cross metathesis processes 
has not been disclosed, investigations of cross metathesis with various classes of olefins 
have led to a general empirical model useful for the prediction of product selectivity 
and stereoselectivity.127b,158 When an olefin of high reactivity is reacted with an olefin 
with lower reactivity (electron-deficient), selective cross metathesis can be achieved. 
The slow rate of dimerisation forces the olefin of lower reactivity to react with cross 
metathesis partner to give high cross meathesis product/dimer ratio and excellent E/Z 
selectivity (up to 95:5). The reaction is even possible with equimolar amounts of cross 
metathesis partners.  
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4.5.2 Applications of cross metathesis in total synthesis 
 
Simultaneously, cross metathesis has been applied in total synthesis generating the rigid 
alkenyl C-C bond motif159. In fact, the central challenges in cross metathesis still centre 
on the elimination of homocoupling products, generating products with good 
stereoselectivity and increasing substrate scope. 
 
Cross metathesis reaction has recently applied to the synthesis of protein kinase C 
activator bistramide A (230) by Kozmin and co-workers (Scheme 4.24).160 They were 
able to install olefin moiety in their intensive approach to the spiroketal domain of the 
targeted product involved the treatment of a mixture of α,β-unsaturated ketone 232 with 
terminal olefin 231 via an intermolecular fragment coupling. They employed cross 
metathesis with Grubbs catalyst II (43) in DCM provided the expected product 234 
with complete E-selectivity. Interestingly, this cross metathesis proceeded efficiently 
employing only one equivalent of each coupling partner, where as many cross-
metatheses require one of the components to be used in an large excess. The convergent 
nature of the synthesis, and the mild reaction conditions of the cross metathesis step 
demonstrate the applicability in total synthesis.  
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Scheme 4.24: Selective cross metathesis reaction in total synthesis of (+)-bistramide A 
230 
 
An excellent use of cross metathesis has been demonstrated by the Ghosh and Gong in 
the total synthesis and structure revision of amphidinolide W (234, Scheme 4.25).161 
Among the various protecting groups and catalysts surveyed, an acetate protecting 
group on the secondary alcohol of 235 and use of Grubbs second generation catalyst 
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(43) (6 mol%) gave the best results in the coupling with intermediate 236. The cross 
metathesis product 237 was formed in 85% yield with good E-selectivity (E/Z = 11:1). 
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Scheme 4.25: Ghosh et al. CM example in total synthesis of amphidinolide W 233 
 
The applications of cross metathesis in several arenas, including materials chemistry, 
bioorganic chemistry and natural product synthesis have been reported. However, the 
grounds for (un) reactivity, and (non) stereoselectivity of specific substrates are still 
somewhat unclear and the use of functionalised olefins often remains a matter of trial-
and-error.  
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4.5.3 Assembling of model substrates 228 and 152 by CM 
 
The revised retrosynthetic approach focussed upon the cross metathesis between the 
two key fragments 228 and 120 (Scheme 4.23, section 4.7). To this end, the required 
coupling partner was synthesised bearing an acetate functionality at the C23 position in 
228. This was readily prepared by treatment of THP allylic alcohol 153 with Ac2O, 
DMAP and NEt3 in DCM, which provided 228 in 95% yield (Scheme 4.26).  
 
OO
Ac2O, DMAP, Et3N
DCM, (95%)
153 228
OH OAc
 
 
Scheme 4.26: Preparation of THP allylic acetate 228. 
 
We then tested THP allylic acetate 228 with available THP allylic alcohol 152 in an 
attempt to find improved conditions for the CM reaction (Scheme 4.27). Initially, the 
Grubbs first generation catalyst was employed, followed by Grubbs second generation 
catalyst, but neither were able to give the desired product. Motto and co-workers had 
previously demonstrated that Grubbs II catalyst would effect this transformation.162 The 
desired product 237 was eventually obtained using Hoveyda-Grubbs second generation 
catalyst (46), however the yields were intolerably low. Further investigation towards 
improving the yield of this reaction halted at this stage, as it became clear that this 
strategy could not be applied effectively in the synthesis of C9-C34 fragment. 
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 Scheme 4.27: CM model studies between 228, 152 
 
 4.5.4 Attempts for assembling C9-C20 and C21-C34 subunits  
 
Applying this catalytic system to couple our targeted C22-C34 (228) and C9-C21 (120) 
subunits therefore proved unsuccessful (Scheme 4.28). We attempted to optimise the 
conditions by using different solvents such as refluxing toluene and benzene but this led 
to significant decomposition of starting materials and didn’t provide any information in 
this reaction. The use of THP vinyl ketone 239 also failed to provide coupled product 
240 (Scheme 4.29). 
Entry Conditions Results 
1 
2 
3 
Grubbs I Cat. 160 (10 mol %), DCM, Δ, 6h 
Grubbs II Cat. 43 (10 mol%), DCM, Δ, 10h 
Hoveyda- Grubbs-II Cat. 46,  DCM, Δ, 16h 
decomposed 
uncharacterised 
37% 
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O
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238
OBn
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Ac H
conditions
see table
+
 
 
 
 
 
 
Scheme 4.28: Attempted CM between fragments 228 and 120 
Entry Conditions Results 
1 
2 
3 
4 
Grubbs I Cat.160 (10 mol %), DCM, Δ, 16h 
Grubbs II Cat.43 (10 mol%), DCM, Δ, 12h 
Grubbs II Cat.43 (10 mol%), Toluene, Δ, 6h 
Hoveyda- Grubbs-II Cat.46,  DCM, Δ, 10h 
No reaction 
Uncharacterised 
Decomposed 
Recovered 224 
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Scheme 4.29: Attempted CM between fragments 239 and 120 
 
With these most obvious failures of the Rh-catalysed etherification and cross metathesis 
reactions we suspected that the co-ordination of the Rh catalyst with the oxygen of 
tetrahydropyranyl and/or tetrahydrofuranyl oxygen with allylic double bond leads to the 
formation of a stable six membered rhoda-cycle (241 or 242) which may account for 
deactivation of the catalytic system (Figure 4.4). These problems precluded further 
work on this route, and a reassessment of our approach to the C9-C34 BCD fragment 
was required. 
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Figure 4.4: Possible six membered Rh-cycle 
 
In conclusion, possible model studies documented here offer a considerable insight into 
an approach towards the construction of BCD fragment by repeated applications of 
RCM, CM and etherification reactions. However, none of the approaches to the C9-C34 
(BCD) backbone of chamuvarinin proved to be practical at this stage and an alternative 
approach was required. These studies are detailed in chapter 5.  
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Chapter Five 
Results and Discussion 
Second Generation Approach Towards the Synthesis of 
Chamuvarinin  
 
Since the difficulties posed in the union of C22-C34 and C9-C21 subunits by both 
Evans etherification and Grubbs cross metathesis, a change of direction was required. 
Revising our reterosynthetic approach to a viable alternative method to couple these 
two fragments was required to complete the entire C9-C34 fragment. 
 
5.1 Revised retrosynthetic analysis: Alkyne addition strategy 
 
Based on previously unsatisfactory results, we decided to reconsider our synthetic 
strategy with the goal of formation of the BCD unit by the union of the key C22-C34 
and C9-C21 subunits. Our revised retrosynthetic analysis is depicted in Scheme 5.1. 
BCD unit 227 would be carried on to compleation of chamuvarinin in the same manner 
as described in Chapter 1 (section 1.6, Scheme 1.11). According to the revised strategy, 
the C9-C34 intermediate 243 could be realised via an alkynation approach.163 In this 
approach a C21-C34 alkyne 244 could be coupled with the C9-C20 aldehyde 119 
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(Scheme 5.1). This alternative route commenced with the synthesis of C21-C34 alkyne 
244. 
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Scheme 5.1: Revised retrosynthetic approach to BCD fragment 227 
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5.2 Synthesis of syn-THP alkyne partners 
 
With the revised coupling strategy in place, efficient access was quickly realised using 
established precursors. Thus, introduction to the requisite alkyne functionality was 
readily achieved by treatment of TMS acetylene with n-BuLi at -78 0C in THF, 
followed by addition to the C23-C34 aldehyde 151 (Scheme 5.2). This reaction 
provided a diastereomeric mixture of the corresponding THP alkynyl alcohols 245 
(78% isolated yield) and 246 (10%) favouring the 1,2-syn product. This work follows 
the predicted Felkin-Anh model of a nucleophile to an aldehyde 151.  
 
O
H
O
TMS
O
OH
TMS
O
OH
TMS
+
n-BuLi, THF, -78 oC
(88%)
151
245 , 78% 246 , 10%  
 
 
Scheme 5.2: Preparation of syn-THP alkyne partners 245, 246. 
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Next, the major diastereomer 245 readily underwent desilylation by treatment with 
K2CO3 in MeOH. This provided the terminal alkyne 247 in 95% yield (Scheme 5.3). At 
this stage the sterochemical outcome of the expected Felkin-Anh addition product was 
established by Mosher ester analysis.  
 
K2CO3, MeOH
(95%)
O
OH
247
O
OH
TMS
245
 
Scheme 5.3: Synthesis of THP alkyne 247 
 
5.2.1 Mosher ester analysis of C-23 hydroxyl in 247  
 
Confirmation of the all syn-configuration in 247 was achieved by Mosher ester 
analysis. To this end, the (R)- and (S)-MTPA ester derivatives 248 and 249 of alcohol 
247 were synthesised in 32% and 41% yields, respectively, (Scheme 5.4) from the 
appropriate Mosher acid, DCC and DMAP in DCM.118 
Analysis of the 1H NMR shifts of the Mosher ester derivatives 248 and 249 (Table 5.1) 
confirmed the (R)-configuration of the C-23 hydroxyl centre, consistent with the 
Felkin-Anh addition model.  
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Scheme 5.4: (R)- and (S)- Mosher ester derivatives for 247 
 
Position δS (ppm) δR (ppm) δS-δR (Δ  ppm) 
H21 2.52 2.48 +0.04 
H23 5.69 5.70 -0.01 
OCH3 3.58 3.59 -0.08 
H24 3.54 3.63 -0.09 
H25 Obs Obs - 
H26 Obs Obs - 
H27 Obs Obs - 
H28 3.25 3.32 -0.07 
H34 0.87 0.87 +0.00 
 
Table 5.1: Mosher analysis of (R)- and (S)-MTPA ester derivatives of alcohol 247 
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5.2.2 Felkin-Anh model for alkynation of 151 
 
Aldehydes such as 151, that possess an α-oxygen at C-24 centre, can be exploited to 
induce synthetically useful levels of stereoselectivity (Figure 5.1). The Felkin-Anh 
model can be used to explain the origins of 1,2-stereoinduction, where (RL= O) is either 
the largest substituent or the group with the lowest lying σ*-orbital.164,165,166 The 
nucleophile attacks from an angle of 109.5o (as prescribed by the Bürgi-Dunitz 
angle)167,168 with a preference for the least hindered approach. Thus the stereogenic α-
centre in 151 is open to Felkin addition-resulting in 1,2-syn product 245 as a major 
diastereomer (~10:1 dr).  
O
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OH
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Figure 5.1: Felkin-Anh model for aldehyde 151 
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5.2.3 Synthesis of C21-C34 fragment 250 
 
Though, the stereochemistry of the C-20 hydroxyl in the major diastereomer 245 
emerged in the undesired configuration, it would be possible to correct it by taking an 
extra step to epimerise this stereocentre. However, the decision was made at this point 
to use the major diastereomer 245 in order to optimise the conditions for the elaboration 
of full C9-C34 fragment.  As both diastereomeric alcohols were serviceable according 
to the synthetic blue print in order to achieve library of BCD systems. We first focussed 
on the major diasteromer 245 for further exploration.  
 
In order to complete the revised C21-C34 fragment, the free hydroxyl in 247 was 
protected as its TBS ether in 88% yield in readiness for the coupling investigation 
(Scheme 5.5)  
 
O
OH
247
O
OTBS
250
TBSCl, Imid., DMAP
DCM, RT, (88%)
 
 
Scheme 5.5: Synthesis of syn-THP alkyne 250 
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5.2.4 Key fragments coupling 
 
With the alkyne 250 in hand, the coupling with aldehyde was then explored to 
demonstrate the applicability of this approach towards the C20-C21 connectivity. The 
desired 1,2-syn selectivity relative to C19, was ideal for this reaction. The overall 
stereocontrol in the reaction is expected to be in favour of 1,2-syn by operation of 
Felkin-Anh control (Figure 5.2). This preference can be enhanced by the bulky nature 
of incoming nucleophile enhancing Felkin-Anh induction and 1,2-syn selectivity. To 
this end, treatment of terminal alkyne 250 with n-BuLi in THF, followed by the 
addition of aldehyde 119 after work-up gave propargylic alcohols 251 and 252 in 81% 
yield with 90:10 dr (Scheme 5.6). The diastereomers proved separable by 
chromatography at this stage but the C20 stereocentre remained undefined. The major 
product 251 (presumed to be the Felkin-Anh diastereomer). However, the method of 
MTPA ester analysis was not deemed viable upon this small amount of material and the 
issue of stereochemical assignment would be addressed at a later stage.  However, it 
was planned that the use of this material would enable further exploration to completing 
into a BCD fragment. 
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Scheme 5.6: Coupling of two key fragments 250 and 119 
 
Having found the solution to the long-standing problem of coupling between two key 
C9-C21 and C21-C34 subunits and establishing the discrimination of the C23 and C20 
hydroxyl groups. Construction of the central C ring via SN2 displacement was required 
and is discussed in the following section.  
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Figure 5.2: Felkin-Anh model for aldehyde 119 
 
5.2.5 Completion of the central BCD fragment 
 
With the two key fragments coupled, our revised approach, reduction of the C21-C22 
alkyne was required. Activation of the resulting alcohol by either mesylation or 
tosylation followed by removal of both TBS ethers would then allow SN2 cyclisation to 
provide a central BCD fragment (Scheme 5.1). 
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5.2.6 Hydrogenation of C21-C22 alkyne 
 
The very first few milligrams of coupled alkyne were gathered after chromatographic 
separation of the two diasteromeric alcohols. The major alcohol 251 was then used in 
studies on the reduction of the C21-C22 alkyne. To this end we first attempted the 
reduction of alkyne with 5% Pt/C under H2 balloon (atm.), this only led to the reduced 
product 253 in 20% yield, however the major product was olefin 254 in 40% along with 
~10% starting material 251 (Scheme 5.7). 
 
Alternative reaction conditions intended to circumvent this problem were explored. One 
such solution was identified in the literature when Takahashi and co-workers were 
successfully employed 10 mol% PtO2 for the reduction of similar system.170 We 
adopted these conditions (10 mol% PtO2 in H2 (atm.) to our system (Table 5.2). At first 
the reaction was very slow and it was later found that extended reaction times were 
needed to drive the reaction to completion.  Unfortunately, this turned to be a very 
costly solution, after a significant amount of intermediate 251 was lost and also benzyl 
deprotection at C9 was observed, which is crucial for discriminating the free hydroxyl 
group in the next step. This protocol served as a prime example of an unreliable 
reaction for the reduction of alkyne in our system. Subsequently, alternative reaction 
conditions intended to circumvent this problem were explored. The hydroxyl-directed 
hydrogenation catalyst [Ir(cod)(PCy3)(py)]PF6 (255) was used.171 However, once again 
only a trace amount of the desired product was formed and it could not be separated 
very well from the major by-product alkene and small amounts of starting alkyne 251.   
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Scheme 5.7: Hydrogenation of C21-C22 alkyne in 251 
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Table 5.2: conditions for hydrogenation of 251 
 
Unfortunately, we couldn’t re-attempt this reaction due to the lack of advanced 
intermediate 251, and its precursor THF aldehyde 119. Further synthetic studies are 
currently in progress in the Florence group. However, the valuable intermediate 251 
was efficiently synthesised from the coupling of two key fragments 250, 119. 
 
In conclusion, we finally identified a feasible approach for the synthesis of the central 
core BCD fragment in order to identify its stereochemistry and subsequently finish the 
total synthesis of the challenging molecule chamuvarinin (225). The synthetic route 
developed here will allow access to the key fragments. The future studies along these 
lines will be discussed separately in the following chapter. 
Entry Conditions Results 
1 
 
2 
 
3 
5% Wt Pt/C (5 mol%), H2 (balloon),DCM, 10 h 
 
PtO2 (10 mol%), H2, EtOH, 2 days 
 
Crabtree’s catalyst 255 (5 mol%), EtOH, H2, 10 h 
20% (253) + 40% 
(254) + 31% (251)   
10% (253) + 
Uncharacterised 
13% (253)+ 25% (251) 
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Chapter Six 
Summary and Future Work  
 
6.1 Final steps towards the BCD fragment  
 
The proposed strategy for the synthesis of the BCD fragment is outlined in Scheme 6.1. 
Activation of the C20 alcohol in 257 as a good leaving group, such as a mesylate, and 
subsequent silyl deprotection at C15 and C23 should induce the SN2 cyclisation to 
provide the 2,5-trans-THF system in 256.   
 
O O
OBn
OTBS
OO
TBS H
253
O O O
OBn
OH
1. MsCl , NEt3, DCM
2. F-, THF
256  
Scheme 6.1: Final steps to BCD fragment 256 
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6.2 Synthesis of proposed BCD fragment 227 
 
Having successfully demonstrated the viability of the alkyne coupling procedure to 
access the advanced intermediate 251 (chapter 5, section 5.2.4), the next focus will be 
the synthesis of the BCD unit 227 proposed by Poupon. This will be achieved by 
Mitsunobu inversion of the C23 centre in 247, followed by TBS protection and 
coupling with aldehyde 119. The advanced intermediate 243 would then be carried 
through the C9-C34 BCD unit by reducing C21-C22 alkyne and application of the SN2 
cyclisation sequence to provide 2,5-cis-THF ring in 227 (Scheme 6.2). 
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Scheme 6.2: Proposed synthesis of BCD unit 227 
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6.2.1 Proposed synthesis of butenolide (C1-C9) unit 
 
The butenolide C1-C9 sidechain would be synthesised following a similar strategy to 
that developed by Marshall and co-workers.172 Our proposed synthesis generates the 
desired butenolide/phosphonium salt, which will be coupled to 284 by means of a 
Wittig olefination.  
 
The known lactone 259 can be readily prepared from phenylthioacetic acid 257 and (S)-
propylene oxide (258, Scheme 6.3).173 Alkylation of the enolate derived from 259 with 
alkyl iodide 260 will provide 261. Oxidation and elimination of sulfoxide will allow the 
formation of butenolide 262. Finally, silyl deprotection of butenolide 262 will provide 
an alcohol, which can be converted to corresponding phosphonium salt (50). 
 
PhS
OH
O
O
O
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O
O
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Scheme 6.3: Proposed synthesis for butenolide side chain 50 
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6.2.2 Completion of chamuvarinin 225 
The completion of chamuvarinin 225 requires a few further steps from the intermediate 
227, this includes the synthesis of aldehyde 284, and will be achieved via TBS 
protection at C15, debenzylation of C9 and subsequent oxidation. This will now set a 
stage for the Wittig olefination with butenolide 50. Finally, the selective reduction of 
the C9-C10 internal olefin (introduced from Wittig reaction) in the presence of 
unsaturated lactone with Wilkinson’s catalyst in ethanol, and the global deprotection 
with TBAF would provide 225.  
O O O
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1. 50, Wittig condition
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O O O
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Scheme 6.4: Completion of chamuvarinin 225 
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Finally, further analogues of the chamuvarinin natural products could be targeted for 
synthesis. This would provide further information on the structure activity relationship 
of the unnatural acetogenin class of compounds, and could generate analogues with 
improved biological characteristics.174  
 
6.3 Summary 
 
The synthesis of the C9-C21 subunit 120, and eight C22-C34 diastereomers has been 
completed. The initial studies in this project into the coupling of these two key subunits 
were unfortunately unsuccessful. However, a number of different synthetic strategies 
were examined and the limits of these various approaches to the synthetic target were 
also examined. Significant progress was been made towards the natural product and the 
reactivity of these systems is better understood. 
 
Beyond the valuable synthetic information gleaned, a substantial number of key 
intermediates for the synthesis of a library of analogues were successfully synthesised. 
And most importantly, after much experimentation and pain-staking process of union 
two key fragments was achieved, which in turn provided an advanced fragment 255 in 
an excellent yield. Further advancement of this fragment to the BCD tricyclic ring 
motif of chamuvarinin will require a further two steps, which will then allow the 
investigation of the stereochemistry around this region to begin.  
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In conclusion, whilst the synthesis of the final target natural product was not completed, 
significant progress was achieved and useful information regarding the BCD fragment 
of chamuvarinin was obtained as a result of these studies. 
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Chapter Seven  
Experimental 
7.1 General Procedures 
All reactions were performed in oven or flame-dried glassware under positive pressure 
of Ar with magnetic stirring unless otherwise stated. 
1H NMR (nuclear magnetic resonance) spectra were recorded on Bruker Avance 300 
(300.1 MHz) instrument, Bruker Avance II 400 (400.1 MHz), Bruker Avance 500 
(499.9 MHz) instrument and referenced using deuterated chloroform. The chemical 
shifts are given in parts per million (ppm) on the delta (δ) scale. The solvent peak was 
used as a reference value, for 1H NMR: CDCl3 = 7.26 ppm, C6D6 = 7.15 ppm. The 
multiplicity of each signal is indicated by: s (singlet); br s (broad singlet); d (doublet); t 
(triplet); q (quartet); sp (septet); or m (multiplet); coupling constant (J) and 
interpretation. The number of protons (n) for a given resonance is indicated by nH. 
coupling constants are uncorrected.  
13C NMR spectra were recorded on a Bruker Avance 300 (75 MHz), Bruker Avance II 
400 (100 MHz), Bruker Avance 500 (125 MHz) at ambient probe temperature using an 
internal deuterium lock. The chemical shift data for each signal are reported in ppm on 
the δ scale (δ TMS = 0) The solvent peak was used as a reference value for 13C NMR: 
CDCl3 = 77.00, C6D6 = 128.00.  
IR (Infrared) specta were recorded on a Perkin-Elmer Paragon series 1000 FTIR 
spectrometer as thin films between potassium bromide discs. Absorption maxima are 
reported in wave numbers (cm-1).  
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Optical specific rotations were recorded using a Perkin Elmer Model 341 automatic 
polarimeter instrument, in cells with a path length of 1 cm and are reported as: 
! 
["]
D
20 , 
concentration (c in g/100 mL) and solvent.  
HRMS and LRMS (High and Low resolution mass spectrometry) were recorded using a 
VG AUTOSPEC mass spectrometer or a Micromass GCT (Time-of-Flight), high 
performance, orthogonal acceleration spectrometer coupled to an Aglient Technologies 
6890N GC system. Electrospray mass spectrometry (ESMS) was recorded on a high 
performance orthogonal acceleration reflecting TOF mass spectrometer, coupled to a 
Waters 2975 HPLC by the University of St Andrews mass spectrometry service 
(School of Chemistry and Biomolecular Sciences) and EPSRC national mass 
spectrometry service (Swansea, UK) using Electron Impact (EI), Chemical Ionisation 
(CI), Fast Atom Bombardment (FAB) or Electrospray Ionisation (ES) techniques. The 
parent ion (M+, [M+H]+, [M+Na]+ or [M+NH4]+) is quoted, followed by significant 
fragments with relative intensities. 
Analytical TLC was performed on E.Merck pre-coated (25 µm) silica gel 60F-254 
plates. Reagent grade ethyl acetate, diethyl ether, pentane and hexanes (commercial 
mixture) were purchased and used as is for chromatography. Visualisation was by 
absorption of UV light, or thermal development after dipping in either an aqueous 
solution of potassium permanganate, potassium carbonate and sodium hydroxide or an 
ethanolic solution phosphomolybdic acid (PMA). 
Kugelrohr bulb-to-bulb distillations were carried out using a Büchi GKR-51 machine. 
Boiling Points are the actual oven temperatures.   
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Reagents and solvents were purified by standard means. Dimethyl sulfoxide (DMSO) 
was dried over CaH2, distilled under high vaccum and stored over 4Å molecular sieves. 
Methanol distilled from magnesium methoxide in a recycling still under nitrogen. Ethyl 
acetate was purified by washing with 5% Na2CO3, and saturated aqueous CaCl2 and 
dried with MgSO4. Dichloromethane (DCM), toluene, tetrahydrofuran (THF) and 
diethyl ether (Et2O) were dried by passage through two coloumns of alumina using a 
MBRAUN (SPS-800) solvent purification system. Diisopropylamine (DIPA) and 
triethyl amine (NEt3) were distilled from CaH2 under argon. Oxalyl Chloride was 
distilled from CaH2 into potassium carbonate under argon. Anhydrous DMF was 
purchased from Aldrich UK and dried by distillation from 4Å molecular sieves under 
nitrogen atmosphere. All other reagents were used as purchased from Aldrich UK, 
Acros UK, Avocado UK, or Molekula. All other chemicals were used as received, 
except where otherwise stated in the experimental procedures. The term “brine” 
describes a saturated aqueous solution of sodium chloride. All experiments were 
performed under anhydrous conditions and an inert atmosphere of argon, using a 
vaccum manifold with argon passed through calcium chloride and self-indicating silica 
gel. Hexane refers to n-hexane and petroleum ether to the fraction boiling between 40- 
60 oC. Room temperature refers to the temperature approximately 25 oC.   
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7.2 Experimental for Chapter two 
 
Preparation of (±)-(tert-butyldimethylsilyl)glycidyl ether (63) 
TBSO
O
1820
63  
To a stirring solution of glycidol 62 (18.3 g, 247 mmol) in DCM (250 mL) was added 
imidazole (16.8 g, 247 mmol) and TBSCl (18.6 g, 124 mmol). The resultant mixture 
was stirred for 3 h at RT before the reaction mixture was partitioned between EtOAc 
(500 mL) and NH4Cl (100 mL). The combined organic extracts were washed with brine 
(100 mL), dried (MgSO4), filtered and concentrated. Purification by flash column 
chromatography with (5% EtOAc:Pet.Ether) provided (27.0 g, 88%) of TBS ether 63 as 
a colourless oil. 
63: Rf  0.55 (20% EtOAc:Pet.Ether); 1H NMR (300 MHz, CDCl3) δ 3.84 (1H, dd, J = 
11.9, 3.2 Hz, H20a), 3.65 (1H, dd, J = 11.9, 4.8 Hz, H20b), 3.11-3.05 (1H, m, H19), 2.75 
(1H, dd, J = 5.2, 4.0 Hz, H18a), 2.63 (1H, dd, J = 5.2, 2.7 Hz, H18b), 0.89 (9H, s, Si-
C(CH3)3), 0.08 (3H, s, Si-CH3), 0.07 (3H, s, Si-CH3). 
These data are in good agreement with Peter, R. et al.175 
 
 
 
 
 
 
  
 Chapter Seven 
 
 
 
145 
Preparation of (S)- (tert-butyldimethylsilyl)glycidyl ether (57) 
TBSO
O
1820
57
 
To a stirred solution of (±)-(tert-butyldimethylsilyl) glycidyl ether (63) (10.0 g, 36.7 
mmol), (R,R)-Co (II) salen catalyst 59 (111 mg, 50 µmol) was added AcOH (44 µL, 
1.55 mmol) and THF (0.8 mL). The reaction mixture was stirred at RT for 30 min, 
cooled to 0 oC and H2O (363 µL, 20.1 mmol) was added in one portion. The reaction 
was allowed to warm to room temperature and stir for 12 h. After this time the solvent 
was removed under reduced pressure and purified using Kugelröhr distillation. The 
recovered epoxide was filtered through silica plug to remove residual water, and the 
THF was removed by concentrated to yield TBS ether 57 (3.91 g, 41%).  
57: Rf  0.55 (20% EtOAc:Hexanes);
! 
["]
D
20  +12.6 (c 3.1, C6H6) compared with data 
reported 25D][!  +13.5 (c 2.8, C6H6);
40 1H NMR (300 MHz, CDCl3) δ 3.84 (1H, dd, J = 
11.9, 3.2 Hz, H20a),  3.65 (1H, dd, J = 11.9, 4.7 Hz, H20b), 3.11-3.05 (1H, m, H19), 2.76 
(1H, dd, J = 5.1, 4.1 Hz, H18a), 2.63 (1H, dd, J = 5.1, 2.7 Hz, H18b), 0.89 (9H, s, Si-
C(CH3)3), 0.08 (3H, s, Si-CH3), 0.07 (3H, s, Si-CH3). 
These data are in good agreement with Jacobsen, E. N. et al.40, 74, 175b 
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Preparation of (S)-6-(tert-butyldimethylsilyloxy)hex-1-en-5-ol (65) 
TBSO
OH
20 18 16
65  
 To a cold (-40 oC), stirred solution of 56 (3.51 g, 12.8 mmol) and copper iodide (7.51 
g, 39.8 mmol) in dry THF (40 mL) was added allylmagnesium bromide (3.20 mL, 19.2 
mmol) dropwise. The resultant black reaction mixture was stirred at this temperature 
for 30 min before being allowed to warm to RT over a period of 4 h. The reaction 
mixture was quenched with saturated aqueous NH4Cl (20 mL). The organic phase was 
separated and kept and the aqueous layer extracted with Et2O (3 x 30 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated. Purification 
by flash column chromatography (10% EtOAc:Pet.Ether) provided hydroxy olefin 65 
(3.31 g, 82%), as a colourless oil.  
65: Rf 0.55 (20% EtOAc:Pet.Ether); 
! 
["]
D
20  +7.5 (c 1.8, CHCl3); IR (neat) 3439, 2930, 
2858, 1256, 1113, 837, 778 cm-1; 1H NMR (300 MHz, CDCl3)  δ  5.83 (1H, ddd, J = 
16.9, 13.2, 10.3, 6.6 Hz, H16), 5.04 (1H, app ddt, J = 17.1, 5.2, 1.7 Hz, CHtrans), 4.96 
(1H, app ddt, J = 10.2, 5.1, 1.7 Hz, CHcis), 3.65 (2H, m, H19 + H20a), 3.40 (1H, m, H20b), 
2.31-2.06 (2H, m, H17), 1.57-1.42 (2H, m, H18), 0.90 (9H, s, Si-C(CH3)3), 0.07 (6H, s, 2 
x Si-CH3); 13C NMR (100 MHz, CDCl3) δ 138.4, 114.7, 71.2, 67.1, 31.9, 29.8, 25.8, 
18.3, -5.3, -5.3.; m/z (ES) 253 (100, [M+Na]+); HRMS (ES)+ Calc. for C12H26O2Si1Na 
[M+Na+] 253.1602, found 253.1600.  
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Preparation of (S)-5, 6-bis (tert-butyldimethylsilyloxy) hex-1-en-5-ol (66) 
TBSO
OTBS
20 18 16
66  
To a stirring solution of alcohol 65 (1.01 g, 3.19 mmol) in DMF (30 mL) were added 
imidazole (696 mg, 10.2 mmol) and DMAP (780 mg, 0.639 mmol), followed by TBSCl 
(1.01 g, 6.71 mmol). The resultant mixture was stirred for 10 h at RT. The reaction 
mixture was then quenched with saturated aqueous NH4Cl (10 mL) and the phases were 
separated. The organic phase was kept and the aqueous phase was extracted with DCM 
(3 x 100 mL). The combined organic phases were washed with brine (50 mL), dried 
(Na2SO4) and concentrated. Purification by flash coloumn chromatography (5% 
EtOAc:Pet.Ether) afforded (1.40 g, 98 %) of bis-TBS ether 66 as a colourless oil.  
65: Rf  0.45 (10% EtOAc:Pet.Ether);
! 
["]
D
20  +9.2 (c 2.1, CHCl3); IR (neat) 2930, 2858, 
1472, 1256, 1117, 835, 775 cm-1; 1H NMR (300 MHz, CDCl3)  δ 5.83 (1H, dddd, J = 
17.0, 13.2, 10.2, 6.5 Hz, H16), 5.01 (1H, app ddt, J = 17.0, 5.3, 1.6 Hz, CHtrans), 4.94 
(1H, ddt, J = 10.1, 4.6, 1.2 Hz, CHcis), 3.71-3.62 (1H, m, H19), 3.52 (1H, dd, J = 9.8, 5.4 
Hz, H20a), 3.40 (1H, dd, J = 9.8, 6.5 Hz, H20b), 2.23-1.98 (2H, m, H17), 1.72-1.58 (1H, 
m, H18a), 1.53-1.39 (1H, m, H18b), 0.88 (9H, s, Si-C(CH3)3), 0.88 (9H, s, Si-C(CH3)3),     
-0.04 (3H, s, Si-CH3), -0.04 (3H, s, Si-CH3), -0.05 (6H, s, 2 x Si-CH3); 13C NMR (75 
MHz, CDCl3) δ 139.1, 114.2, 72.6, 67.3, 33.5, 29.3, 25.9, 25.9, 18.3, 18.1, -4.2, -4.7, 
-5.3, -5.3; m/z (CI) 345 (100, [M+H]+); HRMS (CI) Calc. for C18H41O2Si2 [M+H+] 
345.2643, found 345.2645.  
 
Preparation of (2R/S, 5S)-5, 6-bis (tert-butyldimethylsilyloxy)hexane-1,2-diol (67)  
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TBSO
OTBS
OH
OH
20
16
18
67  
To a solution of the olefin 66 (1.10 g, 2.58 mmol) in THF/water (2:1) (30 mL) was 
added N-methylmorpholine N-oxide (0.61 g, 5.16 mmol) followed by osmium 
tetraoxide (250 µL, 0.01 mmol, 2.5% wt) at RT. The reaction mixture was stirred for 5 
h, before solid Na2SO3 and Na2SO4 were added. After filtration through a Celite pad, 
the filtrate was extracted with DCM (3 x 100 mL) and washed with brine. The organic 
phase was dried (Na2SO4) flitered and concentrated. Purification of the resultant residue 
by flash column chromatography (25% EtOAc:Pet.Ether) afforded diol 67 (930 mg, 
78%), as a colourless oil.  
67: Rf  0.25 (25% EtOAc:Pet.Ether); IR (neat) 3387, 2930, 2858, 1472, 1255, 1102, 
836 cm-1; 1H NMR (300 MHz, CDCl3)  δ 3.82-3.59 (3H, m, H 19 +  H20 ), 3.55 (1H, 
ddd, J = 9.0, 5.6, 3.6 Hz, H16), 3.50-3.38 (2H, m, H16-CH2), 1.76-1.62 (1H, m, H18a), 
1.61-1.45 (3H, m, H18b + H17),  0.89 (9H, s, Si-C(CH3)3), 0.88 (9H, s, Si-C(CH3)3), 0.08 
(3H, s, Si-CH3), 0.06 (3H, s, Si-CH3), 0.05 (3H, s, Si-CH3), 0.04 (3H, s, Si-CH3); 13C 
NMR (75 MHz, CDCl3) δ 72.7, 72.6, 72.4, 72.1, 66.9, 66.8, 68.8, 66.1, 53.4, 30.9, 
30.4, 29.8, 28.4, 28.2, 25.9, 25.8, 18.3, 18.3, 18.2, 18.1, -4.3, -4.4, -4.7, -4.8, -5.3, -5.3, 
-5.4; m/z (CI) 379 (100, [M+H]+); HRMS (CI) Calc. for C17H43O4Si2 [M+H+] 
379.2703, found 379.2704.  
 
 
Preparation of (S)-4,5-bis(tert-butyldimethylsilyloxy)pentanal (55) 
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TBSO
OTBS
H
O
16
20 18
55  
To a stirred solution of 1,2-diol 67 (283 mg, 0.74 mmol) in MeOH/H2O (3:2) (10 mL) 
was added NaIO4 (480 mg, 2.24 mmol) at 0 oC. The reaction mixture was allowed to 
stir at this temperature for 30 min, before being diluted with DCM and washed with 
brine. The organic phase was separated and kept and the aqueous layer was extracted 
with DCM (3 x 10 mL). The combined organic phases were dried (Na2SO4), filtered 
and concentrated to leave the crude aldehyde 55 (254 mg, 98%) which was used 
without any further purification. 
55: Rf 0.6 (20% EtOAc:Hexanes); 
! 
["]
D
20  +7.3 (c 3.1, CHCl3); IR (neat) 2930, 2858, 
1712, 1472, 1256, 1091, 835, 776 cm-1; 1H NMR (300 MHz, CDCl3)  δ 9.76 (1H, s, 
H16), 3.76-3.66 (1H, m, H19), 3.53 (1H, dd, J = 9.9, 5.1 Hz, H20a), 3.37 (1H, dd, J = 
10.1, 7.2 Hz, H20b), 2.48 (2H, dt, J = 7.0, 1.7 Hz, H17), 2.00-1.87 (1H, m, H18a), 1.73 
(1H, app qn,  J = 7.1 Hz, H18b), 0.87 (9H, s, Si-C(CH3)3),  0.86 (9H, s, Si-C(CH3)3),  
0.04 (3H, s, Si-CH3), 0.03 (6H, s, 2 x Si-CH3), 0.03 (3H, s, Si-CH3); 13C NMR (100 
MHz, CDCl3) δ 178.7, 71.7, 66.7, 29.3, 28.9, 25.9, 25.8, 18.3, 18.0, -4.3, -4.8, -5.3, 
-5.4.  
 
 
 
 
Preparation of 7-benzyloxy-heptan-1-ol (68)  
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HO OBn
915
68  
To a cold (0 oC), stirred suspension of NaH (1.74 g, 60% in mineral oil, 45.3 mmol) in 
THF (100 mL) was added 1,7-heptanediol 58 (5.01 g, 37.8 mmol) as a solution in THF 
(100 mL) via cannula. After 30 min, benzyl bromide (3.11 g, 21.6 mmol) in THF (100 
mL) was added drop-wise followed by TBAI (7.03 g, 18.9 mmol) in one portion.  The 
reaction mixture was allowed to warm to RT and stirred for an additional 6 h.  The 
reaction mixture was quenched with careful dropwise addition of MeOH (20 mL) then 
satuarated aqueous NH4Cl (100 mL). The aqueous phase was extracted with Et2O (3 x 
200 mL) and the combined organic phases were washed with brine (100 mL), dried 
(Na2SO4), filtered and concentrated. Distillation at reduced pressure yielded the mono 
protected alcohol 68 (3.50 g, 69 %), as a clear pale yellow oil (bp = 121 oC at  1 mm 
Hg); along with recovered diol 58 (1.01 g, 20%). 
68: Rf 0.50 (20% EtOAc:Hexanes); IR (neat) 3382, 2933, 2858, 1539, 1454, 1099, 737, 
698 cm-1; 1H NMR (300 MHz, CDCl3)  δ 7.36-7.33 (4H, m, Ar-H), 7.31-7.27 (1H, m, 
Ar-H), 4.50 (2H, s, Ph-CH2), 3.64 (2H, t, J = 6.6 Hz, H9),  3.47 (2H, t, J = 6.5 Hz, H15), 
1.68-1.51 (4H, m, H14 + H10), 1.45-1.30 (6H, m, H11 + H12 + H13), 1.23 (1H, app broad 
s, OH); 13C NMR (75 MHz, CDCl3) δ 138.9, 128.8, 128.1, 127.9, 78.0, 77.2, 73.0, 
39.0, 33.3, 30.1, 29.6, 26.0.; m/z (CI) 223 (100, [M+H]+); HRMS (CI)  Calc. For 
C14H23O2 ([M+H]+) 223.1695, found 223.1693. These data are in good agreement with 
Feringa, B. L et al.176  
 
Preparation of 5-(7-benzyloxy-heptylsulfanyl)-1-phenyl-1H-tetrazole (69)  
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BnO S N
N
NN
Ph
9 15
69  
To a cold (0 oC), stirred solution of 7-benzyloxy-heptan-1-ol 68 (3.10 g, 13.5 mmol), in 
THF (100 mL) was added 1H-mercaptophenyltetrazole (3.12 g, 17.5 mmol), PPh3 (4.60 
g, 17.5 mmol) followed by DIAD (2.46 mL, 17.5 mmol) drop-wise. The reaction 
mixture was allowed to warm to RT for 1.5 h, before a saturated aqueous NH4Cl (50 
mL) and EtOAc (100 mL) were added. The organic phase was separated and kept, 
whilst the aqueous phase was extracted with EtOAc (3 x 100 mL). The combined 
organic phases were dried (Na2SO4), filtered and concentrated. Purification by flash 
column chromatography (20% EtOAc:Pet.Ether) gave sulfide 69 (4.50 g, 83 %) as a 
colourless oil, which was used directly in the subsequent transformation. 
69: Rf  0.3(25% EtOAc:Pet.Ether); IR (neat) 3064, 3030, 2933, 2857, 1499, 1092, 761, 
696 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.60-7.52 (5H, m, Ar-H), 7.35-7.31 (4H, m, 
Ar-H), 7.31-7.26 (1H, m, Ar-H), 4.49 (2H, s, Ph-CH2), 3.46 (2H, t, J =  6.4 Hz, H9), 
3.39 (2H, t, J = 7.4 Hz, H15), 1.83 (2H, app qn, J = 6.8 Hz, H10), 1.62 (2H, app qn, J = 
6.6 Hz, H14), 1.52-1.35 (6H, m, H11 + H12 + H13); 13C NMR (75 MHz, CDCl3) δ 148.5, 
132.8, 130.0, 129.7, 129.3, 128.3, 127.6, 127.5, 123.8, 123.6, 72.8, 70.2, 33.4, 29.6, 
28.0, 28.8, 25.9; m/z (CI) 383 (100, [M+H]+); HRMS (CI) Calc. For C21H27N4OS 
[M+H+] 383.1902, found 383.1906. 
 
 
 
Preparation of 5-(7-benzyloxy-heptane-1-sulfonyl)-1-phenyl-1H-tertrazole (56)   
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BnO S N
N
NN
Ph
O
O9 15
56  
A mixture of ammonium molybdate (1.60 g, 1.30 mmol) and hydrogen peroxide (2.2 
mL, 59.4 mmol, 30% v/v) were allowed stir at 0 oC for 15 min. An aliquot of the 
resulting bright yellow solution (1.0 mL) was added drop-wise at 0 oC to a solution of 
sulfide 69 (2.00 g, 5.90 mmol) in EtOH (50 mL). The reaction mixture was stirred for 
1 h at RT before the residual oxidant (1.2 mL) was added and stirred for 10 h. The 
reaction mixture was then diluted with EtOH (40 mL) and filtered. The filtrate was 
partioned between water (20 mL) and DCM (60 mL). The organic phases were 
separated and the aqueous layer was extracted with DCM (3 x 20 mL). The combined 
organic phases were dried (Na2SO4), filtered and concentrated. Purification by flash 
coloumn chromatography (20% EtOAc:Pet.Ether) provide a sulfone 56 (1.80 g, 80%) 
as a viscous colourless oil. 
56: Rf  0.25 (25% EtOAc:Pet.Ether); IR (neat) 3064, 3030, 2934, 2858 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.65-7.58 (2H, m, Ar-H), 7.57-7.52 (4H, m, Ar-H), 7.29-7.23 (3H, 
m, Ar-H), 7.23-7.19 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 3.72 (2H, m, H15), 3.46 (2H, 
t, J = 6.3 Hz, H9), 2.02-1.88 (2H, m, H10), 1.67-1.60 (2H, m, H14), 1.54-1.45 (2H, m, 
H11), 1.43-1.32 (4H, m, H12 + H13); 13C NMR (75 MHz, CDCl3) δ 130.3, 130.1, 129.5, 
128.7, 128.0, 127.9, 125.4, 123.8, 77.6, 73.1, 70.3, 56.3, 33.3, 29.9, 29.1, 28.4, 26.2; 
m/z (CI) 437 (100, [M+Na]+); HRMS (CI+) Calc. For C21H26N4O3SNa [M+Na+] 
437.1623 found 437.1624. 
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Preparation of (2S,5E)-(12-(benzyloxy)-1,2-bis(tert-butyldimethylsilyloxy)dodec-ene 
(54) 
20 16
TBSO
OBn
OTBS 9
54  
To a cold (-78 oC), solution of sulfone 57 (438 mg, 1.14 mmol), in DME (6 mL) was 
added NaHMDS (2.0 mL, 0.6 M in toluene, 1.20 mmol). After 5 min, a solution of 
freshly prepared aldehyde 55 (250 mg, 0.78 mmol) in DME (3 mL) was added drop-
wise via a cannula. The reaction mixture was allowed to warm up to -50 oC for 3 h. A 
saturated aqueous NH4Cl (3 mL) was added and the reaction mixture was warmed to 
RT. The aqueous phase was extracted with ethyl acetate (8 x 5 mL) and the combined 
organic extracts were washed with brine. The organic phase was dried (Na2SO4) filtered 
and concentrated. Purification by flash column chromatography (5% EtOAc:Hexanes) 
provided olefin 54 (200 mg, 75%) as (97:3) as a mixture of E:Z isomers as a colourless 
oil. 
 54: Rf 0.4 (10% EtOAc:Hexanes); 
! 
["]
D
20  -21.4 (c 3.1, CHCl3); IR (neat) 3029, 2930, 
2857, 1254, 1115, 835, 776 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36-7.21 (4H, m, Ar-
H), 7.31-7.26 (1H, m, Ar-H), 5.42-5.37 (2H, m, H15 + H16), 4.50 (2H, s, Ph-CH2), 3.73-
3.60 (1H, m, H19), 3.56-3.36 (4H, m, H20 + H9), 2.24-1.91 (4H, m, H17 + H14), 1.69-1.52 
(4H, m, H18 + H10), 1.40-1.27 (6H, m, H13 + H12 + H11), 0.89 (9H, s, Si-C(CH3)3), 0.88 
(9H, s, Si-C(CH3)3), 0.05 (6H, s, 2 x Si-CH3), 0.05 (3H, s, Si-CH3), 0.04 (3H, S, Si-
CH3); 13C NMR (75 MHz, CDCl3) δ 138.6, 130.3, 130.1, 128.3, 127.6, 127.6, 127.4, 
72.8, 72.6, 70.4, 67.3, 34.3, 32.5, 29.7, 29.5, 28.9, 28.2, 26.0, 25.9, 18.3, 18.1, -4.2, -
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4.7, -5.3, -5.3; m/z (CI) 557 (100, [M+Na]+); HRMS (CI+) Calc. for C31H58O3Si2Na 
[M+Na+] 557.3822, found 557.3816. 
Preparation of (2S,5E)-9-benzyloxy-dodec-16ene-19,20diol (99) 
20 16
HO
OBn
OH 9
99  
To a cold (0 oC), stirred solution of olefin 54 (250 mg, 0.46 mmol), in THF (4 mL) was 
added TBAF (2.8 mL, 2.81 mmol, 1 M solution in THF). The reaction mixture was 
stirred at this temperature for 10 min before being allowed to warm to RT for 10 h. The 
reaction mixture was diluted with ethyl acetate (20 mL) and poured into water (5 mL). 
The organic phase was separated and kept. The aqueous layer was extracted with 
EtOAc and washed with brine (5 mL). The combined organic phases were dried 
(Na2SO4), filtered and concentrated. Purification by flash column chromatography (0-
5% MeOH/DCM) gave the diol 99 (126 mg, 88 %) as a colourless oil. 
99: Rf 0.2 (25% EtOAc:Hexanes);
! 
["]
D
20  -19.6 (c 2.7, CHCl3); IR (neat) 3384, 2929, 
2854, 1453, 1402, 1100, 969 cm-1; 1H NMR (300 MHz, CDCl3) δ  7.35-7.32 (4H, m, 
Ar-H ), 7.30-7.26 (1H, m, Ar-H), 5.50-5.33 (2H, m, H16+ H15), 4.49 (2H, s, Ph-CH2), 
3.76-3.66 (1H, m, H19), 3.62 (1H, dd, J = 11.0, 3.0 Hz, H20a), 3.49-3.38 (3H, m, H20b + 
H9), 2.36 (2H, app broad s, 2 x OH), 2.22-2.00 (2H, m, H17), 2.01-1.97 (2H, dd, J = 
11.9, 6.4 Hz, H14), 1.66-1.54 (2H, m, H18), 1.53-1.43 (2H, m, H13), 1.40-1.28 (6H, m, 
H10 + H11 + H12); 13C NMR (300 MHz, CDCl3) δ 138.5, 131.3, 129.2, 128.3, 127.6, 
127.4, 72.8, 71.7, 70.4, 66.6, 32.8, 32.4, 29.6, 29.3, 28.9, 28.6, 26.0; m/z (CI) 329 (100, 
[M+Na]+);  HRMS (CI+) Calc. for C19H30O3Na [M+Na+] 329.2093, found 329.2095. 
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Preparation of (2S,5E) 2-(10-benzyloxy-dec-3-enyl)-oxirane (100)   
20 16
OBn
O 915
100  
To a  cold (0 oC), stirred suspension of NaH (46.3 mg, 1.15 mmol, 60 wt% dispersion 
in mineral oil) in THF (2.0 mL) was added a solution of diol 99 (118 mg, 0.38 mmol) in 
THF (4 mL). The reaction mixture was allowed to warm to RT over 1 h before being 
re-cooled to 0 oC. Slow addition of N-(2,4,6-triisopropylbenzenesulfonyl) imidazole 
(128 mg, 0.38 mmol) in THF (4 mL) then followed via cannula. The reaction mixture 
was allowed to warm to RT and stirred for an additional 2 h. The reaction mixture was 
then cautiously quenched with MeOH (5 mL), followed by NH4Cl (5 mL). The phases 
were separated and the aqueous phase was extracted with Et2O (3 x 20 mL). The 
combined organic phases were washed with brine, dried (Na2SO4), filtered and 
concentrated. Purification of the crude material by flash coloumn chromatography 
(10% EtOAc:Pet.Ether) gave epoxide 100 (89 mg, 81%) as a colourless oil. 
100: Rf  0.5 (25% EtOAc:Pet.Ether);
! 
["]
D
20  -15.1 (c  2.6, CHCl3); IR (neat) 3013, 2929, 
2854, 1453, 1407, 1103, 969, 736 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.32 (4H, 
m, Ar-H), 7.30-7.26 (1H, m, Ar-H), 5.52-5.34 (2H, m, H15 + H16), 4.50 (2H, s, Ph-CH2), 
3.46 (2H, t,  J = 6.6 Hz, H9), 2.96-2.88 (1H, m, H19), 2.74 (1H, dd, J = 5.0, 4.0 Hz, 
H20a),  2.47 (1H, dd, J = 5.0, 2.7 Hz, H20b),  2.24-2.09 (2H, m, H18), 2.02-1.92 (2H, m, 
H17), 1.66-1.54  (4H, m, H14 + H13),  1.41-1.24 (6H, m, H10 + H11 + H12); 13C NMR (75 
MHz, CDCl3) δ 138.6, 131.3, 128.8, 128.3, 127.5, 127.4, 72.8, 70.4, 51.9, 47.2, 32.5, 
32.4, 29.7, 29.4, 28.9, 26.0; m/z (CI) 311 (100, [M+Na]+); HRMS (CI+) Calc. For 
C19H28O2Na ([M+Na+]) 311.1987, found 311. 1984. 
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Preparation of (2S,5R,6R)10-benzyloxy-1-oxiranyl-decane-3,4-diol (53)  
20
OBn
O
OH
OH
16
15
9
53  
To a cold (0 oC), stirred solution of oxirane  100 (1.20 g, 4.16 mmol) in t-BuOH/H2O 
(1:1, 40 mL) was added AD-mix-β (4.95 g, 1.19 g/1 mmol) and methanesulfonamide 
(415 mg, 4.36 mmol). The reaction mixture was allowed to warm to RT for 10 h, before 
being quenched by the addition of sodium sulfite (~500 mg) and stirred for an 
additional 30 min. After dilution with EtOAc (100 mL) and water (20 mL) the organic 
phase was separated and kept. The aqueous phase was extracted with EtOAc (3 x 100 
mL) and the combined organic phases were washed with brine (50 mL), dried 
(Na2SO4), filtered and concentrated. The crude product was used directly used in the 
subsequent transformation. 
53: Rf  0.15 (25% EtOAc:Hexane); IR (DCM) 3512, 3497, 2932, 1402, 1100, 738 cm-1; 
m/z (CI) 345 (100, [M+Na]+); HRMS (CI+) Calc. for  C19H30O4Na [M+Na+] 345. 2042, 
found 345.2046. 
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Preparation of (2S,5S,6R)7-benzyloxy-1-(5-hydroxymethyl-tetrahydro-furan-2yl)-
heptan-1-ol (112) 
O
OH
OBn
20
16
15
9
112
HO
 
To a cold (0 oC), stirred solution of crude diol epoxide 59 (1.70 g, 5.27 mmol), in 
MeOH (60 mL) was added K2CO3 (4.40 g, 31.6 mmol). The reaction mixture was 
allowed to warm to RT for 10 h. The reaction mixture was partitioned between EtOAc 
(100 mL) and NH4Cl (25 mL) and the organic phase separated and kept. The aqueous 
phase was extracted with EtOAc (3 x 100 mL). The combined organic phases were 
dried (Na2SO4), filterered and concentrated. Purification by flash column 
chromatography (40-50% EtOAc:Pet.Ether) gave tetrahydrofuran 112 (1.12 g, 67%) as 
a colourless viscous oil.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
112: Rf 0.2 (30% EtOAc:Pet.Ether); 
! 
["]
D
20  +11.9 (c 2.5, CHCl3); IR (neat) 3520, 3497, 
2929, 2854, 1453, 1407, 1103, 969, 736 cm-1; 1H NMR (300 MHz, CDCl3) δ  7.36-7.32  
(4H, m, Ar-H), 7.31-7.27 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 4.17-4.02 (1H, m, H16), 
3.87-3.72 (2H, m, H20a + H19), 3.58-3.39 (4H, m, H20b + H15 + H9), 2.36 (1H, app broad 
s, C15-OH), 2.13 (1H, app broad s, C20-OH), 2.00-1.91 (2H, m, H17 ), 1.87-1.70 (2H, 
m, H18), 1.69-1.59 (2H, m, H14), 1.54-1.43 (2H, m, H13), 1.42-1.31 (6H, m, H10 + H11 + 
H12); 13C NMR (300 MHz, CDCl3) δ 138.6, 127.6, 82.9, 79.8, 74.3, 72.8, 70.4, 65.2, 
34.0, 29.6, 29.4, 28.2, 27.2, 26.1, 25.6; m/z (CI) 345 (100, [M+Na]+); HRMS (CI+) 
Calc. for C19H30O4Na [M+Na+] 345. 2042 , found 345.2036.  
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Preparation of (R)-7-(bezyloxy)-1-(2R,5R)-5-[(triethylsilyloxy)methyl](terahydrofuran-
2-yl-hept -yloxy)triethylsilane (115) 
O
OTES
OBnTESO
20
15
9
115  
To a cold (-78 oC), stirred solution of tetrahydrofuranyl diol 112 (111 mg, 0.34 mmol), 
in dry DCM (15 mL) was added freshly distilled 2,6-lutidine (200 µL, 1.72 mmol) and 
TESOTf (222 µL, 1.03 mmol). The reaction mixture was stirred at -78 oC for 1.5 h, 
before a saturated aqueous NH4Cl (5 mL) and Et2O (20 mL) were added. The organic 
phase was separated and kept, and the aqueous phase extracted with Et2O (3 x 20 mL). 
The combined organic phases were dried (Na2SO4), filtered and concentrated. 
Purification by flash coloumn chromatography (10% EtOAc:Pet.Ether) provided (148 
mg, 78%) of bis-triethylsilyl ether (115) as a colourless oil.  
115: Rf 0.4 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  +9.8 (c 1.8, CHCl3); IR (CCl4) 3031, 2930, 
2857, 1550, 1471, 1388, 1097, 837 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.31 (4H, 
d, J = 4.5 Hz, Ar-H), 7.31-7.26 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 4.02-3.88 (1H, m, 
H15), 3.87-3.78 (1H, m, H16), 3.67-3.56 (2H, m, H20a + H19), 3.53-3.41 (3H, m, H20b + 
H9), 1.98-1.57 (6H, m, H17 + H18 + H24), 1.51-1.20 (8H, m, H10 + H11 + H12 + H13), 0.95 
(18H, t, J = 7.9 Hz, 2 x Si-CH2(CH3)3), 0.62 (6H, dd, J = 7.8, 2.3 Hz, Si-(CH2)3), 0.57 
(6H, dd, J = 7.7, 1.8 Hz, Si-(CH2)3); 13C NMR (100 MHz, C6D6) δ 140.2, 129.2, 129.0, 
128.0, 83.7, 80.5, 75.0, 73.5, 71.3, 66.5, 35.6, 34.6, 30.8, 30.5, 29.4, 29.2, 28.9, 28.3, 
27.2, 26.8, 26.6, 7.6, 7.5, 5.4, 5.2; m/z (CI) 573 (100, [M+Na]+); HRMS (CI+) Calc. For 
C31H58O4Si2Na [M+Na+] 573.3765, found 573.3771.  
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Preparation of (R)-7-(benzyloxy)-1-(2R,5R)-5-((tert-butyldimethylsilyloxy)methyl)-
tetrahydro -furan-2-yl)heptyloxy(tert-butyldimethylsilane) (117) 
O
OTBS
OBnTBSO
20
15
9
117  
To a cold (-78 oC), stirred solution of tetrahydrofuranyl diol 112 (278 mg, 0.86 mmol), 
in dry DCM (25 mL) was added freshly distilled 2,6-lutidine (200 µL, 1.72 mmol) and 
TBSOTf (0.59 mL, 4.31 mmol). The reaction mixture was stirred at -78 oC for 1.5 h, 
before saturated aqueous NH4Cl (10 mL) and Et2O (30 mL) were added. The organic 
phase was separated and kept, and the aqueous phase extracted with Et2O (3 x 30 mL). 
The combined organics phases were dried (Na2SO4), filtered and concentrated. 
Purification by flash coloumn chromatography (5% EtOAc:Pet.Ether) provided (430 
mg, 91%) of bis-tert-butyldimethylsilyl ether (117) as a colourless oil.  
117: Rf 0.4 (10% EtOAc:Hexane); 
! 
["]
D
20  +12.1 (c 1.9, CHCl3); IR(CCl4) 3031, 2930, 
2857, 1496, 1462, 1361, 1005, 939 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.31 (4H, 
Ar-H), 7.31-7.26 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 4.10-4.03 (1H, m, H15), 3.99-
3.92 (1H, m, H20a), 3.61 (2H, m, H20b + H16), 3.52 (1H, dd, J = 10.3, 4.6 Hz, H19), 3.45 
(2H, t, J = 6.6 Hz, H9), 1.97-1.74 (2H, m,  H17), 1.74-1.57 (4H, m, H18 + H14), 1.45-1.20 
(8H, m, H10 + H11 + H12 + H13), 0.88 (18H, s, 2 x Si-(CH3)3), 0.05 (3H, s, Si-CH3), 0.04 
(3H, s, Si-CH3), 0.04 (6H, s, 2 x Si-CH3); 13C NMR (75 MHz, CDCl3) δ 137.3, 128.7, 
128.0, 127.1, 82.8, 80.0, 78.5, 77.6, 73.2, 70.8, 34.6, 33.3, 31.3, 29.6, 28.5, 26.6, 26.4, 
26.3, 18.2, 18.2, -3.9, -4.2, -4.7, -4.9; m/z (ES) 573 (100, [M+Na]+); HRMS (ES+)  
Calc. for C31H58O4Si2Na [M+Na+] 573.3729, found 573.3771. 
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Preparation of (2R,5R)-5-(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy)heptyl-
tetrahydro-furan-2-yl-methanol (118) 
O
OTBS
OBnHO
20
15
9
118  
Method A: 
To a cold (0 oC), stirred solution of bis-tert-butyldimethylsilyl ether 118 (440 mg, 0.79 
mmol) in MeOH/DCM (1:3, 10 mL) was added CSA (40.3 mg, 0.16 mmol). The 
reaction mixture was stirred at the same temperature for 30 min., before being 
partitioned between NaHCO3 (5 mL) and DCM (20 mL). After dilution with DCM (10 
mL), the organic phase was seperated and kept. The aqueous phase was extracted with 
DCM (3 x 10 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated. Purification by flash chromatography (5-15% EtOAC:Pet.Ether) gave 
alcohol 118 (145 mg, 39%) as a colourless oil and diol 112 (230 mg, 54%). 
 
Method B: 
To a cold (0 oC), stirred solution of bis-tert-butyldimethylsilyl ether 117 (425 mg, 0.77 
mmol) in MeOH/DCM (1:3, 8 mL) was added PPTS (38.3 mg, 0.15 mmol). The 
reaction mixture was stirred at the same temperature for 6 h before quenched by the 
addition of NaHCO3 (4 mL), and extracted with DCM (10 mL). And the organic phase 
was seperated and kept, the aqueous phase was extracted with DCM (3 x 10 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated. Purification 
by flash chromatography (5-15% EtOAC:Pet.Ether) gave alcohol 118 (220 mg, 65%) as 
a colourless oil and along with some starting material 117 (98 mg, 23%). 
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118: Rf  0.4 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  +17.9 (c 3.2, CHCl3); IR (CCl4) 3417, 
2931, 1745, 1250, 1099, 836, 697 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.31 (4H, 
m, Ar-H), 7.31-7.26 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 4.10-4.13 (1H, m, H15), 3.99-
3.92 (1H, m, H16), 3.75 (1H, dd, J = 11.2, 3.0 Hz, H19), 3.61-3.55 (1H, m, H20a), 3.49-
3.42 (3H, m, H20b+ H9), 2.43 (1H, app broad s, OH), 1.96-1.78 (4H, m, H17 + H18), 
1.69-1.53 (4H, m, H14 + H10), 1.41-1.27 (6H, m, H11 + H12 + H13), 0.90 (9H, s, Si-
C(CH3)3), 0.07 (3H, s, Si-CH3), 0.07 (3H, s, Si-CH3); 13C NMR (75 MHz, CDCl3) 
δ 138.6, 128.3, 127.6, 127.4, 81.2, 79.3, 74.7, 72.8, 70.4, 65.3, 33.9, 33.3, 29.7, 27.7, 
27.3, 26.2, 25.9, 25.5, 18.2, -4.3, -4.4; m/z (CI) 454 (100, [M+NH4]+); HRMS (CI+) 
Calc. for C25H48O4NSi [M+NH4+] 454.3339, found 454.3347. 
 
Preparation of (2R,5R)-5-(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy)heptyl-
tetrahydrofuran -2-carbaldehyde (119) 
H
O
OTBS
OBnO
19
15
9
119  
Method A:  
To a cold (-78 oC), stirred solution of oxalyl chloride (24.0 µL, 0.27 mmol) in DCM (3 
mL) was added dimethyl sulfoxide (32.0 µL, 0.45 mmol) in DCM (2 x 1.0 mL) via 
cannula. The reaction mixture was stirred at this temperature for 30 min before the 
addition of a solution of alcohol 118 (40.5 mg, 0.09 mmol) in DCM (2 x 1.0 mL) via 
cannula. The reaction was stirred for a further 1 h before the addition of NEt3 (82.0 µL, 
0.64 mmol) drop wise. The reaction mixture was then stirred at -78 oC for 20 min, -55 
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oC for 15 min and finally -20 oC for 45 min., before being quenched with saturated 
aqueous NH4Cl (3 mL) and diluted with DCM (10 mL). The organic phase was 
separated and kept, and the aqueous phase was extracted with DCM (3 x 10 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated. Purification 
by flash column chromatography (10% EtOAc:Pet.Ether) provided the desired 
aldehyde 119 (18 mg, 43%) as a colourless oil. 
 
Method B: 
To a cold (0 oC), stirring solution of tertrahydrofuranyl alcohol 118 (250 mg, 0.57 
mmol) in DCM (5 mL) was added NaHCO3 (240 mg, 2.86 mmol) followed by Dess-
Martin periodinane (725 mg, 1.71 mmol). The reaction mixture was stirred at 0 oC for 
20 min., then warmed to room temperature and stirred for an additional 30 min. The 
reaction mixture was re-cooled to 0 oC before the addition of cold hexane (5 mL) and 
cold toluene (5 mL). The resultant white suspension was filtered through celite and the 
filtrate concentrated. Purification by flash column chromatography (10% 
EtOAc:Pet.Ether) afforded the desired aldehyde 119 (200 mg, 80%) as a colourless oil.  
119: Rf 0.32 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  +11.3 (c 1.1, CHCl3); IR (CCl4) 3497, 
2929, 2857, 1727, 1462, 1253, 1099, 836, 697 cm-1; 1H NMR (300 MHz, C6D6) δ  9.61 
(1H, s, H20), 7.32 (2H, d, J = 7.2 Hz, Ar-H), 7.21 (2H, d, J = 7.0 Hz, Ar-H), 7.13-7.08 
(1H, m, Ar-H), 4.36 (2H, s, Ph-CH2), 3.88 (1H, app dt J = 6.5, 6.0, 1.3 Hz, H19), 3.75 
(1H, ddd, J = 11.9, 8.0, 2.2 Hz, H15), 3.48 (1H, app q,  J = 5.4 Hz, H16), 3.34 (2H, t, J = 
6.3 Hz, H9), 1.68-1.57 (2H, m, H18), 1.46-1.22 (12H, m, H17 + H14 + H13+ H12 + H11 + 
H10),  1.02 (9H, s, Si-C(CH3)3), 0.16 (3H, s, Si-CH3), 0.13 (3H, s, Si-CH3); 13C NMR 
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(75 MHz, C6D6) δ 202.6, 150.8, 140.1, 130.4, 129.1, 84.4, 838, 75.8, 75.5, 71.0, 34.6, 
30.8, 30.6, 28.5, 27.8, 27.2, 26.8, 26.2, 19.1, -3.3, -3.7; m/z (CI) 452 (100, [M+NH4]+); 
HRMS (ES+) Calc. for C25H46O4NSi [M+NH4+] 452.3195, found 452.3191.  
 
Preparation of (R) and (S)-1-(2R,5R)-5-(R)-7-benzyloxy)-1-(tert-butyldimethylsilyloxy) 
heptyl-tetrahydrofuran-2-yl)prop-2-en-1-ol (120) and (121) 
 
O
OTBS
OBn21 15
9
OH
O
OTBS
OBn
19
15
9
OH
21
121120
19
 
 
Method A: 
To a cold (-40 oC), stirred solution of tertrahydrofuranyl aldehyde 119 (17.6 mg, 0.03 
mmol) in THF (2 mL) was added vinylmagnesium bromide (120 µL, 1 M solution in 
THF, 1.19 mmol). After 10 min, the reaction mixture was allowed to warm to -20 oC 
and then to 0 oC. The reaction mixture was allowed to stir at this temperature for 1 h 
before being quenched by the addition of a saturated aqueous NH4Cl (5 mL) and Et2O 
(10 mL). The organic phase was separated and kept, and the aqueous layer was 
extracted with Et2O (3 x 10 mL). The combined organic phases were then dried 
(Na2SO4), filtered and concentrated. Purification by flash column chromatography 
(20% EtOAc:Pet.Ether) to afforded 120 and 121 (14 mg, 76 %) as with a 
diastereomeric ratio of 1:1 (by 400 MHz 1H NMR spectroscopy). 
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Method B: 
To a cold (-40 oC), stirred solution of tertrahydrofuranyl aldehyde 119 (145 mg, 0.33 
mmol) in THF (6 mL) was added freshly prepared divinyl zinc (1 mL, 1 M solution in 
THF, 1.01 mmol). After 30 min, the reaction mixture was allowed to warm to -20 oC. 
The reaction mixture was allowed to stir at this temperature for 1 h before being 
quenched by the addition of saturated aqueous NH4Cl (3 mL) and Et2O (7 mL). The 
organic phase was separated and kept, and the aqueous layer extracted with Et2O (3 x 8 
mL). The combined organic phases were dried (Na2SO4), filtered and concentrated. 
Purification by flash column chromatography (20% EtOAc:Pet.Ether) afforded 120 and 
121 (93 mg, 63%) in a diastereomeric ratio of 4:1 (by 400 MHz, 1H NMR 
spectroscopy).  
120: Rf  0.6 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  +10.4 (c  0.7, CHCl3); IR (CCl4) 3467, 
2929, 2857, 1453, 1276, 1104, 836, 711 cm-1; 1H NMR (400 MHz, CDCl3) δ  7.33-
7.32 (4H, m, Ar-H), 7.31-7.26 (1H, m, Ar-H), 5.79 (1H, ddd, J = 17.2,10.6, 5.8 Hz, 
H21), 5.33 (1H, app dt, J = 17.1, 3.0 Hz, CHtrans), 5.19 (1H, app dt, J = 10.6, 3.0 Hz, 
CHcis), 4.50 (2H, s, Ph-CH2), 4.34-4.26 (1H, m, H15), 3.99-3.89 (2H, m, H20 + H19), 
3.57-3.50 (1H, m, H16), 3.46 (2H, t, J = 6.6 Hz, H9), 2.17 (1H, dd, J = 3.1,1.5 Hz, C20-
OH), 1.95-1.77 (4H, m, H17+H18), 1.70-1.57 (2H, m, H14), 1.47-1.27 (8H, m, H13 +H12 
+H11 + H10), 0.88 (9H, s, Si-C(CH3)3), 0.06 (3H, s, Si-CH3), 0.05 (3H, s, Si-CH3); 13C 
NMR (125 MHz, CDCl3) δ 138.6, 136.2, 128.3, 127.6, 127.6, 127.4, 116.3, 82.8, 81.7, 
75.1, 73.3, 72.8, 70.4, 32.8, 29.7, 29.6, 27.8, 26.1, 25.9, 25.5, 18.2, -4.1, -4.5; m/z (ES) 
458 (100, [M+Na]+); HRMS (ES+) Calc. for C27H46O4SiNa [M+Na+] 458.3078, found 
485.3063. 
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Preparation of (R)-[(R)-1-(2R,5R)-5-(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy)  
heptyl]tetrahydrofuran-2-yl(allyl)3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (122)  
 
122
O
OBn
OO
MeO
CF3
9
1520
OTBS
 
 
To a stirred mixture of alcohol 120 (6 mg, 0.01 mmol), DCC (50 µL, 1M solution in 
DCM, 0.05 mmol) and  DMAP (7 mg, 0.03 mmol) in DCM (1.0 mL) at RT was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (12 mg, 0.01 mmol) in one 
portion. After 16 h, the crude reaction mixture was purified directly by flash column 
chromotography (5% EtOAc:Pet.Ether) to give (R)-MTPA ester 122 (4 mg, 54%). 
122: Rf  0.21 (10% EtOAc:Pet.Ether); 1H NMR (400 MHz, CDCl3) δ 7.59-7.49 (2H, 
m, Ar-H), 7.44-7.36 (4H, m, Ar-H), 7.35-7.31 (4H, m, Ar-H), 5.89 (1H, ddd, J = 17.1, 
10.6, 6.9 Hz, H21), 5.59-5.54 (1H, m, H20), 5.44-5.38 (1H, m, CHtrans), 5.35-31 (1H, m, 
CHcis), 4.49 (2H, s, Ph-CH2), 4.05-3.99 (1H, m, H15), 3.79-3.72 (1H, m, H19), 3.65-3.60 
(2H, m, H16), 3.54 (3H, s, OCH3), 3.45 (2H, t, J = 6.5 Hz, H9), 1.93-1.57 (4H, m, H17 + 
H18), 1.41-1.22 (10H, m, H14 +H13 + H12 + H11 + H10), 0.85 (9H, s, Si-C(CH3)3), 0.02 
(3H, s, Si-CH3), 0.00 (3H, s, Si-CH3). 
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Preparation of (S)-[(R)-1-(2R,5R)-5-(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy) 
heptyl] tetrahydrofuran-2-yl(allyl)3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (123) 
 
O
OBn
OTBSOO
CF3
MeO
9
15
20
123  
 
To a stirred mixture of alcohol 120 (5 mg, 0.01 mmol), DCC (50 µL, 1M, 0.05 mmol) 
and DMAP (7 mg, 0.03 mmol) in DCM (1.0 mL) at RT was added (-)-(S)-α-methoxy-
α-(trifluoromethyl)-phenylacetic acid (12.3 mg, 0.01 mmol) in one portion. After 16 h, 
the crude reaction mixture was purified directly by flash column chromotography (5% 
EtOAc:Pet. Ether)to give (S)-MTPA ester  123 (3 mg, 47%). 
123: Rf 0.21 (10% EtOAc:Pet.Ether); 1H NMR (400 MHz, CDCl3) δ 7.58-7.53 (2H, m, 
Ar-H), 7.41-7.36 (4H, m, Ar-H), 7.35-7.32 (4H, m, Ar-H), 5.74 (1H, ddd, J = 17.1, 
10.5, 6.4 Hz, H21), 5.64-5.59 (1H, m, H20), 5.31 (1H, app dt, J = 17.1, 2.2 Hz, CHtrans), 
5.26 (1H, app dt, J = 10.5, 2.1 Hz, CHcis), 4.49 (2H, s, Ph-CH2), 4.12-4.05 (1H, m, H15), 
3.91-3.83 (1H, m, H19), 3.55 (3H, s, OCH3), 3.53-3.49 (1H, m, H16), 3.46 (2H, t, J = 6.5 
Hz, H9), 1.96-1.74 (4H, m, H17 + H18), 1.73-1.56 (2H, m, H14), 1.47-1.26 (8H, m, H13 + 
H12 + H11 + H10), 0.86 (9H, s, Si-C(CH3)3), 0.03 (3H, s, Si-CH3), 0.02 (3H, s, Si-CH3). 
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7.3 Experimental details for Chapter three 
 
Preparation of (R)-1,2-epoxyoctane (126) and (S)-octane1,2-diol (131)  
O
126 131
OH
OH
28
34
28
34
 
 
To a stirred solution of (±)-1,2-epoxyoctane 130 (10.0 g, 77.9 mmol) and (R,R)-Co(II) 
salen catalyst 59 (235 mg, 50.0 µmol) were added AcOH (90.2 µL, 1.55 mmol) and 
THF (0.81 mL). The reaction mixture was stirred at RT for 30 min before, cooling to 
0 oC, after which time H2O (0.81 mL, 42.9 mmol) was added in one portion. The 
reaction was allowed to warm to RT and stir for 16 h. After this time the solvent was 
removed under reduced pressure and the residue purified using Kugelröhr distillation. 
The recovered epoxide was filtered through a silica plug to remove residual water, and 
the THF was removed by concentration to yield (R)-1,2-epoxyoctane 126 (4.89 g, 44% 
approx bp 40-60 oC at 1 Hg mm). The diol 131 was also purified by Kugelröhr 
distillation  (3.73 g, 39%, approx. b.p. = 100-120 oC at 1 mm Hg).     
126: Rf 0.60 (25% EtOAc:Hexanes); 
! 
["]
D
20  +9.1 (c 3.2, CHCl3) compared with data 
reported 25D][!  +11.2 (c 2.7, CHCl3)
40; 1H NMR(300 MHz, CDCl3) 2.93-2.87 (1H, m, 
H28), 2.74 (1H, dd, J = 5.0, 3.9 Hz, H27a), 2.46 (1H, dd, J = 5.0, 2.7 Hz,  H27b), 1.57-
1.41 (4H, m, H29 + H30), 1.37-1.24 (6H, m, H31 + H32 + H33), 0.88 (3H, t, J = 6.9 Hz, 
H34); 13C NMR (75 MHz, CDCl3) δ 52.4, 47.1, 32.5, 31.7, 29.1, 25.9, 22.5, 14.0.; 
131: Rf 0.25 (25% EtOAc:Hexanes); 
! 
["]
D
20  -9.8 (c 2.7, CHCl3) compared with data 
reported 
! 
["]
D
20  -10.4 (c 2.3, CHCl3); 1H NMR (300 MHz, CDCl3) 3.75-3.62 (2H, m, H28 
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+ H27a), 3.43 (1H, dd, J = 10.9, 7.6 Hz, H27b), 1.92 (2H, app broad s, 2 x OH), 1.42-1.32 
(3H, m, H29a + H30), 1.29-1.16 (7H, m, H29b+ H31 + H32 + H33), 0.81 (3H, t, J = 6.5 Hz, 
H34); 13C NMR (75 MHz, CDCl3) δ 72.3, 66.8, 33.2, 31.7, 29.3, 25.5, 22.5, 14.0. This 
data in agreement with reported by Jacobson, E. N. et al.74 
 
Preparation of (S)-1-hydroxyoctan-2-yl-4-methylbenzenesulfonate (132) 
132
OTs
OH
28
34
 
To a stirred solution of (S)-octane-1,2-diol 131 (513 mg, 3.50 mmol) in DCM (5 mL) at 
RT was added dibutyltin oxide (45.2 mg, 0.10 mmol), NEt3 (683 µL, 1.21 mmol) and p-
TsCl (735 mg, 3.85 mmol). The resultant bright orange solution was stirred for 10 h 
before the addition of NH4Cl (10 mL). The reaction mixture was diluted with Et2O (20 
mL) the organic phase was separated and kept. The aqueous layer was washed with 
Et2O (3 x 20 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated. Purification by flash column chromatography (10% EtOAc:Pet.Ether) 
afforded the tosylated product 132 (722 mg, 73%) as a colouress oil; which was used 
directly in subsequent transformations. 
132: Rf  0.45 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  -11.6 (c 3.1, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.79 (2H, d, J = 8.3 Hz, Ar-H), 7.28 (2H, d, J = 8.0 Hz, Ar-H), 4.06-4.01 (1H, 
m, H28), 3.91-3.78 (2H, m, H29), 2.45 (3H, s, Ar-CH3), 2.03 (1H, app broad s, C29-OH), 
1.45-1.36 (2H, m, H29), 1.35-1.22 (8H, m, H30 + H31 + H32 + H33), 0.86 (3H, t, J = 6.8 
Hz, CH3); 13C NMR (75 MHz, CDCl3) δ 145.0, 132.7, 129.9, 127.9, 74.0, 69.5, 32.6, 
31.6, 29.1, 25.1, 22.5, 21.6, 14.0; HRMS (CI+) Calc. for C15H24O4NaS ([M+Na+]) 
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323.1290 found 323.1293. This data in agreement with reported by Ogawa, K et al.177 
and Bernard, K. et al.178 
 
Preparation of (S)-1,2-epoxyoctane (129) 
O
129
28
34
 
To a stirring solution of tosylated alcohol 132 (722 mg, 2.40 mmol) in MeOH (12 mL) 
at RT was added K2CO3 (1.66 g, 12.1 mmol) in one portion. The reaction mixture was 
stirred for 12 h and then quenched with H2O and extracted with EtOAc (3 x 10 mL) and 
the organic layer was dried (MgSO4), filtered and concentrated. Purification by flash 
column chromatography (5% EtOAc:Pet.Ether) afforded the desired (S)-1,2-
epoxyoctane 129 (480 mg, 98%) as a colourless oil. 
129: Rf  0.4 (10% EtOAc:Pet.Ether);
! 
["]
D
20-10.3 (c 2.8, CHCl3) compared with data 
reported 
! 
["]
D
20  -11.4 (c 2.5, CHCl3);40 1H NMR (300 MHz, CDCl3)  δ 2.94-2.86 (1H, 
m, H28), 2.74 (1H, dd, J = 5.0, 4.0 Hz, H27a), 2.46 (1H, dd, J = 5.0, 2.6 Hz, H27b), 1.56-
1.40 (4H, m, H29 + H30), 1.37-1.24 (6H, m, H31 + H32 + H33), 0.88 (3H, t, J = 6.8 Hz, 
H34); 13C NMR (75 MHz, CDCl3) δ 52.4, 47.0, 32.5, 31.7, 29.0, 25.9, 22.5, 14.0. 
This data in agreement with reported by Ogawa, K et al.177 and Bernard, K. et al.178 
 
 
 
Preparation of (R)-dodec-1-en-6-ol (125) 
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OH
125
28
34
23
 
To a cold (- 40 oC), stirring solution of 126 (2.0 g, 15.6 mmol) in dry THF (130 mL) 
was added copper(I)iodide (594 mg, 3.11 mmol) and homoallyl magnesium bromide 
bromide 133 (24.2 mL, 1M solution in THF, 23.8 mmol) via cannula. The resulting 
black solution was allowed to warm to -20 oC for 1 h, and finally to 0 oC for 2 h, before 
being quenched by the addition of a saturated aqueous NH4Cl (30 mL) and Et2O (100 
mL). The organic phase was separated and kept, and the aqueous layer extracted with 
Et2O (3 x 100 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated. Purification by flash column chromatography (10-15% EtOAc:Pet.Ether) 
gave hydroxy olefin 125 (2.20 g, 77%) as a colourless oil.  
125: Rf  0.41 (25% EtOAc:Pet.Ether);
! 
["]
D
20  +23.2 (c 3.5, CHCl3); IR (neat) 3412, 2930, 
2858, 1460, 1261, 1097, 1015, 912 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.88 (1H, 
dddd, J = 17.0, 13.3, 10.1, 6.7 Hz, H24), 5.05-4.92 (2H, m, H23), 3.64-3.54 (1H, m, H28), 
2.11-2.04 (2H, m, H25), 1.97 (1H, app broad s, C28-OH), 1.51-1.37 (6H, m, H26 + H27 + 
H29), 1.33-1.23 (8H, m, H30 + H31 + H32 + H33), 0.88 (3H, t, J = 6.8 Hz, H34); 13C NMR 
(75 MHz, CDCl3) δ 139.1, 114.9, 72.2, 37.9, 37.2, 34.1, 32.2, 29.7, 26.0, 25.3, 23.0, 
14.5.; m/z (CI) 202 (100, [M+Na]+); HRMS (CI) Calc. for C12H24ONa [M+Na+] 
202.2165, found 202.2165. 
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Preparation of (2R,6R) and (2S,6R)-[6-hexyltetrahydro-2H-pyran-2-yl]methanol (134, 
135) 
O
OH
134
34
28 23
O
OH
135
34
28 23
 
To a cold (0 oC), stirred solution of hydroxy olefin 125 (400 mg, 2.17 mmol) in DCM 
(20 mL) was added m-CPBA (720 mg, 3.25 mmol). The reaction mixture was allowed 
to warm to RT for 3 h before being re-cooled to 0 oC, and addition of (±)CSA (100 mg, 
0.43 mmol) in one portion. The reaction mixture was stirred at RT for an additional 6 h 
prior to the addition of a saturated solution of NaHCO3 (10 mL) and DCM (30 mL). 
The organic phase was seperated and kept. The aqueous phase was extracted with DCM 
(3 x 10 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated. Purification by flash column chromatography (10-15% EtOAc:Pet.Ether) 
gave the diasteremoeric tertrahydropyranyl alcohols 134 (180 mg, 48%) and 135 (152 
mg, 38%), as colourless oils.  
134: Rf  0.40 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  +21.5 (c 3.0, CHCl3); IR (neat) 3435, 
2932, 2858, 1460, 1204, 1043, 890 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.61-3.39 (3H, 
m, H23 + H24), 3.34-3.25 (1H, m, H28), 2.12 (1H, app broad s, OH), 1.64-1.35 (6H, m, 
H25 + H26 + H27), 1.34-1.24 (10H, m, H29 + H30 + H31 + H32 + H33), 0.87 (3H, t, J = 7.0 
Hz, H34); 13C NMR (75 MHz, CDCl3) δ 77.8, 77.7, 66.3, 36.4, 31.8, 31.5, 29.3, 27.2, 
25.5, 23.1, 22.6, 14.1; m/z (CI) 201 (100, [M+H]+), 169 (10), 165 (8); HRMS (CI) 
Calc. for C12H25O2 [M+H]+ 201.1855, found 201.1863. 
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135: Rf  0.35 (25% EtOAc:Hexanes);
! 
["]
D
20  +27.7 (c 3.5, CHCl3); IR (neat) 3425, 2932, 
2858, 1575, 1260, 1099, 890 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.81-3.70 (2H, m, 
H23), 3.67 (1H, dd, J = 11.0, 8.4 Hz, H24), 3.45 (1H, dd, J = 11.0, 3.6 Hz, H28), 2.01 
(1H, app broad s C23-OH), 1.78-1.51 (4H, m, H25 + H27), 1.44 (4H, m, H26 + H29), 
1.30-1.25 (8H, m, H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34); 13C NMR (75 
MHz, CDCl3) δ 71.7, 70.7, 64.2, 32.4, 31.8, 29.5, 29.3, 26.4, 25.8, 22.6, 18.4, 14.1.; m/z 
(CI) 201 (100, [M+H]+), 169 (10), 165 (8); HRMS (CI) Calc. for C12H25O2  [M+H]+ 
201.1855 found 201.1860.  
 
Preparation of (2R,6R) [6-hexyltetrahydro-2H-pyran-2-yl]methyl-2-nitrobenzoate (136)   
O
34
28 23
O
O NO2
136  
To a cold (0 oC) stirred solution of alcohol 134 (50 mg, 0.25 mmol) in THF (5.0 mL) 
were added 3-nitro-benzoic acid (63.3 mg, 0.37 mmol) and PPh3 (98.4 mg, 0.37 mmol).  
Diethyl diazadicaboxylate (53.2 µL, 0.37 mmol) was added drop-wise via syringe. The 
reaction mixture was allowed to stir at RT for 2 h before quenching with saturated 
aqueous NH4Cl (3 mL) and EtOAc (10 mL). The phases were separated and the organic 
phase kept, the aqueous phase was washed with EtOAc (3 x 10 mL). Combined organic 
phases were dried (Na2SO4), filtered and concentrated. Purification by flash column 
chromatography (10% EtOAc: Pet. Ether) provided ester derivative 136 (76.4 mg, 88 
%) as a colourless oil.  
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136: Rf  0.5 (10% EtOAc:Pet.Ether); 1H NMR (300 MHz, CDCl3) δ 7.89 (1H, dd, J = 
7.3, 1.9 Hz, Ar-H), 7.75 (1H, dd, J = 7.3, 1.9 Hz, Ar-H), 7.63 (2H, app ddt, J = 9.0, 7.5, 
1.6 Hz, Ar-H), 7.53 (1H, app dt, J = 7.5, 1.8 Hz, Ar- H), 4.29 (2H, d, J = 5.5 Hz, H23), 
3.64 (1H, ddd, J = 11.2, 7.3, 1.9 Hz, H24), 3.34-3.23 (1H, m, H28), 1.93-1.80 (1H, m, 
H25a), 1.64-1.53 (3H, m, H25b + H27), 1.41-1.21 (12H, m, H26 + H29 + H30 + H31 + H32 + 
H33), 0.84 (3H, t, J = 6.9 Hz, H34); 13C NMR (75 MHz, CDCl3)  δ 165.2, 148.3, 132.7, 
131.6, 130.0, 127.7, 123.8, 77.9, 74.9, 69.1, 36.3, 31.8, 31.2, 29.3, 27.6, 25.4, 23.1, 
22.5, 14.0. 
 
Preparation of (2R, 6R) [6-hexylterahydro-2H-pyran]-2-carbaldehyde (137) 
O
O
137
34
28
23
H
 
To a cold (-78 oC), stirred solution of oxalyl chloride (400 µL, 4.56 mmol) in DCM (20 
mL) was added dimethyl sulfoxide (650 µL, 9.12 mmol) in DCM (2 x 2.0 mL) via 
cannula. The reaction mixture was stirred at this temperature for 30 min before the 
addition of alcohol 137 (457 mg, 2.21 mmol) as a solution in DCM (2 x 2.0 mL) via 
cannula. The reaction was stirred for a further 1 h, before the dropwise addition of NEt3 
(2.0 mL, 13.6 mmol). The reaction mixture was then stirred at -78 oC for 20 min, -55 oC 
for 15 min and finally -20 oC for 45 min. After the addition of saturated aqueous NH4Cl 
(10 mL), the organic phase was separated and kept. The aqueous phase was extracted 
with DCM (3 x 30 mL) and the combined organic phases were dried (Na2SO4), filtered 
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and concentrated. Purification by flash column chromatography (10% 
EtOAc:Pet.Ether) provided desired aldehyde 137 (396 mg, 88%) as a colourless oil. 
137: Rf 0.60 (20% EtOAc:Pet.Ether); 
! 
["]
D
20  + 21.6 (c 4.2, CHCl3); IR (CCl4) 2933, 
2859, 1733, 1459, 1034, 978 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.62 (1H, s, H23), 
3.78 (1H, dd, J = 11.7, 2.6 Hz, H24), 3.40-3.30 (1H, m, H28), 1.96-1.89 (1H, m, H25a), 
1.67-1.40 (5H, m, H25b + H26 + H27), 1.36-1.24 (10H, m, H29 + H30 + H31 + H32 + H33), 
0.88 (3H, t, J = 7.0 Hz, H34); 13C NMR (75 MHz, CDCl3) δ 202.4, 81.8, 78.1, 36.3, 
31.8, 31.0, 29.3, 26.2, 25.3, 23.0, 22.6, 14.1; m/z (CI) 199 (100, [M+H]+), 163 (10); 
HRMS (CI) Calc. for C12H23O2 [M+H]+ 199.1694 found 199.1693. 
 
Preparation of (2S, 6R)-[6-hexylterahydro-2H-pyran]-2-carbaldehyde (142) 
O
O
142
34
28
23
H
 
To a cold (-78 oC), stirred solution of oxalyl chloride (86.5 µL, 0.99 mmol) in DCM 
(5.0 mL) was added dimethyl sulfoxide (150 µL, 1.91 mmol) in DCM (2 x 1.0 mL) via 
cannula. The reaction mixture was stirred at this temperature for 30 min before addition 
of alcohol 135 (100 mg, 0.49 mmol) as a solution in DCM (2 x 1.0 mL) via cannula. 
The reaction was stirred for a further 1 h before the addition of NEt3 (44.8 µL, 2.99 
mmol) dropwise. The reaction mixture was then stirred at -78 oC for 20 min, -55 oC for 
15 min and finally -20 oC for 45 min. After saturated aqueous NH4Cl (5 mL) the 
organic phase was separated and kept. The aqueous phase was extracted with DCM (3 x 
10 mL) and the combined organic phases dried (Na2SO4), filtered and concentrated. 
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Purification by flash column chromatography (10% EtOAc:Pet.Ether) provided (90.5 
mg, 76%) of desired aldehyde 142 as a colourless oil. 
142: Rf 0.55 (15% EtOAc:Pet.Ether); 
! 
["]
D
20  +27.0 (c 3.5, CHCl3); IR (CCl4) 2932, 
2859, 1729, 1457, 1086, 673 cm-1; 1HNMR (300 MHz, CDCl3) δ 9.84 (1H, s, H23), 
4.20-4.15 (1H, m, H24), 3.62-3.50 (1H, m, H28), 2.06-1.93 (1H, m, H25a), 1.76-1.59 (3H, 
m, H25b + H27), 1.50-1.35 (4H, m, H26 + H26), 1.35-1.24 (10H, m, H29 + H30 + H31 + H32 
+ H33), 0.88 (3H, t, J = 6.8 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 205.4, 78.8, 74.9, 
35.6, 31.8, 30.5, 29.3, 25.3, 24.0, 22.6, 19.8, 14.1; m/z (CI) 199 (100, [M+H]+), 163 
(10); HRMS (CI) Calc. for C12H23O2  [M+H+] 199.1694 found 199.1693 
 
Preparation of (S) and (R)-[1-(2R,6R)-6-hexyltetrahydro-2H-pyran-2-yl)]prop-2-en-1-ol 
(144, 145). 
O
138
OH
34 28
23 22
O
139
OH
34 28
23 22
 
To a cold (-40 oC), stirred solution of tertrahydropyranyl aldehyde 137 (100 mg, 0.50 
mmol) in THF (5 mL) was added vinylmagnesium bromide (1.56 mL, 1 M solution in 
THF, 1.56 mmol). The reaction mixture was allowed to warm to 0 oC over a period of 
4 h. The reaction mixture was allowed to stir at this temperature for 1 h before being 
quenched by the addition of a saturated aqueous NH4Cl (5 mL) and Et2O (10 mL). The 
organic phase was separated and kept, and the aqueous layer was extracted with Et2O (3 
x 10 mL). The combined organic phases were dried (Na2SO4), filtered and 
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concentrated. Purification by flash column chromatography (10-15% EtOAc:Pet.Ether) 
afforded 138 (24.2 mg, 32%) and 139 (40.5 mg, 58 %) as colourless oils.  
138: Rf  0.50 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  +9.4 (c 1.6, CHCl3); IR (neat) 3437, 2931, 
2858, 1630, 1461, 1040, 922 cm-1; 1H NMR (400 MHz, CDCl3)  δ  5.80 (1H, ddd,  J = 
17.1, 10.5, 6.7 Hz, H22), 5.35 (1H, dt, J = 17.2, 3.0 Hz, CHtrans), 5.21 (1H, dq,  J = 10.4, 
2.9 Hz, CHcis), 3.92-3.86 (1H, m, H23), 3.33-3.25 (1H, m, H24), 3.15 (1H, ddd, J = 9.8, 
7.7, 2.0 Hz, H28), 2.96 (1H, d, J = 1.9 Hz, OH), 1.87-1.80 (1H, m, H25a), 1.61-1.57 (1H, 
m, H25b), 1.56-1.50 (2H, m, H27), 1.50-1.37 (4H, m, H26 + H29), 1.33-1.24 (8H, m, H30 + 
H31 + H32 + H33), 0.88 (3H, t, J = 6.9 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 136.5, 
117.5, 80.4, 78.0, 76.3, 36.3, 31.8, 31.5, 29.3, 27.2, 25.5, 23.1, 22.6, 14.1; m/z (CI) 199 
(249, [M+Na]+), 209 (10); HRMS (CI) Calc. for C14H26O2Na [M+Na+] 249.1827, 
found 249.1825.  
139: Rf 0.45 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  +15.3 (c 1.8, CHCl3); IR (neat) 3437, 2931, 
2858, 1630, 1461, 1040, 922 cm-1; 1H NMR (400 MHz, CDCl3) δ  5.87 (1H, ddd, J = 
16.9, 10.5, 6.2 Hz, H22), 5.29 (1H, dt, J = 17.3, 3.1 Hz, CHtrans), 5.18 (1H, dt, J = 10.5, 
3.1 Hz, CHcis), 4.15-4.10 (1H, m, H23), 3.37 (1H, ddd, J = 9.5, 5.9, 2.1 Hz, H24), 3.34-
3.27 (1H, m, H28), 2.34 (1H, d, J = 5.0 Hz, OH), 1.88-1.81 (1H, m, H25a), 1.59-1.52 
(1H, m, H25b), 1.52-1.46 (2H, m, H27), 1.43-1.36 (H, m, H26), 1.32-1.24 (10H, m, H29 + 
H30 + H31 + H32 + H33), 0.88 (3H, t, J = 7.0 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 
137.5, 116.1, 79.8, 78.2, 75.0, 36.4, 31.8, 31.5, 29.3, 25.4, 25.1, 23.1, 22.6, 14.1; m/z 
(CI) 199 (249, [M+Na]+), 209 (10); HRMS (CI) Calc. for C14H26O2Na [M+Na+] 
249.1825, found 249.1831.  
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Preparation of (S) and (R)-[1-(2S,6R)-6-hexyltetrahydro-2H-pyran-2yl]prop-2-en-1-ol 
(143, 144) 
O
144
OH
34 28
23 22
O
143
OH
34 28
23 22
 
To a cold (-40 oC), stirred solution of tetrahydropyranyl aldehyde 142 (65.1 mg, 0.32 
mmol) in THF (4 mL) was added vinylmagnesium bromide (1.00 mL, 1 M solution in 
THF, 0.99 mmol). After 10 min, the reaction mixture was allowed to warm to -20 oC , 
then to 0 oC. The reaction mixture was allowed to stir at this temperature for 1 h before 
being quenched by the addition of saturated aqueous NH4Cl (3 mL) and Et2O (7 mL). 
The organic phase was separated and kept, and the aqueous layer extracted with 
Et2O (3 x 8 mL). The combined organic phases were dried (Na2SO4), filtered and 
concentrated. Purification by flash column chromatography (15-20% EtOAc:Pet.Ether) 
afforded 143 (31.2 mg, 48%) and 144 (21.0 mg, 30 %) as colourless oils.  
143: Rf  0.55 (25% EtOAc:Hexanes); 
! 
["]
D
20  +18.0 (c 2.1, CHCl3); IR (CCl4) 3432, 
2931, 2858, 1643, 1461, 1378, 1040, 725 cm-1; 1H NMR (300 MHz, CDCl3)  δ 5.76 
(1H, ddd, J = 17.2, 10.3, 6.6 Hz, H22), 5.35 (1H, app dt, J = 17.2, 2.9 Hz, CHtrans), 5.22 
(1H, app dq, J = 10.3, 2.6 Hz, CHcis), 4.16-4.09 (1H, m, H23), 3.81-3.71 (1H, m, H24), 
3.49-3.41 (1H, m, H28), 2.84 (1H, d, J = 1.9 Hz, OH), 1.75-1.58 (4H, m, H25 + H26 + 
H27), 1.51-1.33 (4H, m, H27 + H29), 1.32-1.24 (8H, m, H30 + H31 + H32 + H33), 0.88 (3H, 
t, J = 6.9 Hz, H34); 13C NMR (75 MHz, CDCl3) δ 136.9, 117.8, 73.7, 73.3, 72.0, 32.9, 
31.8, 29.6, 29.2, 25.8, 25.7, 22.6, 18.4, 14.0; m/z (CI) 249 (100, [M+Na]+), 209 (10); 
HRMS (CI) Calc. for C14H26O2Na  [M+Na+] 249.1825, found 249.1831.  
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144: Rf  0.45 (25% EtOAc:Hexanes); 
! 
["]
D
20  +13.5 (c 2.1, CHCl3); IR (neat) 3450, 2933, 
2859, 1630, 1550, 1378, 1086, 925 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.90 (1H, ddd, 
J = 16.9, 10.5, 6.0 Hz, H22), 5.31 (1H, dt, J = 17.1, 3.2 Hz, CHtrans), 5.20 (1H, dt, J = 
10.5, 3.0 Hz, CHcis), 4.16-4.09 (1H, m, H23), 3.90-3.80 (1H, m, H24), 3.63-3.54 (1H, m, 
H28), 2.14 (1H, d, J = 5.0 Hz, OH), 1.70-1.59 (4H, m, H25 + H27), 1.54-1.33 (4H, m, H26 
+ H29), 1.33-1.26 (8H, m, H30 + H31 + H32 + H33), 0.88 (3H, t,  J = 6.9 Hz, H34); 13C 
NMR (75 MHz, CDCl3) δ 137.0, 116.2, 74.3, 73.0, 72.1, 31.8, 30.9, 29.2, 28.7, 25.9, 
25.1, 22.6, 18.1, 14.0; m/z (CI) 249 (100, [M+Na]+), 209 (10); HRMS (CI) Calc. for 
C14H26O2Na  [M+Na+] 249.1825, found 249.1831.  
 
Preparation of (R)-[(R)-1-(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]allyl-3,3,3-trifluoro 
-2-methoxy-2-phenylpropanoate (140)  
O
O O
34
28
23 22
140
MeO
CF3
 
To a stirred mixture of alcohol 139 (5 mg, 0.02 mmol), DCC (80 µL, 1M in DCM, 0.08 
mmol) and DMAP (7 mg, 0.06 mmol) in DCM (1.0 mL) at RT was added (+)-(R)-α-
methoxy-α-(trifluoromethyl)-phenylacetic acid (6 mg, 0.02 mmol) in one portion. After 
16 h, the crude reaction mixture was purified directly by flash column chromotography 
(5% EtOAc:Hexanes) to give (R)-MTPA ester  140 (4 mg, 43%). 
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140: Rf 0.3 (10% EtOAc:Hexanes); 1H NMR (300 MHz, CDCl3) δ  7.57-7.52 (2H, m, 
Ar-H), 7.41-7.35 (3H, m, Ar-H), 5.89 (1H, ddd, J = 17.4, 10.5, 6.9 Hz, H22), 5.51 (1H, 
app ddt, J = 6.9, 4.5, 1.0 Hz, H23), 5.37 (1H, app dt, J = 17.2, 2.5 Hz, CHtrans), 5.30 (1H, 
app dt, J = 10.5, 2.3 Hz, CHcis), 3.54 (3H, s, O-CH3), 3.43 (1H, ddd, J = 11.2, 4.4, 1.9 
Hz, H24), 3.19 (1H, app qn, J = 9.6 Hz, H28), 1.97-1.87 (2H, m, H25), 1.78-1.62 (2H, m, 
H27), 1.39-1.14 (12H, m, H26 + H29 + H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, 
CH3).  
 
Preparation of (S)- [(R)-1-(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]allyl-3,3,3-trifluoro 
-2-methoxy-2-phenylpropanoate (141) 
O
O O
34
28
23 22
141 F3C
OMe
 
To a stirred mixture of alcohol 139 (6 mg, 0.02 mmol), DCC (100 µL, 1M in DCM, 
0.10 mmol) and  DMAP (9 mg, 0.08 mmol) in DCM (1.0 mL) at RT was added (-)-(S)-
α-methoxy-α-(trifluoromethyl)-phenylacetic acid (7 mg, 0.03 mmol) in one portion. 
After 16 h, the crude reaction mixture was purified directly by flash column 
chromotography (5% EtOAc:Pet.Ether) to give (S)-MTPA ester  141 (6 mg, 54%). 
141: Rf 0.35 (10% EtOAc:Pet.Ether); 1H NMR (300 MHz, CDCl3) δ 7.65-7.59 (2H, m, 
Ar-H), 7.41-7.36 (3H, m, Ar-H), 5.79 (1H, ddd, J = 16.9, 10.6, 6.2 Hz, H22), 5.62-5.56 
(1H, m, H23), 5.29-5.24 (1H, m, CHtrans), 5.23-5.21 (1H, m, CHcis), 3.59 (3H, s, OCH3), 
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3.56-3.45 (1H, m, H24), 3.35-3.24 (1H, m, H28), 1.98-1.83 (2H, m, H25), 1.78-1.67 (1H, 
m, H27), 1.35-1.20 (12H, m,  H26 + H29 + H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.8 
Hz, H34). 
 
Preparation of (R)-[(S)-1-(2S,6R)-6-hexyltetrahydro-2H-pyran-2-yl]allyl-3,3,3-trifluoro 
-2-methoxy-2-phenylpropanoate (151)  
O
O O
34
28
23 22
145
MeO
CF3
 
To a stirred mixture of alcohol 144 (6 mg, 0.03 mmol), DCC (120 µL, 1M in DCM, 
0.12 mmol) and DMAP (11.2 mg, 0.09 mmol) in DCM (1.0 mL) at RT was added (+)-
(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (25.1 mg, 0.11 mmol) in one 
portion. After 16 h, the crude reaction mixture was purified directly by flash column 
chromotography (5% EtOAc:Hexanes) to give (R)-MTPA ester 145 (6 mg, 42%). 
145: Rf  0.21 (10% EtOAc:Hexanes); 1H NMR (300 MHz, CDCl3) δ 7.60-7.52 (2H, m, 
Ar-H), 7.41-7.34 (3H, m, Ar-H), 5.89-5.65 (2H, m, H22 + H23), 5.48-5.40 (1H, m, 
CHtrans), 5.36-5.30 (1H, m, CHcis), 3.81-3.70 (1H, m, H24), 3.54 (3H, s, OCH3), 3.25-
3.13 (1H, m, H28), 1.98-1.87 (2H, m, H25), 1.79-1.68 (2H, m, H27), 1.36-1.17 (12H, m,  
H26 + H29 + H30 + H31 + H32 + H33), 0.86 (1H, t, J = 7.0 Hz, H34).  
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Preparation of (S)-[(S)-1-(2S,6R)-6-hexyltetrahydro-2H-pyran-2-yl]allyl-3,3,3-trifluoro-
2-methoxy-2-phenylpropanoate (146)  
O
O O
34
28
23 22
146 F3C
OMe
 
To a stirred mixture of alcohol 144 (7 mg, 0.03 mmol), DCC (130 µL, 1M in DCM, 
0.13 mmol) and  DMAP (12.6 mg, 0.10 mmol) in DCM (1.0 mL) at RT was added (-)-
(S)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (10 mg, 0.14 mmol) in one 
portion. After 16 h, the crude reaction mixture was purified directly by flash column 
chromotography (5% EtOAc:Hexanes) to give (S)-MTPA ester  146 (7 mg, 45%). 
146: Rf 0.25 (10% EtOAc:Hexanes); 1H NMR (300 MHz, CDCl3) δ 7.62-7.59 (2H, m, 
Ar-H), 7.40-7.34 (3H, m, Ar-H), 5.77-5.61 (2H, m, H22 + H23), 5.36-5.29 (1H, m, 
CHtrans), 5.27-5.23 (1H, m, CHcis), 3.88-3.77 (1H, m, H24), 3.61 (3H, s, O-CH3), 3.35-
3.23 (1H, m, H28), 1.97-1.86 (2H, m, H25), 1.78-1.69 (2H, m, H27), 1.40-1.13 (12H, m, 
H26 + H29 + H30 + H31 + H32 + H33), 0.86 (3H, t, J = 7.0 Hz, H34).  
 
 
 
 
 
 
Preparation of (S)-1,2-epoxyoctane (129)  
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O
129
28
34
 
Following the same procedure as 126, the kinetic resolution of the (±) octane epoxide 
130 (10.0 g, 80.0 mmol) with (S,S)-Co(II) catalyst 148 (235 mg, 0.38 mmol) in THF 
(0.81 mL), water (0.80 mL, 44.1mmol) in catalytic amounts of AcOH (100 µL, 1.60 
mmol) gave the enantiomerically pure (S)-1,2-epoxyoctane 129, (4.20 g, 41%) as a 
colourless oil, after Kugelröhr distillation.  
129: Rf 0.4 (10% EtOAc:Pet.Ether);
! 
["]
D
20  -9.6 (c 2.8, CHCl3) compared with data 
reported 25D][!  -11.4 (c 2.5, CHCl3);
40 1H NMR (300 MHz, CDCl3) δ 2.94-2.86 (1H, m, 
H28), 2.74 (1H, dd, J = 5.0, 4.0 Hz, H27a), 2.46 (1H, dd, J = 5.0, 2.6 Hz, H27b), 1.56-1.40 
(4H, m, H29 + H30), 1.37-1.24 (6H, m, H31 + H32 + H33), 0.88 (3H, t, J = 6.8 Hz, H34); 
13C NMR (75 MHz, CDCl3) δ 52.4, 47.0, 32.5, 31.7, 29.0, 25.9, 22.5, 14.0. This data in 
agreement with reported by Jacobson, E. N. et al.74  
 
Preparation of (S)-dodec-1-en-6-ol (128) 
128
28
34
23
OH
 
Following the same procedure as 125, with the (S)-epoxide 129 (2.50 g, 19.4 mmol) 
and copper(I)iodide (11.5 g, 60.4 mmol) in dry THF (150 mL) at -40 oC was added 
freshly prepared homoallylmagnesium bromide (23.0 mL, 1 M solution in THF, 23 
mmol) by cannula. Upon completion, the reaction mixture was quenched with aqueous 
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saturated NH4Cl (30 mL), and extracted with Et2O (3 x 30 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated. Purifiication by flash column 
chromatography afforded 128 (2.61 g, 72%).  
128: Rf  0.4 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  -23.4 (c 3.5, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.81 (1H, dddd, J = 16.9, 13.3, 10.1, 6.7 Hz, H24), 5.05-4.92 (1H, m, H23a), 
4.97-4.92 (1H, m, H23b), 3.65-3.53 (1H, m, H28), 2.12-2.02 (2H, m, H25), 1.97 (1H, app 
broad s, C28-OH), 1.46-1.37 (6H, m, H26 + H27 + H29), 1.32-1.25 (8H, m, H30 + H31 + 
H32 + H33), 0.88 (3H, t, J = 7.0 Hz, H34); 13C NMR (75 MHz, CDCl3) δ 139.1, 114.9, 
72.2, 37.9, 37.2, 34.1, 32.2, 29.7, 26.0, 25.5, 23.0, 14.5. 
The characterisation data for 128 were identical to those reported for 125 so no further 
characterisation was performed.  
 
Preparation of (2S,6S) and (2R,6S)-[6-hexyltetrahydro-2H-pyran-2-yl]methanol (149, 
150) 
O
OH
149
34
28 23
O
OH
150
34
28 23
 
Performing the same procedure 134, 135, with 128 (1.50 g, 8.13 mmol) in DCM (20 
mL) at 0 oC.  To this solution was added m-CPBA (3.10 g, 14.0 mmol) and after stirring 
for 3 h at RT, (±) CSA (378 mg, 162 mmol) was added. After 6 h the aqueous phase 
was extracted with Et2O and concentrated in vaccuo. Purification by flash column 
chromatography provided a separable mixture of alcohols 149 and 150 as colourless 
oils with 5:4 ratio (1.20 g, 73%).   
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149: Rf 0.3 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  -23.6 (c 1.6, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 3.61-3.39 (3H, m, H23 + H24), 3.34-3.24 (1H, m, H28), 2.14 (1H, dd, J = 8.2, 
3.6 Hz, OH), 1.63-1.46 (6H, m, H25 + H26 + H27), 1.32-1.24 (10H, m, H29 + H30 + H31 + 
H32 + H33), 0.86 (3H, t, J = 6.6 Hz, H34); 13C NMR (75 MHz, CDCl3) δ77.9, 77.8, 66.3, 
36.4, 31.8, 31.6, 29.3, 27.2, 25.5, 23.1, 22.6, 14.0. 
 150: Rf  0.4 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  -21.1 (c 2.1, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 3.81-3.70 (2H, m, H23), 3.65 (1H, ddd, J = 11.0, 8.4, 2.9 Hz, H24), 3.45 (1H, 
ddd, J = 11.2, 8.4, 3.6 Hz, H28), 2.09 (1H, app dd, J = 8.4, 3.1 Hz, C23-OH), 1.75-1.51 
(4H, m, H25 + H27), 1.44-1.27 (12H, m, H26 + H29 + H30 + H31 + H32 + H33), 0.86 (3H, t, 
J = 7.0 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 71.2, 70.7, 64.1, 32.4, 31.8, 29.4, 
29.2, 26.4, 25.8, 22.6, 18.4, 14.0.  
The characterisation data for 149 and 150 were identical to those reported for 134, 135 
respectively so no further characterisation was performed.  
 
Preparation of (2S,6S) [6-hexylterahydro-2H-pyran]-2-carbaldehyde (151) 
O
O
151
34
28
23
H
 
Using the same procedure as for 137, with alcohol 149 (600 mg, 2.99 mmol) was added 
to a solution of DMSO (1.06 mL, 14.9 mmol) and oxalyl chloride (0.78 mL, 8.98 
mmol) in DCM (25 mL) at -78 oC. After stirring for 3 h at the same temperature, the 
reaction mixture was quenched with NEt3 (2.70 mL, 20.9 mmol) and stirred for another 
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30 min at -20 oC then extracted with DCM, dried (Na2SO4) and concentrated. 
Purification by flash column chromatography gave the product 151 (450 mg, 76%).  
151: Rf 0.55 (20% EtOAc:Pet.Ether); 
! 
["]
D
20  -33.0 (c 3.8, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 9.62 (1H, s, H23), 3.79 (1H, dd, J = 11.7, 2.6 Hz, H24), 3.39-3.31 (1H, m, H28), 
1.96-1.89 (1H, m, H25a), 1.84-1.77 (1H, m, H25b), 1.66-1.58 (2H, m, H27), 1.48-1.39 
(2H, m, H26), 1.34-1.25 (10H, m, H29 + H30 + H31 + H32 + H33), 0.88 (3H, t, J = 6.8 Hz, 
H34); 13C NMR (75 MHz, CDCl3) δ 202.5, 81.8, 78.1, 36.2, 31.7, 31.0, 29.3, 26.2, 25.3, 
22.9, 22.6, 14.0. 
The characterisation data for 151 were identical to those reported for 137 so no further 
characterisation was performed.  
 
Preparation of (2R,6S) [6-hexylterahydro-2H-pyran]-2-carbaldehyde (154) 
O
O
154
34
28
23
H
 
Using the same procedure as for 142, alcohol 150 (330 mg, 1.64 mmol) was added to a  
solution of DMSO (0.60 mL, 8.23 mmol) and oxalyl chloride (431 µL, 4.94 mmol) in 
DCM at -78 oC. After 3 h at the same temperature, the reaction mixture was quenched 
with NEt3 (1.50 mL, 11.5 mmol) and stirred for another 30 min at -20 oC before 
extracted with DCM, dried (Na2SO4) and concentrated. Purification by flash column 
chromatography gave the product 154 (300 mg, 91%).  
154: Rf  0.55 (20% EtOAc:Pet.Ether); 
! 
["]
D
20  -24.5 (c 1.8, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 9.84 (1H, s, H23), 4.17 (1H, dd, J = 6.1, 3.0 Hz, H24), 3.60-3.51 (1H, m, H28), 
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2.03-1.96 (1H, m, H25a), 1.74-1.63 (3H, m, H25b + H27), 1.50-1.36 (4H, m, H26 + H29), 
1.34-1.25 (8H, m, H30 + H31 + H32 + H33), 0.88 (3H, t, J = 6.7 Hz, H34); 13C NMR (75 
MHz, CDCl3) δ 205.4, 78.8, 74.8, 35.6, 31.8, 30.5, 29.2, 25.3, 24.0, 22.6, 19.8, 14.1. 
The characterisation data for 154 were identical to those reported for 142 so no further 
characterisation was performed.  
 
Preparation of (S) and (R)-[1-(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl)]prop-2-en-1-ol 
(152, 153) 
O
152
OH
34 28
23 22
O
153
OH
34 28
23 22
 
Following the same procedure as for both 138, 139, to aldehyde 151 (300 mg, 1.51 
mmol) in THF (10 mL) was added vinylmagnesium bromide (4.53 mL, 1M solution in 
THF, 4.53 mmol) at -40 oC. After completion, the reaction was quenched with saturated 
aqueous NH4Cl and the mixture was extracted with Et2O. Purification by flash column 
chromatography afforded 152 (150 mg, 46%) and 153 (120 mg, 37%).  
152: Rf  0.50 (25% EtOAc:Pet.Ether); 
! 
["]
D
20-18.0 (c 2.3, CHCl3); 1H NMR (400 MHz, 
CDCl3)  δ  5.80 (1H, dq, J = 17.2, 10.5, 6.6 Hz, H22), 5.35 (1H, dt, J = 17.2, 2.9 Hz, 
CHtrans), 5.21 (1H, dq, J = 10.4, 2.6 Hz, CHcis), 3.93-3.85 (1H, m, H23), 3.33-3.24 (1H, 
m, H24), 3.19-3.10 (1H, m, H28), 2.96 (1H, d, J = 1.9 Hz, OH), 1.88-1.79 (1H, m, H25a), 
1.61-1.57 (1H, m, H25b), 1.54-1.36 (6H, m, H26 + H27 + H29), 1.32-1.24 (8H, m, H30 + 
H31 + H32 + H33), 0.88 (3H, t, J = 6.9 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 136.5, 
117.5, 80.4, 78.0, 76.3, 36.4, 31.8, 31.4, 29.3, 27.2, 25.5, 23.1, 22.6, 14.0. 
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153: Rf  0.45 (25% EtOAc:Pet.Ether); 
! 
["]
D
20  -11.0 (c 2.1, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ  5.87 (1H, ddd, J = 17.3, 10.5, 6.2 Hz, H22), 5.29 (1H, dt, J = 17.3, 3.1 Hz, 
CHtrans), 5.18 (1H, dt, J = 10.5, 3.1 Hz, CHcis), 4.16-4.09 (1H, m, H23), 3.37 (1H, ddd, J 
= 9.8, 5.8, 2.1 Hz, H24), 3.33-3.25 (1H, m, H28), 2.35 (1H, d, J = 5.0 Hz, OH), 1.89-1.80 
(21H, m, H25), 1.55-1.32 (4H, m, H26 + H27), 1.31-1.24 (10H, m, H29 + H30 + H31 + H32 
+ H33), 0.88 (3H, t, J = 6.7 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 137.5, 116.1, 79.8, 
78.2, 75.0, 36.4, 31.8, 31.5, 29.3, 25.4, 25.1, 23.1, 22.6, 14.1. 
The characterisation data for 152 and 153 were identical to those reported for 138, 139 
so no further characterisation was performed.  
 
Preparation of (S) and (R)-[1-(2R,6S)-6-hexyltetrahydro-2H-pyran-2-yl)]prop-2-en-1-ol 
(155, 156) 
O
156
OH
34 28
23 22
O
155
OH
34 28
23 22
 
Following the same procedure as for both 143, 144, to aldehyde 154 (550 mg, 2.77 
mmol) in THF (20 mL) was added vinylmagnesium bromide (5.50 mL, 5.54 mmol) at -
40 oC. After completion, the reaction was quenched with aqueous NH4Cl solution and 
the mixture was extracted with Et2O. Purification by flash column chromatography 
afforded 155 (312 mg, 54 %) and 156 (190 mg, 31 %). 
155: Rf  0.50 (25% EtOAc:Pet.Ether);
! 
["]
D
20  -14.0 (c 2.3, CHCl3); 1H NMR (300 MHz, 
CDCl3)  δ 5.76 (1H, ddd, J = 17.2, 10.4, 6.7 Hz, H22), 5.36 (1H, dt, J = 17.1, 1.6 Hz, 
CHtrans), 5.22 (1H, app dq, J = 10.4, 1.6 Hz, CHcis), 4.17-4.08 (1H, m, H23), 3.82-3.71 
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(1H, m, H24), 3.50-3.41 (1H, m, H28), 2.85 (1H, d, J = 1.8 Hz, OH), 1.75-1.56 (6H, m, 
H25 + H26 + H27), 1.41-1.24 (10H, m, H29 + H30 + H31 + H32 + H33), 0.88 (3H, t, J = 6.5 
Hz, H34); 13C NMR (75 MHz, CDCl3) δ 136.9, 117.7, 73.7, 73.3, 72.0, 32.9, 31.7, 29.5, 
29.2, 25.8, 25.7, 22.6, 18.4, 14.0. 
156: Rf  0.45 (25% EtOAc:Pet.Ether);
! 
["]
D
20  -9.2 (c 1.8, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.90 (1H, ddd, J = 16.8, 10.5, 6.0 Hz, H22), 5.31 (1H, dt, J = 17.2, 3.2 Hz, 
CHtrans), 5.20 (1H, dt, J = 10.5, 3.2 Hz, CHcis), 4.16-4.09 (1H, m, H23), 3.89-3.80 (1H, 
m, H24), 3.62-3.55 (1H, m, H28), 2.17 (1H, d, J = 5.0 Hz, OH), 1.70-1.60 (4H, m, H25 + 
H27), 1.54-1.35 (4H, m, H26 + H29), 1.33-1.26 (8H, m, H30 + H31 + H32 + H33), 0.88 (3H, 
t,  J = 6.9 Hz, H34); 13C NMR (75 MHz, CDCl3) δ 137.0, 116.2, 74.3, 73.0, 72.1, 31.8, 
30.9, 29.2, 28.7, 25.9, 25.1, 22.6, 18.1, 14.0. 
The characterisation data for 155 and 156 were identical to those reported for 143 and 
144 so no further characterisation was performed.  
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7.4 Experimental details for Chapter four  
  
Preparation of (2R,6R)-2-[(S)-1-allyloxyallyl]-6-hexyltetrahydro-2H-pyran (175) 
O
O
175
34
23
28
21
1´ 3´
 
To a cold (0 oC), stirred suspension of NaH (33.8 mg, 0.88 mmol, 60% dispersion in 
mineral oil) in THF (1.0 mL) was added a solution of solution of THP alcohol 139 
(46.6 mg, 0.22 mmol) in dry THF (2.0 mL). The reaction mixture was allowed to warm 
to RT over 1 h before being  re-cooled to 0 oC, and allyl bromide (36 µL, 0.44 mmol) in 
THF (1.0 mL) was added slowly via cannula. The reaction mixture was allowed to stir 
at RT for 4 h, before being cautiously quenched with MeOH (2 mL) followed by 
saturated aqueous NH4Cl (3 mL) and the phases were separated. The aqueous phase 
was extracted with Et2O (3 x 10 mL) and the combined organic phases were washed 
with brine, dried (Na2SO4), filtered and concentrated. Purification of the crude material 
by flash column chromatogaphy (10% EtOAc:Pet.Ether) gave THP dienyl ether 175 
(48 mg, 81% yield). 
175: Rf  0.42 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  +14.0 (c 1.2, CHCl3); IR (neat) 2933, 
2859, 1457, 1378, 1088, 1045, 927 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.97-5.71(2H, 
m, H22 + H2´), 5.32-5.19 (3H, m, H21 + H3´a), 5.17-5.11 (1H, m, H3´b), 4.15-4.05 (1H, m, 
H23), 3.92 (1H, app ddt, J = 12.7, 7.4, 2.8 Hz, H1´a), 3.73-3.62 (1H, m, H1´b), 3.41-3.17 
(2H, m, H24 + H28), 1.90-1.68 (2H, m, H25), 1.53-1.31 (6H, m, H27 + H26 + H29), 1.31-
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1.24 (8H, m, H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34); 13C NMR (300 
MHz, CDCl3) δ 136.4, 135.7, 117.7, 116.6, 82.7, 80.1, 82.7, 80.1, 78.1, 69.0, 31.8, 
31.6, 27.2, 25.2, 23.4, 22.6, 14.0; m/z (ES+) 289 (100, [M+Na]+); HRMS (ES+) Calc. 
for C17H30O2Na [M+Na+] 289.2136, found 289.2144.  
 
Preparation of (2R,6R)-2-(S)-2,5-dihydrofuran-2-yl)-6-hexyltetrahydro-2H-pyran (176) 
O O
176
23
34
22
28
20
 
To a stirred solution of Grubbs I cat. 160 (4.40 mg, 5.44 µmol) in DCM (25 mL) at 
room temperature was added a solution of THP dienylether 175 (29.0 mg, 0.10 mmol) 
in DCM (10 mL) and the mixture was heated to reflux for 10 h. Following 
concentration, the crude product was purified by flash column chromatography (10% 
EtOAc:Pet.Ether) to provide dihydrofuran 176 as a colourless oil (23.2 mg, 89%). 
176: Rf  0.40 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  +10.2 (c 1.3, CHCl3); IR (neat) 2359, 
1559, 1457, 1384, 957 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.97-5.88 (1H, m, H21), 
5.81-5.76 (1H, m, H22), 4.81-4.73 (1H, m, H23), 4.72-4.65 (1H, m, H20a) 4.65-4.60 (1H, 
m, H20b), 3.38 (1H, ddd, J = 11.3, 7.4, 2.0 Hz, H24) 3.28-3.18 (1H, m, H28), 1.90-1.78 
(2H, m, H25), 1.74-1.64 (2H, m, H27), 1.56-1.37 (4H, m, H26 + H29), 1.27-1.15 (8H, m, 
H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34); 13C NMR (300 MHz, CDCl3) δ 
127.7, 127.0, 88.7, 80.5, 78.1, 75.7, 36.4, 31.8, 31.6, 31.2, 29.3, 27.2, 25.6, 23.2, 22.6, 
14.0; m/z (ES+) 261 (100, [M+Na]+); HRMS (ES+) Calc. for C15H26O2Na [M+Na+] 
261.1836, found 261.1839.  
Preparation of (2R,6R)-2-hexyl-6-[(S)-tetrahydrofuran-2-yl]tetrahydro-2H-pyran (177) 
  
 Chapter Seven 
 
 
 
191 
O O
177
23
34
28
20
 
The argon atmosphere over a stirred suspension of dihydrofuran 176 (21.1 mg, 0.08 
mmol) and Pd/C (9.31 mg, 8 µmol, 10% wt Pd on C) in EtOH (2.0 mL) was replaced 
with H2 and the reaction mixture was stirred under positive H2 pressure for 4 h. After 
this time, the mixture was passed through a plug of celite which was washed with 
EtOAc (20 mL). The filtrate was concentrated and the crude was purified by flash 
column chromatography (5% EtOAc:Pet.Ether) to give 177 as a colourless oil (19.8 
mg, 93%). 
177: Rf  0.32 (5% EtOAc:Pet.Ether); 
! 
["]
D
20  +13.4 (c 0.9, CHCl3); IR (CCl4) 2359, 1559, 
1457, 1384, 957 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.94-3.85 (1H, m, H24), 3.79-3.68 
(2H, m, H23 + H20a), 3.21-3.23 (2H, m, H28 + H20b), 1.93-1.78 (4H, m, H21 + H22), 1.68-
1.44 (6H, m, H25 + H26 + H27), 1.41-1.23 (10H, m, H29 + H30 + H31 + H32 + H33), 0.86 
(3H, t, J = 6.6 Hz, H34); 13C NMR (75 MHz, CDCl3) δ  81.7, 80.1, 77.9, 68.4, 36.5, 
31.8, 31.2, 29.4, 27.7, 25.6, 25.5, 23.5, 22.6, 14.1; m/z (ES+) 241 (100, [M+H]+); 
HRMS (ES+) Calc. for C15H29O2 [M+H+] 241.2165, found 241.2162.  
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Preparation of (R)-1-(2R,5R)-5-[R-1-(allyloxy)allyl]tetrahydrofuran-2-yl)-7-
(benzyloxy)heptyloxy)(tert-butyl)dimethylsilane (178) 
O
OTBS
OBn
O
178
9
1520
1´3´
22
 
To a cold (0 oC), stirred suspension of NaH (3.3 mg, 0.08 mmol, 60% dispersion in 
mineral oil) in THF (1 mL) was added a solution of THF alcohol 120 (10 mg, 0.02 
mmol) in dry THF (1 mL). The reaction mixture was allowed to warm to RT over 1 h 
before being  re-cooled to 0 oC, and allyl bromide (5 µL, 0.04 mmol) in THF (1 mL) 
was added slowly via cannula. The reaction mixture was then cautiously quenched with 
MeOH (2 mL), followed by saturated aqueous NH4Cl (2 mL) and phases separated. The 
aqueous phase was extracted with Et2O (3 x 10 mL) and the combined organic phases 
were washed with brine and dried (Na2SO4), filtered and concentrated. Purification of 
the crude material by flash column chromatogaphy (10% EtOAc:Pet.Ether) gave THF 
dienylether 178 as a colourless oil (9 mg, 86% yield). 
178: Rf 0.35 (10% EtOAc:Pet.Ether); 
! 
["]
D
20  +4.0 (c 0.8, CHCl3); IR (CCl4) 2927, 2855, 
2360, 1457, 1264, 1097 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.32 (4H, m, Ar-H), 
7.30-7.26 (1H, m, Ar-H), 5.97-5.82 (1H, m, H21), 5.81-5.64 (1H, m, H2´), 5.31-5.20 
(3H, m, H22 + H3´a), 5.17-5.10 (1H, m, H3´b), 4.50 (2H, s, Ph-CH2); 4.13-4.03 (1H, m, 
H15), 4.01-3.80 (3H, m, H1´ + H20), 3.80-3.61 (2H, m, H19 + H16), 3.45 (2H, t, J = 6.4 
Hz, H9), 1.92-1.70 (2H, m, H18), 1.70-1.57 (2H, m, H17), 1.40-1.20 (10H, m, H14 + H13 
+ H12 + H11), 0.87 (18H, s, Si-C(CH3)3), 0.07-0.02 (6H, m, 2 x Si-CH3); m/z (ES+) 515 
(100, [M+H]+); HRMS (ES+) Calc. for C30H50O4Si [M+H+], found 515.3153. 
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Preparation of (R)-7-(benzyloxy)-1-(2R,2´R,5R)-octahydro-2,2´-bifuran-5-yl) heptyloxy 
(tert-butyl)dimethylsilane (179) 
O
OTBS
OBn
O
179
9
15
20
23
 
To a stirred solution of Grubb’s first generation ruthenium catalyst 160 (1 mg, 1.01 
µmol) in DCM (5 mL) at room temperature was added a solution of THF dienylether 
178 (7 mg, 0.01 mmol) in DCM (2 mL). The reaction mixture was heated to reflux for 
10 h. Following concentration the crude product was subjected to hydrogenation with 
Pd/C (1.5 mg, 1.01µmol, 10% wt Pd on C) in EtOH (1.0 mL). The argon atmosphere 
over a stirred suspension was replaced with H2 and the reaction mixture was stirred 
under positive H2 pressure for 4 h. After this time, the mixture was passed through a 
plug of celite, which was washed with EtOAc (10 mL). The filterate was concentrated 
and the crude product then purified by flash column chromatography (5% 
EtOAc:Pet.Ether) to give 179 (4 mg, 68%) as colourless oil. 
179: Rf 0.42 (5% EtOAc:Pet.Ether); 
! 
["]
D
20  +3.9 (c 0.6, CHCl3); IR (CCl4) 2960, 2929, 
2856, 1461, 1261, 1097, 973 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36-7.32 (4H, m, 
Ar-H), 7.30-7.26 (1H, m, Ar-H), 4.49 (2H, s, CH2-Ph), 4.44-4.35 (1H, m, H15), 4.00-
3.82 (2H, m, H19 + H20), 3.66-3.49 (3H, m, H19 + H23), 3.46 (2H, t, J = 6.4 Hz, H9), 
1.98-1.72 (4H, m, H17 + H18), 1.65-1.56 (2H, m, H21), 1.37-1.33 (2H, m, H22), 1.30-1.25 
(10H, m, H14 + H13 + H12 + H11 + H10), 0.88 (9H, s, Si-C(CH3)3), 0.06 (3H, s, Si-CH3), 
0.05 (3H, s, Si-CH3); 13C NMR (125 MHz, CDCl3) δ 128.2, 127.4, 127.3, 126.7, 81.2, 
77.3, 76.8, 74.4, 72.7, 70.4, 56.9, 33.9, 31.9, 29.4, 29.2, 27.6, 27.4, 26.2, 25.4, 24.7, 
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22.4, 18.9, -4.6, -3.9; m/z (ES+) 499 (100, [M+Na]+); HRMS (ES+) Calc. for 
C28H48O4NaSi [M+Na+] 499.3237, found 499.3220.  
 
Preparation of but-3-en-2-yl-tert-butyl carbonate (219) 
OBoc
1
4
219  
To a cold (-78 oC), stirred solution of allylic alcohol 218 (1.4 mL, 16.6 mmol) in dry 
THF (60 mL) was added n-BuLi (12.5 mL, 1.6M in hexane, 20.0 mmol) dropwise. The 
reaction mixture was stirred for 10 min before a solution of Boc2O (4.00 g, 18.2 mmol) 
in THF (10 mL) was added. The reaction mixture was stirred at the same temperature 
for 30 min and was allowed to warm to RT before the reaction was quenched with 
saturated aqueous NH4Cl (10 mL) and EtOAc (20 mL). The organic phase was 
seperated and kept. The aqueous layer was then extracted with EtOAc (3 x 30 mL) and 
the combined organic phases were washed with brine, dried (Na2SO4), filtered and 
concentrated. Purification by flash column chrmatography (5-10% EtOAc:Hexane) 
gave the desired allylic carbonate 219 as a colourless oil (2.51g, 87%). 
219: Rf  0.60 (10% EtOAc:Hexane); IR (neat) 2983, 2936, 1740, 1276, 875, 793 cm-1; 
1H NMR (300 MHz, CDCl3) δ 5.83 (1H, ddd, J = 16.8, 10.5, 6.2 Hz, H3), 5.24 (1H, 
ddt, J = 14.7, 2.7, 1.2 Hz, H4a), 5.15-5.05 (2H, m, H4b + H2), 1.46 (9H, s, C(CH3)3), 1.32 
(3H, d, J = 6.5 Hz, H1); 13C NMR (100 MHz, CDCl3) δ 152.8, 137.4, 116.0, 81.8, 73.9, 
27.7, 19.9; m/z (ES+) 195 (100, [M+Na]+); HRMS (ES+) Calc. for C9H16O3Na [M+Na+] 
195.0994, found 195.0997. 
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Preparation of (2S,6R)-2-[(1R)-1-(but-3-en-2-yloxy)allyl]-6-hexyltetrahydro-2H-pyran 
(220) 
O
O
34 28
23
1´
3´
230  
Trimethyl phosphite (3.6 µL, 0.02 mmol) was added directly to a suspension of 
Wilkinson’s catalyst (14.1 mg, 0.02 mmol) in anhydrous THF (1.5 mL). The catalyst 
was allowed to form over ca. 15 min resulting in a light-yellow homogeneous solution. 
In a separate flask, lithium bis(trimethylsilyl) amide (615 µL, 0.58 mmol, 1.0 M 
solution in THF) was added dropwise to a suspension of copper (I) iodide (116 mg, 
0.61 mmol), trimethyl phosphite (72 µL, 0.61 mmol) and secondary THP alcohol 139  
(92.2 mg, 0.43 mmol) in dry THF (1.5 mL). The anion was allowed to form over ca. 2 
minutes until a light green homogeneous solution was obtained, and the catalyst and the 
copper alkoxide solutions were cooled to 0 oC, and the former was added via cannula to 
the copper enolate/alkoxide solution followed by the addition of allylic carbonate 219 
(40 mg, 0.25 mmol) in dry THF (1 mL) via cannula. The reaction was allowed slowly 
warm to RT over a period of 16 h. The resulting brown heterogeneous solution was 
quenched with NH4Cl solution (5 mL) and partioned between Et2O and NH4Cl solution. 
The combined organic phases were dried (Na2SO4), filtered and concentrated. 
Purification by flash column chromatography (5-10% EtOAc:Hexane) furnished the 
allyl ether 220 as a colourless oil (32.0 mg, 39%). 
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220: Rf 0.42 (5% EtOAc:Hexanes); 
! 
["]
D
20  +3.8 (c 0.8, CHCl3); IR (CCl4) 3384, 2929, 
2854, 1453, 1402, 1100, 969 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.87-5.62 (2H, m, 
H22 + H2´), 5.27-5.20 (1H, m, CHtrans), 5.19-5.11 (2H, m, CHcis + H3´a), 5.05-5.00 (1H, 
m, H3´b), 3.95-3.85 (1H, m, H23), 3.85-3.78 (1H, m, H24), 3.78-3.70 (1H, m, H1´), 3.66-
3.60 (1H, m, H28), 1.74-1.54 (6H, m, H25 + H26 +  H27), 1.33-1.24 (10H, m, H29 + H30 + 
H31 + H32 + H33), 1.23 (3H, d, J = 6.4 Hz, CH3), 0.88 (3H, t, J = 7.0 Hz, CH3); 13C 
NMR (100 MHz, CDCl3) δ 117.6, 116.9, 114.9, 114.4, 79.6, 75.6, 72.9, 71.6, 32.9, 
32.1, 31.8, 29.6, 29.3, 26.5, 25.7, 22.6, 20.7, 18.6, 14.0; HRMS (ES+) Calc. for 
C18H36O2N [M+NH4+], found 298.2379.  
 
Preparation of [(1R)-benzyloxy)-1-(2R,5R)-5-(1R)-1-(but-3-en-2-yloxy)allyl]tetra 
-hydrofuran-2-yl)heptyloxy)(tert-butyl)dimethylsilane (221) 
O
OTBS
OBn
O
221
9
15
19
21
1´
3´
 
Trimethyl phosphite (2.8 µL, 0.02 mmol) was added directly to a suspension of 
Wilkinson’s catalyst (10.1 mg, 0.02 mmol) in dry THF (1.0 mL). The catalyst was 
allowed to form over ca. 15 min resulting in a light yellow homogeneous solution. In a 
separate flask, lithium bis(trimethylsilyl) amide (225 µL, 0.22 mmol, 1.0 M solution in 
THF) was added dropwise to a suspension of copper (I) iodide (80.0 mg, 0.42 mmol), 
trimethyl phosphite (62 µL, 0.42 mmol) and secondary THF alcohol 120 (50.0 mg, 0.10 
mmol) in dry THF (1.0 mL). The anion was allowed to form over ca. 2 minutes until a 
light green homogeneous solution was obtained, and the catalyst and the copper 
  
 Chapter Seven 
 
 
 
197 
alkoxide solutions were cooled to 0 oC, and the former was added via cannula to the 
copper enolate/alkoxide solution followed by the addition of allylic carbonate 219 (38.0 
mg, 0.21 mmol) in dry THF (1 mL) via cannula. The reaction was allowed slowly 
warm to RT over a period of 16 h. The resulting brown heterogeneous solution was 
then quenched with NH4Cl solution (5 mL) and partioned between Et2O (10 mL) and 
NH4Cl solution. The organic phases were combined, dried (Na2SO4), filtered and 
concentrated. Purification by flash column chromatography (5-10% EtOAc:Hexane) 
furnished the bis-allyl ether 221 as a colourless oil (14.2 mg, 27%).  
221: Rf  0.40 (10% EtOAc:Hexanes); 
! 
["]
D
20  -1.8 (c 0.5, CHCl3); IR (CCl4) 3384, 2929, 
2854, 1453, 1402, 1100, 969 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.33 (4H, m, Ar-H), 
7.30-7.26 (1H, m, Ar-H), 5.93-5.69 (2H, m, H21+ H2´), 5.39-5.28 (1H, m, CHtrans), 5.25-
5.07 (3H, m, CHcis + H3´), 4.50 (2H, s, Ph-CH2), 4.42-4.36 (1H, m, H15), 4.35-4.26 (1H, 
m, H20), 4.02-3.92 (2H, m, H16 + H19), 3.61-3.53 (1H, m, H1´), 3.46 (2H, t, J = 6.6 Hz, 
H9), 1.66-1.57 (4H, m, H17 + H18), 1.32-1.27 (4H, m, H10 + H14), 1.27-1.24 (6H, m, H13 
+ H12 + H11), 0.91 (9H, s, Si-C(CH3)3), 0.08 (3H, s, Si-CH3), 0.06 (3H, s, Si-CH3); 13C 
NMR (75 MHz, CDCl3) δ 132.8, 129.5, 128.3, 127.6, 117.9, 117.7, 117.3, 116.0, 82.6, 
82.2, 80.7, 74.3, 72.8, 70.4, 65.0, 32.7, 29.7, 28.6, 27.8, 26.3, 25.9, 25.8, 25.6, 23.6, 
18.2, -3.5, -4.4.  
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Preparation of tert-butyl(R)-1-[(2S,6R)-6-hexyltetrahydro-2H-pyran-2-yl]allylcarbonate 
(159) 
O
OBoc
159
34
23
28
21
 
To a cold (-78 oC), stirred solution of THP allylic alcohol 139, (50 mg, 27 mmol) in dry 
THF (25 mL) was added n-BuLi (2.0 mL, 1.6 M in hexane, 12.0 mmol) dropwise. The 
reaction mixture was stirred for 10 min before a solution of Boc2O (120 mg, 27.0 
mmol) in THF (10 mL) was added. The reaction mixture was stirred at the same 
temperature for 30 min and was allowed to warm to RT before the reaction was 
quenched with saturated NH4Cl. The aqueous layer was extracted with EtOAc (3 x 10 
mL), and the combined organic phases were washed with brine, dried (Na2SO4), filtered 
and concentrated. Purification by flash column chrmatography (10% EtOAc:Hexane) 
gave the THP allylic carbonate 159 as a colourless oil (60 mg, 85%).  
159: Rf  0.45 (5% EtOAc:Hexanes); 
! 
["]
D
20  +10.4 (c 2.3, CHCl3); IR (neat) 2981, 2933, 
2889, 1742, 1444, 1277, 1120, 932 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.93 (1H, ddd, 
J = 17.3, 10.5, 6.3 Hz, H22), 5.30 (1H, app dt, J = 17.3, 2.7 Hz, CHtrans), 5.23 (1H, dt, J 
= 10.6, 2.7 Hz, CHcis), 4.95-4.89 (1H, m, H23), 3.40 (1H, ddd, J = 7.9, 5.7, 2.1 Hz, H24), 
3.29-3.19 (1H, m, H28), 1.91-1.57 (4H, m, H25 + H27), 1.52 (9H, s, tBu-H), 1.34-1.20 
(12H, m, H26 + H29 + H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34); 13C NMR 
(300 MHz, CDCl3) δ 152.9, 133.8, 117.0, 82.0, 79.5, 78.5, 78.0, 31.8, 31.3, 29.3, 27.8, 
27.4, 25.3, 23.1, 22.6, 14.0; m/z (ES+) 327 (100, [M+H]+); HRMS (ES+) Calc. for 
C19H35O4 [M+H+] 327.2530, found 325.2527. 
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Preparation of (R)-1-[(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]allyl acetate (228)  
228
O
OAc
34 28 24
22
 
To a stirred solution of alcohol 152 (200 mg, 0.94 mmol) in DCM (7.0 mL) were added 
NEt3 (241 µL, 1.88 mmol), Ac2O (300 µL, 2.82 mmol) and DMAP (23.0 mg, 0.18 
mmol) at RT.  The reaction mixture was stirred at the same temperature for 15 h before 
being quenched with saturated aqueous NH4Cl (3 mL) and diluted with DCM (10 mL). 
The organic phase was separated and kept. The aqueous layer was extracted with DCM 
(3 x 10 mL). The organic phases were combined, washed with brine, dried (Na2SO4), 
filtered and concentrated. Purification by flash column chromatography (5-10% 
EtOAc:Pet.Ether) gave allylic acetate 228 as a colourless oil (241 mg, 95%).  
228: Rf  0.60 (10% EtOAc:Hexanes); 
! 
["]
D
20  -22.9 (c 1.1, CHCl3); IR (neat) 2932, 2858, 
1747, 1371, 1263, 1089, 923 cm-1; 1H NMR (300 MHz, C6D6) δ 5.78 (1H, ddd,  J = 
17.2, 10.4, 7.0 Hz, H22), 5.55-5.48 (1H, m, H23), 5.33 (1H, app dt, J = 17.2, 2.5 Hz, 
CHtrans), 5.24 (1H, app dt, J = 10.4, 2.4 CHcis), 3.78-3.68 (2H, m, H24 + H28), 2.09 (3H, 
s, -O(C=O)CH3), 1.71-1.53 (6H, m, H25 + H26 + H27), 1.50-1.23 (10H, m, H29 + H30 + 
H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, CH3); 13C NMR (75 MHz, C6D6) δ 170.2, 
133.6, 118.5, 74.2, 72.1, 71.7, 32.2, 31.8, 29.7, 29.2, 26.0, 25.6, 22.6, 21.2, 18.5, 14.1; 
m/z (ES+) 291 (100, [M+Na]+); HRMS (ES+) Calc. for C16H28O3Na [M+Na+] 
291.1928, found 291.1936.  
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Preparation of (1R,4S,E)-1,4-bis[(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]-4-hydroxy 
-but-2-enyl-acetate (237) 
237
O
OAc
O
OH
1 7
12
15
20
26
 
To a stirred solution of unprotected allylic alcohol 152 (13.4 mg, 0.06 mmol) and 
allylic acetate 228 (37.3 mg, 0.18 mmol) in DCM (2.0 mL) was added Hoveyda-Grubbs 
second generation catalyst 46 [Cl2(IMes) Ru=CH-o-Oi-PrC6H4] (2.01 mg, 3 µmol). The 
reaction mixture was stirred for 3 h at RT, before being heated to reflux for 18 h and re-
cooled to RT. Following concentration, the crude product was purified by flash column 
chromatography (5-10% EtOAc:Pet.Ether) provided recovered allylic acetate (10 mg, 
20%) and cross metathesis product 237 as a colourless oil (8 mg, 37%). 
 237: Rf 0.4 (5% EtOAc:Hexanes); 
! 
["]
D
20-16.3 (c 3.2, CHCl3); IR (neat) 2929, 2359, 
1653, 1457, 1009 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.84 (1H, dd, J = 15.3, 5.3 Hz, 
H13), 5.69 (1H, app ddt J = 15.3, 7.8, 1.3 Hz, H14), 5.62-5.55 (1H, m, H12), 4.20-4.13 
(1H, m, H15), 3.89-3.79 (1H, m, H11), 3.78-3.66 (2H, m, H16 + H20), 3.60-3.52 (1H, m, 
H7), 2.23 (1H, broad s, OH), 2.08 (3H, s, -O-(C=O)CH3), 1.80-1.51 (12H, m, H8 + H9 + 
H10 + H17 + H18 + H19), 1.37-1.19 (20H, m, H2 + H3 + H4 + H5 + H6 + H21 + H22 + H23 + 
H24 + H25), 0.92-0.83 (6H, m, H1 + H26); 13C NMR (75 MHz, CDCl3) δ 169.2, 134.0, 
128.2, 77.6, 73.8, 73.5, 72.8, 72.3, 72.0, 34.2, 34.0, 32.3, 32.2, 31.2, 30.3, 29.7, 29.7, 
29.1, 29.0, 26.5, 26.3, 26.0, 25.3, 23.0, 21.6, 20.9, 18.4, 14.5; m/z (ES+) 489 (100, 
[M+Na]+); HRMS (ES+) Calc. for C28H50O5Na [M+Na+] 489.3550, found 489.3556.  
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Preparation of 1-(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl)prop-2-en-1-one (239) 
239
O34
28
23
21
O
 
To a cold (0 oC), stirred solution of THP allylic alcohol 153 (60.0 mg, 0.28 mmol) in 
DCM (5 mL) was added NaHCO3 (120 mg, 1.40 mmol) followed by Dess-Martin 
periodinane (180 mg, 0.56 mmol). The reaction mixture was stirred at the same 
temperature for 20 min., before being warmed to RT and stirred for an additional 30 
min. The reaction mixture was re-cooled to 0 oC before the addition of cold hexane (5 
mL) and cold toluene (5 mL). The resultant white suspension was filtered through celite 
and the filtrate concentrated. Purification by flash chromatography (5% 
EtOAc:Pet.Ether) gave THP allylic ketone 239 as a colourless oil (52.3 mg, 82%). 
239: Rf  0.60 (10% EtOAc:Pet.Ether);
! 
["]
D
20  -28.6 (c  2.5, CHCl3); IR (CCl4) 2928, 
2857, 2364, 2346, 1699, 1559, 1459, 1089, 987 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 6.83 (1H, dd, J = 17.5, 10.6 Hz, H22), 6.38 (1H, dd, J = 15.5, 1.9 Hz, CHtrans), 5.75 
(1H, dd, J = 8.7, 1.9 Hz, CHcis), 3.96 (1H, dd, J = 9.3, 2.4 Hz, H24), 3.35 (1H, app qn, J 
= 9.8 Hz, H28), 1.95-1.83 (2H, m, H25), 1.64-1.57 (2H, m, H27), 1.50-1.41 (2H, m, H26), 
1.35-1.23 (10H, m, H29 + H30 + H31 + H32 + H33), 0.88 (3H, t, J = 6.9 Hz, H34); 13C 
NMR (300 MHz, CDCl3) δ 199.2, 131.5, 129.2, 82.1, 78.3, 36.3, 31.8, 31.0, 29.3, 27.8, 
25.5, 23.3, 22.6, 14.0; m/z (ES+) 247 (100, [M+Na]+); HRMS (ES+) Calc. for 
C14H24O2Na [M+Na+] 247.1683, found 247.1685. 
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7.5 Experimental details for Chapter five  
 
Preparation of (R) and (S)-1-[(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]-3-trimethyl 
-silyl-prop-2-yn-1-ol (245, 246) 
O
OH
TMS
O
OH
TMS
246245
2323
34 3428
28
 
 
To a cold (-78 oC), stirred solution of TMS acetylene (600 mL, 4.03 mmol) in THF (10 
mL) was added a solution of n-BuLi (2.50 mL, 1.6 M in hexane, 4.03 mmol). After the 
reaction mixture had stirred for 1 h at -78 oC, a solution of THP aldehyde 151 (400 mg, 
2.01 mmol) in THF (2 x 5 mL) was added via cannula. After stirring for an additional 
2 h, the reaction was quenched by the addition of saturated, aqueous NH4Cl (10 mL) 
and diluted with Et2O (20 mL). The phases were separated and the aqueous phase was 
washed with Et2O (3 x 20 mL). The combined organic phases were washed with brine 
(10 mL), dried (Na2SO4), filtered and concentrated. Purification of the crude material 
by flash column chromatography (10% EtOAc:Pet.Ether) provided major diastereomer 
245 (441 mg, 78%) and minor daistereomer 246 (55.5 mg, 10%), as colourless oils.  
245: Rf 0.51 (5% EtOAc:Pet.Ether); 
! 
["]
D
20  -21.6 (c, 1.2 CHCl3); IR (neat) 3434, 2988, 
2933, 1464, 1240, 909 cm-1; 1H NMR (300 MHz, C6D6) δ  4.44 (1H, t, J = 4.8 Hz, 
H23), 3.37-3.30 (1H, m, H24), 3.13-3.02 (1H, m, H28), 2.44 (1H, d, J = 6.0 Hz, C23-
OH), 1.67-1.37 (6H, m, H25 + H26 + H27), 1.32-1.18 (10H, m, H29 + H30 + H31 + H32 + 
H33), 0.90 (3H, t, J = 6.5 Hz, H34), 0.16 (9H, s, Si(CH3)3); 13C NMR (75 MHz; C6D6)  δ 
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105.9, 90.4, 80.4, 78.8, 66.6, 37.3, 32.8, 32.2, 30.4, 26.6, 26.3, 23.9, 23.6, 14.9, -0.5; 
m/z (ES+) 314 (100, [M+Na]+); HRMS (ES+) Calc. for C17H36O2N1Si ([M+NH4+]) 
314.2508, found 314.2510.  
246: Rf 0.55 (5% EtOAc:Hexanes); 
! 
["]
D
20  -4.2 (c, 0.5 CHCl3); IR (neat) 3434, 2958, 
2872, 1550, 1048, 844 cm-1; 1H NMR (300 MHz, C6D6) δ  4.34 (1H, dd, J = 7.1, 3.7 
Hz, H23), 3.42-3.36 (1H, m, H24), 3.07-2.97 (1H, m, H28), 2.75 (1H, d, J = 3.8 Hz, C23-
OH), 1.82-1.71 (2H, m, H25), 1.59-1.51 (2H, m, H27), 1.33-1.16 (12H, m, H26 + H29 + 
H30 + H31 + H32 + H33), 0.90 (3H, t, J = 6.7 Hz, H34), 0.16 (9H, s, Si-(CH3)3); 13C NMR 
(75 MHz, C6D6) δ 105.8, 90.6, 81.1, 78.7, 67.5, 37.2, 32.7, 32.1, 30.3, 28.1, 26.3, 23.8, 
23.6, 14.9, 0.5; m/z (ES+) 297 (100, [M+H]+); HRMS (ES+) Calc. for C17H33O2Si 
([M+H+]) 297.2244, found 297.2244.  
 
Preparation of (S)-1-[(2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl]prop-2-yn-1-ol (247) 
O
OH
247
23
34 28
21
 
To a cold (0 oC), stirred solution of TMS alkyne 245 (400 mg, 1.35 mmol) in MeOH 
(20 mL) was added K2CO3 (560 mg, 4.05 mmol) as a solid in one portion. The reaction 
mixture was allowed to warm to RT and stirred for 4 h, before saturated aqueous 
NH4Cl (10 mL) was added and the resulting mixture was diluted with EtOAc (10 mL). 
The organic phase was separated and kept whilst the aqueous layer was extracted with 
EtOAc (3 x 10 mL). The combined organic phases were dried (Na2SO4), filtered and 
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concentrated. Purification by flash column chromatography (5% EtOAc:Pet.Ether) gave 
alkyne 247 (285 mg, 95%), as a colourless oil.  
 247: Rf  0.41(5% EtOAc:Pet.Ether); 
! 
["]
D
20  -24.5 (c 0.8, CHCl3);  IR (neat) 3450, 3270, 
2933, 2859, 1548, 1457, 1199, 1081, 921 cm-1; 1H NMR (400 MHz, C6D6) δ 4.36-4.31 
(1H, m, H23), 3.31-3.24 (1H, m, H24), 3.10-3.02 (1H, m, H28), 2.66 (1H, app broad s, 
OH), 2.08 (1H, d, J = 2.3 Hz, H21), 1.64-1.44 (6H, m, H25 + H26 + H27), 1.31-1.19 (10H, 
m, H29 + H30 + H31 + H32 + H33), 0.89 (3H, t, J = 6.9 Hz, H34); 13C NMR (75 MHz, 
C6D6) δ  82.8, 79.8, 78.3, 73.6, 65.4, 36.6, 32.2, 31.6, 29.7, 25.9, 23.2, 23.0, 20.5, 14.3; 
m/z (ES+) 225 (100, [M+Na]+); HRMS (CI+) Calc. for C14H25O2 [M+H+] 225.1862, 
found 225.1855.  
  
Preparation of (R)-[(S)-1-((2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl)prop-2-ynyl)]3,3,3-
trifuoro-2-methoxy-2-phenylpropanoate  (248) 
O
O O
CF3
MeO
253
23
28
34
21
 
To a stirred mixture of alcohol 247 (6 mg, 0.02 mmol), DCC (80 µL, 1M solution in 
DCM, 0.08 mmol) and DMAP (8 mg, 0.06 mmol) in DCM (1.0 mL) at RT was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (6 mg, 0.02 mmol) in one 
portion. After 16 h, the crude reaction mixture was purified directly by flash column 
chromotography (5% EtOAc:Hexanes) to give (R)-MTPA ester  248 (3 mg, 32%). 
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248: Rf 0.25 (10% EtOAc:Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.68-7.58 (2H, m, 
Ar-H), 7.42-7.36 (3H, m, Ar-H), 5.70 (1H, dd, J = 3.4, 2.3 Hz, H23),3.66-3.60 (1H, ddd, 
J = 10.8, 5.6, 3.2 Hz, H24), 3.59 (3H, s, O-CH3), 3.36-3.29 (1H, m, H28), 2.48 (1H, d, J 
= 2.3 Hz, H21), 1.92-1.73 (1H, m, H25a), 1.56-1.35 (5H, m, H25a + H26 + H27), 1.31-1.23 
(10H, m, H29 + H30 + H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34).  
 
Preparation of (S)-[(S)-1-((2S,6S)-6-hexyltetrahydro-2H-pyran-2-yl)prop-2-ynyl]3,3,3-
trifluoro-2-methoxy-2-phenylpropanoate (249) 
O
O O
254
23
28
34
21
MeO
F3C
 
To a stirred mixture of alcohol 247 (7 mg, 0.03 mmol), DCC (120 µL, 1M solution in 
DCM, 0.12 mmol) and  DMAP (10.9 mg, 0.09 mmol) in DCM (1.0 mL) at RT was 
added (-)-(S)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (9 mg, 0.03 mmol) in 
one portion. After 16 h, the crude reaction mixture was purified directly by flash 
column chromotography (5% EtOAc:Hexanes) to give (S)-MTPA ester 249 (6 mg, 
41%) as a colourlesss oil. 
249: Rf 0.25 (10% EtOAc:Hexanes);  1H NMR (400 MHz, CDCl3) δ 7.58-7.53 (2H, m, 
Ar-H), 7.44-7.40 (3H, m, Ar-H), 5.69 (1H, dd, J = 4.3, 2.2 Hz, H23), 3.58 (3H, s, O-
CH3), 3.57-3.52 (1H, m, H24), 3.29-3.21 (1H, m, H28), 2.52 (1H, d, J = 2.2 Hz, H21), 
1.84-1.64 (2H, m, H25), 1.56-1.38 (4H, m, H27 + H29), 1.32-1.22 (10H, m, H29 + H30 + 
H31 + H32 + H33), 0.87 (3H, t, J = 6.9 Hz, H34). 
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Preparation of tert-butyl[(S)-1-((2S,6S)-6-hexyltertrahydro-2H-pyran-2-yl)prop-2-
ynyloxy) dimethylsilane (250) 
O
OTBS
250
23
34 28
21
 
To a stirring solution of 247 (100 mg, 0.45 mmol) in DCM (5 mL) at RT were added 
imidazole (61.2 mg, 0.98 mmol) and TBSCl (136 mg, 0.98 mmol). The resultant 
mixture was stirred for 6 h at RT, before the reaction mixture was quenched with 
saturated aqueous NH4Cl (3 mL) solution. After dilution with DCM (10 mL) the 
organic phase was separated and kept. The aqueous phase was extracted with DCM (3 x 
10 mL) and the combined organic phases were washed with brine (50 mL), dried 
(Na2SO4) and concentrated. Purification by flash column chromatography (5% 
EtOAc:Pet.Ether) provided TBS alkyne 250 (125 mg, 88 %), as a colourless oil.  
250: Rf 0.55 (10%  EtOAc:Pet.Ether); 
! 
["]
D
20  -31.1 (c 1.3, CHCl3);  IR (neat) 3312, 
2931, 2858, 1549, 1361, 1199, 1090, 970 cm-1; 1H NMR (300 MHz, C6D6) δ 4.48 (1H, 
dd, J = 4.7, 2.3 Hz, H23), 3.42 (1H, ddd, J = 11.0, 6.8, 2.1 Hz, H24), 3.19-3.08 (1H, m, 
H28), 2.05 (1H, d, J = 2.1 Hz, H21), 1.93-1.82 (1H, m, H25a), 1.74-1.62 (1H, m, H25b), 
1.61-1.43 (4H, m, H26 + H27), 1.41-1.22 (10H, m, H29 + H30 + H31 + H32 + H33), 0.91 
(3H, t, J = 6.5 Hz, H34), 1.03 (9H, s, Si-C(CH3)3), 0.22 (3H, s, Si-CH3), 0.17 (3H, s, Si-
CH3); 13C NMR (75 MHz, C6D6) δ 83.9, 80.5, 78.0, 72.2, 66.1, 36.4, 31.9, 31.6, 29.3, 
26.3, 25.7, 25.4, 23.2, 22.6, 18.3, 14.0, -4.7, -4.9; m/z (ES+) 356 (100, [M+NH4]+); 
HRMS (ES+) Calc. for C20H42O2NSi ([M+NH4+]) 356.2975, found 356.2979.  
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Preparation of (1R,4S)-1-((2R,5R)-5-[(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy) 
heptyl)tertrahydrofuran-2-yl]-4-(tert-butyldimethylsilyloxy)-4-((2S,6S)-6-hexyltetra 
-hydro-2H-pyran-2-yl)but-2-yn-1-ol  (251) 
 
O
OTBS
O
OTBS
OBn
OH
9
15
20
23
2834
251  
 
To a cold (-78 oC), stirred solution of THP alkyne 250 (45 mg, 0.138 mmol) in dry THF 
(2 mL) was added n-BuLi (90 µL, 1.6 M in hexane, 0.14 mmol). After the reaction 
mixture had stirred for 1 h at -78 oC, a solution of THF aldehyde 119 (30 mg, 0.07 
mmol) in THF (2 x 1.0 mL) was added via cannula. After stirring for an additional 2 h, 
the reaction was quenched by the addition of saturated, aqueous NH4Cl (5 mL) and 
diluted with Et2O (10 mL). The organic phase was kept, and the aqueous phase was 
washed with Et2O (3 x 10 mL). The combined organic phases were washed with brine 
(5 mL), dried (Na2SO4), filtered and concentrated. Purification of the crude material by 
flash column chromatography (10% EtOAc:Pet.Ether) gave alkyne 251 (43 mg, 81%)   
and recovered starting material 250 (5 mg, 10%) as colourless oils.  
251: Rf 0.43 (10% EtOAc:Pet.Ether);
! 
["]
D
20  -6.7 (c 1.1, CHCl3); IR (CCl4) 3384, 2931, 
2858, 2366, 2346, 1559, 1453, 1256, 1096, 836 cm-1; 1H NMR (400 MHz, CDCl3) δ  
7.36-7.31 (4H, m, Ar-H), 7.30-7.26 (1H, m, Ar-H), 4.53-4.42 (3H, m, Ph-CH2 + H23), 
4.34-4.26 (1H, m, H15), 4.14-4.06 (1H, m, H20), 4.05-3.98 (1H, m, H19), 3.60-3.50 (1H, 
m, H24), 3.46 (2H, t, J = 6.6 Hz, H9), 3.36-3.28 (1H, m, H16), 3.28-3.19 (1H, m, H28), 
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2.29 (1H, d, J = 5.8 Hz, OH), 2.02-1.92 (2H, m, H17 ), 1.89-1.71 (4H, m, H25 + H18), 
1.70-1.56 (6H, m, H14 + H26 + H27), 1.55-1.39 (6H, m, H13 + H12 + H10), 1.30-1.24 
(12H, m, H11 + H29 + H30 + H31 + H32 + H33), 0.91-0.86 (21H, m, 2 x Si-C(CH3)3 + H34), 
0.11 (3H, s, Si-CH3), 0.09 (3H, s, Si-CH3), 0.06 (3H, s, Si-CH3), 0.04 (3H, s, Si-CH3); 
13C NMR (100 MHz, CDCl3) δ 138.7, 128.3, 127.6, 127.4, 85.9, 83.3, 81.9, 81.4, 80.6, 
80.5, 78.0, 77.2, 75.1, 72.8, 70.4, 66.2, 64.5, 36.5, 32.9, 31.9, 31.5, 29.7, 29.3, 26.5, 
26.1, 25.9, 25.8, 25.6, 25.5, 23.2, 22.6, 18.3, 18.2, 14.1, -4.1, -4.5, -4.6, -4.9; m/z (ES+) 
795 (100, [M+NH4]+); HRMS (ES+) Calc. for C45H80O6Si2Na [M+Na+] 795.5396, 
found 795.5391. 
 
Preparation of (1R,4S)-1-((2R,5R)-5-[(R)-7-(benzyloxy)-1-(tert-butyldimethylsilyloxy) 
heptyl)tertrahydrofuran-2-yl]-4-(tert-butyldimethylsilyloxy)-4-((2S,6S)-6-hexyltetrahy 
-dro-2H-pyran-2-yl)butan-1-ol (253) and (1R,4S,E)-1-((2R,5R)-5-[(R)-7-(benzyloxy)-1-
(tert-butyldimethylsilyloxy)heptyl)tertrahydrofuran-2-yl]-4-(tert-butyldimethylsilyl 
-oxy)-4-((2S,6S)-6-hexyl -tetrahydro-2H-pyran-2-yl)but-2-en-1-ol (254)  
 
O
OTBS
O
OTBS
OBn
OH
O
OTBS
O
OTBS
OBn
OH
34
9
1520
23
28
254
34 28
23
20 15
9
253
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Method A:  
A mixture of alkyne 251 (15.0 mg, 0.01 mmol) and Pt/C (1.2 mg, 20 mol%, 5% Pt on 
C) in EtOAc (2.0 mL) was vigorously stirred at RT for 8 h under a hydrogen 
atmosphere (balloon). The suspension was filtered through a pad of celite. The celite 
pad was washed throughly with EtOAc (3 x 5 m L). The filtrate and washings were 
combined and concentrated. Purification of the resultant residue by flash column 
chromatography (5% EtOAc:Pet.Ether) gave the alkane 253 (4 mg, 20%) as a 
colourless oil, alkene 254, (6 mg, 40%) as a colourless oil and starting material 251 (4.5 
mg, 31%).  
 
Method B: 
A suspension of PtO2 (2 mg, 10 mol%) and TBS-protected alkyne 251, (6 mg, 0.01 
mmol) in EtOAc (1 mL) was vigorously stirred in an over sized flask (10 mL) at RT 
under an atmosphere of hydrogen (balloon) for 10 h. The suspension was filtered 
through a celite pad in a pipette to remove the catalyst. Purification by short column 
chromatography using pipette (5% EtOAc:Pet.Ether) provided product 253 
(2 mg, 10%).  
 
Method C: 
To an suspesion of Crabtree catalyst {[Ir(COD)(Pyr)P(c-Hex)3]PF6}255 (2 mg, 5 
mol%) in DCM (1.0 mL) was added alkyne 251 (6 mg, 90.0 µmol) via cannula under 
an argon atmosphere, which is gradually changed to hydrogen atmosphere by balloon. 
The mixture was stirred for 7 h at RT. The suspension was filtered through a celite pad 
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and washed thoroughly with EtOAc (3 x 5 mL). The combined washings and filtrate 
were dried (Na2SO4), filtered and concentrated. Purification by flash column 
chromatography (2% EtOAc:Pet.Ether) provided alkane 253 (2 mg, 13%) and 
recovered starting material 251 (3 mg, 25%). 
Alkane (253): Rf 0.50 (10% EtOAc:Pet.Ether); IR (CCl4) 3384, 2929, 2856, 2370, 
2346, 1655, 1559, 1457, 1261, 1096, 836 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-
7.31 (4H, m, Ar-H), 7.30-7.27 (1H, m, Ar-H), 4.50 (2H, s, Ph-CH2), 4.00-3.78 (2H, m, 
H15 + H23), 3.73-3.59 (2H, m, H16 + H20), 3.59-3.50 (1H, m, H24), 3.46 (2H, t, J = 6.7 
Hz, H9), 3.27-3.13 (2H, m, H28 + H19), 1.92-1.74 (4H, m, H21 + H22), 1.71-1.58 (8H, m, 
H17 + H18 + H25 + H27), 1.36-1.23 (22H, m, H10 + H11 + H12 + H13 + H14 + H29 + H29 + 
H30 + H31 + H32 + H33), 0.90-0.83 (21H, m, 2 x Si-C(CH3)3 + H34), 0.08-0.00 (12H, m, 2 
x Si(CH3)2); 13C NMR (300 MHz, CDCl3) δ 138.6, 128.3, 127.6, 127.5, 82.6, 81.9, 
81.0 80.2, 75.1, 74.7, 72.8, 72.0, 70.5, 36.5, 31.8, 31.6, 31.4, 30.9, 30.1, 29.7, 29.3, 
28.7, 28.1, 27.7, 26.3, 26.1, 25.9, 25.5, 23.4, 36.4, 23.4; m/z (ES+) 799 (100, [M+Na]+); 
HRMS (ES+) Calc. for C45H84O6Si2Na [M+Na+] 799.5705, found 799.5704.  
Alkene (254): Rf 0.47 (10% EtOAc:Pet.Ether); IR (CCl4) 2931, 2858, 2366, 2346, 
1655, 1559, 1453, 1363, 1256, 1096, 836 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36-
7.30 (4H, m, Ar-H), 7.30-7.26 (1H, m, Ar-H), 5.53-5.35 (2H, m, H22 + H23), 4.49 (2H, 
s, Ph-CH2), 3.99-3.86 (1H, m, H15), 3.72-3.59 (1H, m, H20), 3.59-3.50 (1H, m, H24), 
3.45 (2H, t, J = 6.8 Hz, H9), 3.27-3.14 (2H, m, H19 + H16), 3.11-3.01 (1H, m, H28), 1.98-
1.78 (4H, m, H17 + H18), 1.71-1.58 (4H, m, H27 + H25), 1.37-1.21 (22H, m, H10 + H11 + 
H12 + H13 + H14 + H26 + H29 + H30 + H31 + H32 + H33), 0.90-0.82 (21H, m, 2 x Si-
C(CH3)3 + H34), 0.08-0.02 (12H, m, 2 x Si(CH3)2); 13C NMR (300 MHz, CDCl3) 
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δ 138.6, 133.6, 129.5, 128.3, 127.6, 127.4, 82.5, 82.0, 80.2, 78.1, 75.0, 72.8, 72.0, 70.4, 
69.8, 36.4, 32.7, 32.6, 31.8, 31.6, 31.4, 30.9, 30.1, 29.7, 29.3, 28.7, 28.1, 27.6, 26.1, 
25.8, 25.5, 22.6, 18.3, 18.1, 14.0, -4.0, -4.1, -4.3, -4.5, -4.7, -5.0; m/z (ES+) 797 (100, 
[M+Na]+); HRMS (ES+) Calc. for C45H82O6Si2Na [M+Na+] 797.5521, found 797.5548.  
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